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ABSTRACT 
The aim of this research was to evaluate the utility of innovative in vitro techniques as an 
alternatives for human/animal tissues to study the transdermal uptake of organic flame 
retardants from indoor dust and consumer products. Firstly, we successfully designed and 
applied an in vitro physiologically based extraction test to provide new insights into the 
dermal bioaccessibility of various FRs from indoor dust. These investigations revealed the 
bioaccessible fraction for the brominated flame retardants (BFRs) α-, β-and γ- HBCD and 
TBBPA to 1:1 (sweat/sebum) mixture to be 41 %, 47 %, 50 % and 40 %, respectively, while 
for the phosphate flame retardants (PFRs) TCEP, TCIPP and TDCIPP, the values were 10 %, 
17 % and 19 %. With the exception of TBBPA, the presence of cosmetics had a significant 
effect (p <0.05) on the bioaccessibility of our target FRs from indoor dust. The presence of 
cosmetics decreased the bioaccessibility of HBCDs from indoor dust, whereas shower gel 
and sunscreen lotion enhanced the bioaccessibility of target PFRs. Secondly, we developed a 
protocol for studying dermal uptake of legacy and novel brominated flame retardants using 
two 3D-HSE (three dimensional human skin equivalent tissue) models, EpiDerm™ and 
EPISKIN™ in compliance with the OECD guidelines 428. Overall, results showed a 
significant negative correlation between the permeability constant of FRs and their Log KOW 
values. We also mimicked real life exposure scenarios by exposing the skin surface in turn to 
FR-containing dust, reference material plastics and upholstered fabrics. Our findings showed 
that under such scenarios dermal exposure to FRs was appreciable for UK adults and 
toddlers. For example, for dust exposure, our estimates of daily intake indicated toddlers to 
be 10 times more highly exposed than adults in the presence of sweat and sebum. This 
differential exposure is likely attributable to more dust adhering to toddler’s skin and their 
higher exposed skin surface area to body weight ratio compared to adults.  
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CHAPTER I 
INTRODUCTION 
 
Some passages in this chapter have been quoted verbatim from a review article: 
Abdallah, MA-E, Pawar, G & Harrad, S 2015, 'Evaluation of in vitro vs. in vivo 
methods for assessment of dermal absorption of organic flame retardants: A review' 
Environment International, vol 74, pp. 13-22. 
 
1.1:  Flame retardants  
Fire has been a major cause of property damage, injuries and death over many centuries. 
Efforts to reduce such fire hazards and to increase associated safety standards resulted in the 
development of flame retardants (FRs). FRs are a group of chemicals added during the 
manufacture of polymers and textiles to inhibit or delay the spread of fire by suppressing the 
chemical reactions in the flame or by the formation of a protective layer on the surface of a 
material. The most common classes of flame retardants are: Brominated, Phosphorous, 
Nitrogen, Chlorinated and Inorganic. Among the brominated group, the important ones are 
polybrominated diphenyl ethers (PBDEs), hexabromocyclododecane (HBCD), 
tetrabromobisphenol A (TBBP-A), novel brominated flame retardants (NBFRs), as well as 
organophosphate flame retardants (PFRs) (Ghosh, Hageman and Bjorklund 2011, van der 
Veen and de Boer 2012b) 
PBDEs are a class of anthropogenic chemicals with 209 theoretical congeners 
(Fromme et al. 2016). They have been used as additive flame retardants in plastics, textiles, 
casings for electronic devices and circuitry. The fully brominated product (Deca-BDE) 
dominated the market worldwide with a global demand of 56,100 t in 2001 when compared 
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to 7,500 and 3,790 t for the less brominated Penta-BDE and Octa-BDE formulations, 
respectively (BSEF 2013).  
           The major application of Hexabromocyclododecane (HBCD) is polystyrene foams 
(expanded and extruded) used mainly for thermal insulation of buildings. It has also been 
applied in the back coating of fabrics for textiles and to a lesser extent in high impact 
polystyrene (HIPS) (KEMI (National Chemicals Inspectorate) 2008). Commercial HBCD 
formulations consist mainly of the γ-HBCD diastereoisomer (75–89%), while the α- and β-
HBCD are present in considerably lower amounts (10–13% and 1–12%), respectively (Tao, 
Abdallah and Harrad 2016b). The global market demand for HBCD in 2001 (the last publicly 
available figures) was estimated at about 16,700 tons, 57% of which was in Europe (Covaci 
et al. 2006a) 
TBBP-A is the most widely used BFR with a global market of 120,000 to 150,000 
tons/year, including TBBP-A derivatives. It is applied mainly for epoxy resins used in printed 
circuit boards of consumer electronics (TVs, vaccum cleaners, washing machines etc), fax 
machines and photocopiers, vacuum cleaners, coffee machines and plugs/socket.(Wang et al. 
2015, Covaci et al. 2009)  
As is the case with PBDEs, HBCD and ~20% of the production of TBBP-A are 
blended physically within (and referred to as “additive” FRs) rather than bound chemically 
(and known as “reactive” FRs) to polymeric materials. Such additive FRs more readily 
migrate from products and their environmental persistence and bioaccumulative nature leads 
to contamination of the environment including humans (Harrad et al. 2010a). Hence, there is 
great concern owing to their potential health risks such as endocrine disruption, neuro-
developmental and behavioural disorders, hepatotoxicity & possibly cancer (Darnerud 2008, 
Oulhote, Chevrier and Bouchard 2016, Wikoff and Birnbaum 2011), cryptorchidism (Main et 
al. 2007), thyroid hormone homeostasis (Turyk et al. 2008), effects on male hormones and 
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semen quality (Johnson et al. 2013, Meeker et al. 2009, Abdelouahab, Ainmelk and Takser 
2011, Wikoff and Birnbaum 2011) and impaired fecundability in adult women (Harley et al. 
2010a). Further, they lower birth weight and length (Chao et al. 2007, Lignell et al. 2013). 
Such evidence has contributed to complete EU bans for the Penta- and Octa-BDE 
formulations, and restrictions on the use of Deca-BDE. In addition, PBDEs associated with 
Penta and Octa-BDE are listed under the UNEP Stockholm Convention on POPs, while 
Deca-BDE is currently under consideration for listing under Annexes A, B and/or C of the 
convention (Stockholm Convention on POPs 2009). Furthermore, HBCD will be phased out 
following its recent listing under Annex A of the Stockholm Convention (Stockholm 
Convention on POPs 2013). Despite such restrictions on their production and use, human 
exposure to PBDEs and HBCD is likely to continue for some time, given the ubiquity of 
flame retarded products remaining in use and entering the waste stream, coupled with the 
environmental persistence of these BFRs. (Harrad and Diamond 2006) 
These restrictions on the use of PBDEs and HBCD have paved the way for the use of so-
called novel BFRs (NBFRs) as replacements with an estimated global production volume of 
100,000 tonnes in 2009 (Covaci, Harrad and Abdallah 2011a). Major NBFRs are: DBDPE 
(Decabromodiphenylethane), BTBPE (1,2-bis(2,4,6 tribromophenoxy) ethane), EH-TBB (2-
ethylhexyl 2,3,4,5-tetrabromobenzoate), and BEH-TEBP (Bis (2-
ethylhexyl)tetrabromophthalate) (Table 1.3). These chemicals are either new to the market or 
have been detected recently in the environment. NBFRs are now being found as ubiquitously 
as PBDEs and they have been observed in indoor (Stuart et al. 2008, Covaci et al. 2011b, Ali 
et al. 2011, Karlsson et al. 2007) and outdoor environments (Shi et al. 2009, Ismail et al. 
2009).Some NBFRs (EH-TBB,TBPH) have been reported to display endocrine disruption 
activity (Saunders et al. 2013, Patisaul et al. 2013a). However, very little is known about the 
toxicological properties and the pathways and magnitude of human exposure to NBFRs. 
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Nevertheless, several NBFRs bear striking structural similarity to PBDEs (e.g. DBDPE is a 
very close analogue of BDE-209) and are reported to have similarly low vapour pressures and 
water solubilities, as well as high KOW values, and PBT characteristics. (Covaci et al. 2011b) 
In addition to BFRs, PFRs have been associated with a wide range of applications (Table 
1.4). Likely linked to the aforementioned restrictions on PBDEs, EU market demand for 
PFRs increased from 83,700 tons in 2004 to 91,000 tons in 2006 (EFRA 2007). Tris (2-
chloroethyl) phosphate (TCEP), tris (2-chloro-1-methylethyl) phosphate (TCIPP) and tris (1, 
3-dichloro-2-propyl) phosphate (TDCIPP) were all subject to an EU risk assessment process 
under an Existing Substances Regulation (EEC 793/93) (Regnery and Püttmann 2010). 
Despite lower stability and overall environmental persistence than PBDEs, they were 
classified as persistent organic compounds in the aquatic environment and reported to fulfil 
Persistent bioaccumulative and Toxic (PBT) criteria. In addition, several studies have 
reported them to display adverse effects including reproductive toxicity and carcinogenic 
effects on lab animals.(Regnery et al. 2011). Hence TCEP is classified by the EU as a 
“potential human carcinogen” (Regnery and Püttmann 2010), while TDCIPP is classified 
under regulation EC 1272/2008 as a category 2 carcinogen (ECHA 2010). 
                                              Fig 1.1: Chemical structure of PBDEs 
 
PBDE congeners are formed by substitution of H atom with Br atoms at 
1,1’,2,2’,3,3’4,4’,5,5’,6,6’ positions of benzene ring
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Table 1.1: Molecular weights and LogKow values for PBDE congeners (Pubchem, 
National Center for Biotechnology Information. PubChem Compound Database) 
BDE # Bromine substitution CAS NO  Mol.Wt (g/mol)  LogKow 
28 2,4,4’-tri BDE 41318756 405.8 5.94 
47 2,2’,4,4’-tetra BDE 5436431 485.79 6.2 
99 2,2’,4,4’,5-penta BDE 32534819 564.69 6.9 
100 2,2’,4,4’,6-penta BDE 189084648 564.69 6.9 
153 2,2’,4,4’,5,5’-hexaBDE 68631492 643.587 7.6 
183 2,2’,3,4,4’,5’6-hepta BDE 207122165 722.483 8.3 
209 2,2',3,3',4,4',5,5',6,6'-deca BDE 1163195 959.17 10.3 
  
Fig 1.2: Chemical structures of selected brominated and phosphorus flame retardants 
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                             (TnBP)                                                                       (TEHP) 
 
Table 1.2: Molecular weight and LogKow values of BFRs (Pubchem, National Center 
for Biotechnology Information. PubChem Compound Database) 
BFRS Abbrev. CAS NO Mol.Wt (g/mol)  Log Kow 
α-Hexabromocyclododecane α-HBCD 678970-15-5 641.7 5.07 
β-Hexabromocyclododecane β-HBCD 678970-16-6 641.7 5.12 
γ-Hexabromocyclododecane γ-HBCD 678970-17-7 641.7 5.47 
Tetrabromobisphenol-A TBBP-A 121839-52-9 543.9 5.90 
Tris(2-chloroethyl)phosphate TCEP 115-96-8 285.49 1.44 
Tris(2-chloroisopropyl) phosphate TCIPP 13674-84-5 327.57 2.59 
Tris(1,3-dichloroisopropyl)phosphate TDCIPP 13674-87-8 430.91 3.56 
Triphenyl phosphate TPhP 115-86-6 326.29 4.59 
Tri-o-cresyl-phosphate ToCP 78-30-8 368.37 6.34 
Tri-m-cresyl-phosphate TmCP 563-04-2 368.37 6.34 
Tri-p-cresyl-phosphate TpCP 78-32-0 368.37 6.34 
2-Ethylhexyl diphenyl phosphate EHDPP 1241-94-7 362.41 5.73 
Tri-n-butyl phosphate TnBP 126-73-8 266.32 4.0 
Tris (2-ethylhexyl) phosphate TEHP 78-42-2 434.65 9.49 
Tris (2-butoxyethyl) phosphate TBOEP 78-51-3 398.48 3.75 
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Fig 1.3: Chemical structures of Novel brominated flame retardants. 
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Table 1.3: Physicochemical properties of Novel  brominated flame retardants 
NBFRs Abbrev. CAS NO Mol.Wt 
(g/mol) 
Log KOW 
Pentabromoethylbenzene PBEB 85-22-3 500.645 7.96 
2-ethylhexyl-2,3,4,5-tetrabromobenzoate EH-TBB 183658-27-7 549.9 7.73 
Bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate BEHTEBP 26040-51-7 706.2 11.95 
1,2-Bis(2,4,6-tribromophenoxy)ethane BTBPE 37853-59-1 687.6 9.1 
Hexabromobenzene HBB 87-82-1 551.49 6.07 
2,3-dibromopropyl-2,4,6-tribromophenyl ether DPTE 35109-60-5 530.67 6.34 
Pentabromotoluene PBT 87-83-2 486.621 5.87 
Pentabromobenzene PBBz 608-90-2 472.59 5.4 
Tetrabromoethylcyclohexane TBECH 3322-93-8 399.74 3.73 
Decabromodiphenylethane DBDPE 84852-53-9 971.22 13.6 
Dechlorane plus Syn/anti DP 13560-89-9 653.72 9.0 
Note : some of the molecular weight and log KOW values have been estimated by ACD/Labs software 
 
 
 
 
 
 
 
 
 
 
 
Table 1.4:  Applications, concentrations in Indoor dust and different human matrices 
and potential toxicity of key flame retardants.
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Target 
Compounds 
Applications /conc. in 
consumer goods 
Concentrations in UK Home (H) 
and Office (O) dust 
Concentrations in human matrices  Potential Toxic Effects 
 
BDE-28 
 
< 0.2% by weight in Penta-
BDE  commercial 
products.1 
 
H = (<0.5 – 2.10 µg/kg)4 
 (<0.03-15 ng/g ,n =45)5 
O=(dl-11)*(<0.03-22ng/g, n=47)5 
 
 
UK Serum (<0.03-0.55 ng/g lw, n=20)2, 
breast milk (0.02-0.31 ng/g lw, n=6)2,  
China hair (0-5 ng/g,dw & serum(0-7ng/g 
lw)3,  
Spain Cord serum (nd-0.03 ng/ml, 
n=308)6,placenta (nd-0.04 ng/g 
,n=49)6,maternal serum (nd-0.02 ng/ml, 
n=308)6 
US56 hair =(0.23-8.6 ng/g,n=50), 
fingernail=(0.22-8.5 ng/g, n=50) 
,toenail(0.21-8.5ng/g,n=50), serum=(0.36-
6.6 ng/g lw, n=50) 
 
 
Potential liver toxicity, thyroid 
toxicity, developmental toxicity, 
and developmental neurotoxicity 
 
 
BDE-47 
 
 
 
38-42 % in Penta-BDE 
commercial products 
 
 
H = (1.2-58 ng/g)4 (0.04-50 ng/g ,n 
=45)5 
O = (2.6-380 ng/g)*(7.1-660, n=47 
ng/g)5 
 
 
 
 
 
UK Breast milk (0.17-14.65 ng/g lw)7 
Serum (<0.36-4.87 ng/g lw, n= 20)2, breast 
milk (0.32-13.0 ng/g lw, n=6)2, China hair 
(2-400 ng/g,dw & serum(14-148 ng/g lw)3,  
Spain Cord serum (nd-0.0.28 ng/ml, 
n=308)6,placenta (nd-0.008 ng/g 
,n=49)6,maternal serum (nd-0.13 ng/ml, 
n=308)6 
US56 hair =(5.2-890 ng/g,n=50), 
fingernail=(4.5-8.5 ng/g, n=50) 
,toenail (3.9-910 ng/g,n=50), 
serum=(4.3-240 ng/g lw, n=50) 
Egypt57 serum = (<LOQ-8.31 ng/glw,n=32) 
 
 
Inhibits the cells viability, increase 
LDH leakage, and induces cell 
apoptosis in fibroblastic cell lines8 
& disrupts hypothalamic–pituitary 
thyroid function9, ↓thyroid 
hormone T410.Alters growth, and 
morphology, cardiac and neural 
development in zebrafish11.  
 13 
 
 
BDE-99 
 
Polyurethanes     
(10-18%) 
Major component in DE-
71 or Penta Technical 
product (50-62%) 
 
H= (2.8-180 ng/g)4 
 (5-92 ng/g ,n =45)5 
O=(4.2-490)4 
(15-480,n=47 ng/g)5 
 
 
 
 
 
 
UK Breast milk (<0.06-3.43 ng/g lw)7, 
Serum (<0.26-5.61 ng/g lw, n= 20)2, breast 
milk (0.12-3.74 ng/g lw, n=6)2, China hair 
(1-569 ng/g,dw & serum (nd -22 ng/g lw)3,  
Spain Cord serum (nd-0.22 ng/ml, 
n=308)6,placenta (nd-0.005 ng/g 
,n=49)6,maternal serum (nd-0.16 ng/ml, 
n=308)6 
USyy hair =(2.2-1020 ng/g,n=50), 
fingernail=(2.1-1460 ng/g, n=50) 
,toenail (2.1-1600 ng/g,n=50), 
serum=(1.1-108 ng/g lw, n=50) 
Egypt57 Serum = (<LOQ-6.11 
ng/glw,n=32) 
 
In rats (oral,28 days) disturbed 
redox homeostasis, induced liver 
microsomal enzymes & fatty 
degeneration in liver.12 
In rodents-thyroid hormone 
disruption, developmental 
neurotoxicity, some changes of 
fetal development, and hepatotoxic 
effects.13 
-In male rats reduced sperm 
production and delayed onset of 
puberty.14             
 
 
 
 
 
Penta-BDE is more toxic than octa- 
and deca-BDE -LD50 in rats -0.5-
5g/kg13 
 
Induces mitochondrial 
impairment.15  
Immune modulating effects16 
 
 
BDE-100 
 
Polyurethanes (10-18%) 
Present in (7.8-13%) 
 
H= (<dl-17 ng/g)4 
 (0.75-16 ng/g ,n =45)5 
O = (<dl-79)4 
(1.9-120, n=47 ng/g)5 
 
UK Breast milk (<0.05-1.86 ng/g lw)7 
Serum (0.57-80 ng/g lw, n= 20)2, breast 
milk (0.07-2.19 ng/g lw, n=6)2 
China hair (0-98 ng/g,dw & serum (nd -19 
ng/g lw ,n =32)3 
US56 hair =(0.48-176 ng/g,n=50), 
fingernail=(0.74-274 ng/g, n=50) 
,toenail (0.99-304 ng/g,n=50), 
serum=(0.49-32 ng/g lw, n=50) 
Egypt57 Serum = (<LOQ-3.29 
ng/glw,n=32) 
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BDE-153 
 
Plastics,textiles,coatings 
and electrical & electronic 
appliances 
 
H = (<dl-110 ng/g)4 
 (0.025-24 ng/g ,n =45)5 
O=(<dl-99)4(0.025-190,n=47 ng/g)5 
 
UK Breast milk (<0.06-4.57 ng/g lw)7, 
Serum (0.12-4.0 ng/g lw, n= 20)2, breast 
milk (0.70-1.68 ng/g lw, n=6)2 hair (1-62 
ng/g,dw China serum (5 -82 ng/g lw, n=32)3 
Belgium Adipose tissue (0.70-25.1 ng/g lw, 
n=53)18 
US56 hair =(1.4-78 ng/g,n=50), 
fingernail=(2.2-135 ng/g, n=50) 
,toenail (3.3-180 ng/g,n=50), 
serum=(2.7-55 ng/g lw, n=50) 
Egypt57Serum = (<LOQ-3.78 ng/glw,n=32) 
 
In neonatal mice impairs learning, 
memory and decreases 
hippocampal cholinergic receptors 
in adult mice. 
 
BDE-183 
 
Styrene Copolymers (12-
15%) 
  
H = (<dl-550 ng/g)4 
 (<0.13-51 ng/g ,n =45)5 
O = (<dl-24)4(0.065-220, n=47 
ng/g)5 
UK Serum (<0.03-0.33 ng/g lw, n= 20)2, 
breast milk (0.02-0.23 ng/g lw, n=6)2 
China hair (1-11 ng/g,dw & serum (3 -162 
ng/g lw, n=32)3 
Belgium Adipose tissue (<Decision limit-
15.4 ng/g lw, n=53)18 
Egypt57Serum = (<LOQ-2.22 ng/glw,n=32) 
"may cause harm to unborn child", 
and "possible risk of impaired 
fertility".(IRIS, EPA) 
Decrease in serum thyroxine T4 in 
rats. 
Delayed neurotoxic effects. 
 
BDE-209 
 
HIPS (11-15%) 
Polyamides (13-16%) 
Polyolefins (5-8%) 
H= (<dl-2200000 ng/g)4 
 (160-370000-51 ng/g,n =45)5 
O=(620-280000)4(200-110000, 
n=47 ng/g)5 
UK Breast milk (<0.06-0.92 ng/g lw)7 
Serum (<0.03-0.33 ng/g lw, n= 20)2, breast 
milk (0.02-0.23 ng/g lw, n=6)2 
China hair (1-11 ng/g,dw & serum (3 -162 
ng/g lw, n=32)3 
US56 hair =(1.2-950 ng/g,n=50), 
fingernail=(1.8-706 ng/g, n=50) 
,toenail (1.9-840 ng/g,n=50), 
serum=(3.1-44.0 ng/g lw, n=50) 
Egypt57Serum=(<LOQ-21.39 ng/glw,n=32) 
Suggestive evidence of 
carcinogenic potential (EPA,2006b) 
Decrease in serum T3,increase in 
TSH19 
Changes in sperm’s motion  
velocity, sperm count20 
Liver enlargement, induced hepatic 
EROD,PROD and UGT activities.21 
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HBCD 
 
Thermal insulation 
XPS & EPS), Fabrics, 
Furniture and casing of 
electronics (HIPs)         
(0.8-4%) 
 
∑HBCD H = (140-140000 ng/g)4 
(50-110000-51ng/g,n =45)5 
O=(90-6600)4 (150-6400, n=47 
ng/g)5 
 
USA Adipose tissue (n=20)-<0.0026-2.41 
ng/glw)22 
Sweden Milk (<0.20-2.4 ng/g lw, 
n=33)23,(0.4-20 ng/g lw,n=85)23, 
Netherland cord serum (<0.16-4.2 ng/g 
lw,n=12)23, Maternal serum (<0.16-7.0 ng/g 
lw,n=78)23 
HBCDs are cytotoxic in Hep G2 
cells –γ-HBCD >β-HBCD > α-
HBCD by ROS formation.24 
Developmental toxic.25 
HBCD induces liver fatty acids and 
modulates thyroid hormone 
receptors  genes 26 
 
TBBP-A 
 
Epoxy resin (19-33%) 
Polycarbonate & phenolic 
resins in printed circuit 
boards 
 
H = (<0.06-382 ng/g, n =35)27 
O = (<0.06-382 ng/g, n =140)27 
 
USA Adipose tissue (n=20)-<0.0033-0.464 
ng/glw)22 
UK Milk = (<0.04-0.65 ng/glw, n=34)29 
France Milk = (34-9400 pg/g lw,n =26)30 
Maternal serum = (2-783 pg/g fw,n =26)30  
cord serum = (2-1012 pg/g fw, n=26) 30 
LD50 > 5 g/kg in rats, acts as a 
thyroid and oestrogen agonist, 
neurotoxic, immunotoxic 
(endocrine disruption)28 
Reduced fetal weight, increased 
malformations, and increased fetal 
death in rats.(WHO,1995) 
 
TCEP 
 
Additive plasticiser, PUF 
and upholstered fabrics & 
textiles (furniture),roof 
insulation  
 
H = (<0.06-28 µg/g, n =10)31 
H = (138-6265 ng/g, n =10)32 
China Serum = (200.0–958.2 ng/g lipid, 
n=10)33 Japan Milk  (ND-20 ng/g lw, n 
=20) Payatas (ND-152 ng/g lw, n =20) 
USyy hair =(60-2740 ng/g,n=50), 
fingernail=(93-1860 ng/g, n=50) 
toenail (100-150 ng/g,n=50), 
Carcinogenic for animals (WHO 
1998) is a neurotoxin in rats and 
mice.34 
TCEP  increased both 17-estradiol 
(E2) and testosterone (T) 
concentrations in H295R cells.35 
 
TCIPP 
 
Polyurethane (PU) rigid 
and flexible foam 
 
 
  
 
H = (2.4-370 µg/g, n =10)31 
H = (18331-1010000 ng/g, n =10)32 
U.S BCIPP Urine =Mothers (<0.12-0.64 
pg/ml, n=22)36, children (<0.12-0.46 pg/ml, 
n=26)36  U.S Hand wipe = (Geo mean 45.4 
2 ng  ,max = 255 ng, n=38)54 
BCIPP Urine = max = 0.57 ng, n=40)54 
USyy hair =(100-9840 ng/g,n=50), 
fingernail=(74-2410 ng/g, n=50) 
toenail (90-5150 ng/g,n=50), 
Potentially Carcinogenic.37 
It increases both 17-estradiol (E2) 
and testosterone (T) concentrations 
in H295R cells. and  could alter sex 
hormones.38 
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TDCIPP 
 
 
flexible polyurethane 
foams for upholstered 
furniture and automotive 
products  (EU, 2009) 
 
H = (0.11-740 µg/g, n =10)31 
H = (346-3792 ng/g, n =10)32 
 
U.S BDCIPP Urine =Mothers (0.37-11.0 
pg/ml, n=22)36, children (0.89-251 pg/ml, 
n=26)ee Hand wipe = (Geo mean 108.3 ng  
,max = 535 ng, n=38)54 
BDCIPP Urine = (Geo mean 2.321 ng  max 
= 21.21 ng, n=40)54 
Norway Female (Finger nails   = 63.5 ± 52, 
n=4) (Toenails = 41.9 ± 26, n=4) Male 
(Finger nails = 54.0 ± 72, n=5) (Toenails = 
27.9 ± 6, n=2) 55 
US hair =(70-10490 ng/g,n=50) 
fingernail=(90-1410 ng/g, n=50) 
toenail (75-2300 ng/g,n=50) 56 
 
Developmental toxicity in 
zebrafish39 and showed 
neurotoxicity in rats40 
 
TPhP 
 
Vinyl automotive 
upholstery and in cellulose 
acetate articles; also as 
ingredient in FM-550 
flame retardant 
formulation 
 
 
H = (0.27-170 µg/g, n =10)31 
H = (190-9549 ng/g, n =10)32 
China Serum = (1.3–4.2 ng/g lipid, n=10)33 
U.S DPHP Urine =Mothers (<0.18-68.7 
pg/ml, n=22), children (0.68-140 pg/ml, 
n=26)36 
U.S Hand wipe = (Geo mean =22.41ng  
,max=416.7 ng, n=38)54 DPHP Urine = (Geo 
mean =1.137 ng  max= 26.77 ng, n=40)54 
Norway Female (Finger nails DPHP = 
40002 ± 106, n=4) (Toenails = 6815 ± 209, 
n=4) Male (Finger nails DPHP = 80.5 ±180, 
n=5) (Toenails = 18.5 ± 66, n=2) 55 
USyy hair =(70-4710 ng/g,n=50) 
fingernail=(110-59800 ng/g, n=50) 
toenail (54-232900 ng/g,n=50) 
ER and/or ER agonistic activity. 
Immunomodulating agent and 
immunotoxic.42 neurotoxic43 
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      TCP 
 
Additive in plastics and 
lubricant oils (Pubchem) 
 
H = (0.01-5.6 µg/g, n =10)31 
H = (83-1052 ng/g, n =10)32 
 
China TmCP Serum = (3.3–23.1 ng/g lipid, 
n=10)33 
Norway Sum of all isomers  
Hair =Mothers(<2-134 ng/g, n=48)50, 
children (<2 -74 ng/g, n=54)50 
Induces immunotoxicity,testicular 
toxicity and neurotoxicity in 
animals. Inhibition of esterases 
enzyme- AChE and also inhibits 
neurotoxic esterases45 OPIDN–
paralysis of lower and upper 
extremities. Saligenin cyclic-o-tolyl 
phosphate (SCOTP), an activated 
metabolite of TOCP ( one of the 
isomer of TCP), markedly inhibited 
NTE activity in spermatogonial 
stem cells and decreases the sperm 
count in mouse testis)44 
 
EHDPP 
Primarily as a flame 
retardant in plastics and 
flexible PVC and food 
packaging in 
US.(Environment agency 
2009a) 
 
H = (0.29-11 µg/g, n =10)31 
H = (292-9172 ng/g, n =10)32 
 
Sweden blood donor plasma 0.73-1.2 μg/g 
plasma , n=3  
Norway Hair =Mothers(5-265ng/g, n=48)50, 
children (2-346 ng/g, n=54)50 
 
Dose related changes in blood, 
liver, kidney, adrenal glands, testes 
and ovaries in rats (375-425 mg/kg 
day in diet for 90 days study.(UK 
environ. Risk evaluation report).  
 
TnBP 
 
Plasticizer nitrocellulose & 
cellulose acetate 
 
H = (< 0.03-1.2 µg/g, n =10)31 
H = (210-479 ng/g, n =10)32 
 
China Serum = (1.8–46.5 ng/g lipid, 
n=10)33 
Germany Metabolite-DPP found in crew 
members in airlines, 0.2-1.1µg/L in urine.49 
Norway Hair =Mothers(5-672 ng/g, 
n=48)50, children (3-150 ng/g, n=54)50 
 
 
urinary bladder hyperplasia,47 
AR/GR antagonistic activity & 
PXR agonistic activity.48 
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TEHP 
 
Plasticiser in PVC in low 
temperature applications 
and in clothing. 
(OEHHA,2011a) 
 
H = (96.2-465 ng/g, n =10)32 
 
Norway Hair =Mothers (<1.0-53ng/g, 
n=48)50, children (<1.0-114 ng/g, n=54)50 
 
Follicular cell hyperplasia of the 
thyroid gland in male and female 
B6C3F1 mice, some evidence of 
carcinogenicity in female B6C3F1 
mice (1,000 mg/kg).51 
 
TBOEP 
 
Floor polishes, rubber 
stopper & plastics 
 
H = (225-58745 ng/g, n =10)32 
Norway Serum = (Mean 5.7 ng/g lipid, 
n=10)33 Hair =Mothers(14-1253ng/g, 
n=48)50, children (34-2411 ng/g, n=54)50 
Norway Female (Finger nails   = 3.8 ng/g, 
n=1) (Toenails <2.2 ng/g) Male (Finger nails 
= <2.2 ng/g , n=1) (Toenails =4.1 ng/g, 
n=1)55 
 
PXR agonist.52 Increases both 17-
estradiol (E2) and testosterone (T) 
concentrations in H295R cells and 
could alter steroidogenesis or 
estrogen metabolism.53 
  
    PBEB 
 
Thermoset Polyster resins 
and thermoplastic resins. 
 
H= (< 0.010-21 ng/g,n =45)5 
O=(0.36-10, n=47 ng/g)5 
 
US56 hair =(0.1-2.6 ng/g,n=50), 
fingernail=(0.25-1.1 ng/g, n=50) 
,toenail (0.20-1.1 ng/g,n=50), 
serum=(ND) 
 
It is a brominated analogue of 
ethylbenzene which is listed as 
known to cause cancer under 
Proposition 65. 
 
EH-TBB 
 
Widely used in furniture 
foam. Found in baby 
products containing 
polyurethane foam. 
Component of FM-550 
(40-70%) 
 
H= (< 0.010-85 ng/g,n =45)5 
O=(<0.010-2000, n=47 ng/g)5 
H = (2.5-32.0 ng/g, n =10)32 
 
 
 
 
 
 
US  hair =(7.6-4540 ng/g,n=50), 
fingernail=(11.0-1210 ng/g, n=50) 
,toenail (13.0-2310 ng/g,n=50), 
serum=(1.3-54.0 ng/g lw, n=50)56 
Urine TBBA = Mothers (<3.0-62.2 pg/ml 
,n=22) TBBA Children (<3.0-84.9 
pg/ml,n=26) Canada63 maternal serum = 
(ND-68 ng/g lw, n= 102), milk = ND-24 
ng/g lw, n= 105 
 
 
EH-TBB affects fecundity in 
medaka fish.Invitro tests showed 
that EHTBB modulate endocrine 
function through interactions with 
estrogen (ER) and androgen 
receptors (AR) and via alterations 
to synthesis of 17-β-estradiol (E2) 
and testosterone (T).58 
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BEH-TEBP 
 
 polyurethane 
foam in furniture and  
juvenile products, often as 
a replacement for 
pentaBDE  
 
 
H= (16-3500 ng/g,n =45)5 
O=( 54-25000, n=47 ng/g)5 
H = (18.0-234 ng/g, n =10)32 
 
 
 
 
US56 hair =(13-2600 ng/g,n=50), 
fingernail=(18-1120 ng/g, n=50) 
,toenail (18-1990 ng/g,n=50), 
serum=(19-69 ng/g lw, n=50) 
Canada63 maternal serum = (ND-164 ng/g 
lw, n= 102), milk = ND-19 ng/g lw, n= 105) 
 
Endocrine disruptive 
compound.58,62 
In a porcine primary testicular cell 
mode TBPH produces greater conc. 
of Testosterone and Estradiol by 
regulation of CYP11A.59 
 
BTBPE 
 
acrylonitrile-butadiene-
polystyrene, and high 
impact polystyrene 
 
H = (<dl-1900 ng/g)4 
 (0.01-110 ng/g ,n =45)5 
O = (<dl-40)*(0.019-4700000, 
n=47 ng/g)5 
H = (<1.3-100.0 ng/g, n =10)32 
 
 
 
Canada63 maternal serum = (3.9-16 ng/g lw, 
n= 102), milk = n.d 
Metabolism of BTBPE  by 
ingestion in mammals, ether 
cleavage of  BTBPE may yield 2, 
4,6-tribromophenol which is a 
neurotoxicant in Sprague Dawley 
rat.60 Induced AhR- and CXR 
mediated CYP responses, in 
addition to affecting deiodinase 
transcription in in vitro-in ovo 
toxicity testing.61 
 
HBB 
 
Used in manufacturing of 
paper,woods,textiles,plasti
cs and electronic goods  
 
H= (< 0.0030-12 ng/g,n =45)5 
O=(<0.030-84, n=47 ng/g)5 
US56 hair =(0.11-9.0 ng/g,n=50), 
fingernail=(0.20-3.0 ng/g, n=50) 
,toenail (0.24-5.3 ng/g,n=50), 
serum=(2.1 ng/g lw, n=50) 
Japan adipose tissue = 2.1-4.1 ng/g wet wt  
& 1,2,4,5 TBB metabolite.65 
Elevation in GST activity in 
zebrafish embryo model.64 
effects on liver, enzyme inhibition, 
induction, or change in blood or 
tissue levels and on esterases in rats 
when given oral continuously.66 
 
DPTE 
Flame retardant in 
extrusion grade 
polypropylene. 
   
Not detected in indoor dust 
 
 
  Not found any study 
 
 
Substructures similar to both 2, 3,-
dibromo-1-propanol and 2, 4, 6-
TBP. 2, 3-Dibromo-1-propanol is 
listed under Proposition 65 as 
known to cause cancer. 2,4,6-TBP 
is a thyroid hormone disrupting 
chemical.69 
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PBT 
 
Unsaturated polyesters, 
polyethylene,polypropylen
es,polystyrene, SBR-latex, 
textiles, rubbers, ABS 
( NPCA TA-2462/2008) 
 
 
H= (< 0.010-90 ng/g,n =45)5 
O=(<0.010-59, n=47 ng/g)5 
 
 
China Serum = (Highest 5.7  ng/g lipid, 
n=10)33 
 
Subacute and subchronic studies 
mild dose-dependent 
histopathological changes were 
observed in the thyroid, liver and 
kidney of rats fed PBT diets.68 
       
      PBBz 
 
Not available 
 
H= (< 0.010-12 ng/g,n =45)5 
O=(< 0.010-23, n=47 ng/g)5 
Serum = (Highest 10.0  ng/g lipid, n=10)33 
US 56 hair =(0.33-4.9 ng/g,n=50), 
fingernail=(0.90-1.3 ng/g, n=50) 
,toenail (0.72-2.9 ng/g,n=50), 
serum=(0.99-3.7 ng/g lw, n=50) 
 
Not available  
 
TBECH 
(DBE-DBCH) 
 
used as an additive in 
polystyrene and 
polyurethane products 
 
α-TBECH–H  (<0.7-5.6 ng/g, 
n=10)32 
β-TBECH-H(<0.6-1.7ng/g, n=10)32 
 
                Not found 
TBECH is an endocrine disrupting 
chemical in humans, to bind and 
activate human androgen receptors 
(hAR), γ- and δ-isomers are more 
potent activators of hAR than the α- 
and β-isomers, induce prostate 
specific antigen at 100 nM amounts 
in vitro.69 
 
DBDPE 
 
electrical and electronic 
equipment, wire, textile 
coatings and blends, and 
polyester products, high  
impact polystyrene (HIPS) 
  
H = (<dl-3400 ng/g)4 
 (<1.2-2300 ng/g ,n =45)5 
O=(<dl-860)4(<1.20-17000,n=47 
ng/g)5 
H (<531-39221 ng/g, n  =10)32 
 
Canada63 maternal serum = (ND-123 ng/g 
lw, n= 102), milk = (n.d-25 ng/g lw, n= 105) 
 
 
 
 
 
 
Its ill effects on hepatocyte 
detoxification metabolism and its 
oestrogenicity were confirmed by 
using the in vitro hepatocyte 
assay.70 
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Syn/anti DP 
 
Thermoplastic materials 
(PE, PVA, PP) in 
electronic wire and cable 
applications (5-35%) 
(ECHA 2007) 
 
 
 
 
 
Syn-DP H= (<0.26-28 ng/g,n =45)5 
O=(< 0.26-640, n=47 ng/g)5 
Anti-DP H= (<0.15-170 ng/g,n 
=45)5 O=(< 0.15-2100, n=47 ng/g)5 
 
 
 
Syn –DP US56 hair =(0.10-4.0 ng/g,n=50), 
fingernail=(0.22-1.3 ng/g, n=50) 
,toenail (0.24-2.3 ng/g,n=50), 
serum=(0.69-1.3 ng/g lw, n=50) 
Anti–DP US56 hair =(0.36-3.7 ng/g,n=50), 
fingernail=(0.70-3.4 ng/g, n=50) 
,toenail (0.59-5.4 ng/g,n=50), 
serum=(0.98-1.0 ng/g lw, n=50) 
DP interferes with metabolism and 
was associated with proteins related 
to apoptosis and cell differentiation. 
effects on the generalized stress 
response, small G-protein signal 
cascades, Ca2+signaling pathway, 
and metabolic process, and may 
induce apoptosis in the liver of 
juvenile Chinese sturgeon.72 
DP accumulates in the liver when 
rats were exposed at 10 and 100 
mgkg /g.73 
 
2,4,6 TBP 
 
 
 
 
Epoxy resins, phenolic 
resins, 
polyester resins, 
polyolefins 
 
              Not found 
 
Nicaraguan women waste disposal sites 
increases TBP levels 
 
Oral LD50 -1995 (Male) and 1819 
mg/kg (Female) 
Signs of toxicity included 
decreased motor activity, nasal 
discharge, lacrimation, tremors, 
prostration, clonic convulsions and 
developmental abnormalities and 
behavioral changes of the newborn 
pup.71 
 
1- (Alaee et al. 2003) 2- (Bramwell et al. 2014) 3- (Zheng et al. 2014) 4- (Stuart et al. 2008) 5 - (Tao et al. 2016b) 6 - (Vizcaino et al. 2014) 7 - 
(Abdallah and Harrad 2014) 8- (Jin et al. 2010), 9-(Chan and Chan 2012), 10-(Hallgren et al. 2001), 11 -(Lema et al. 2007) 12 -(Bruchajzer et al. 
2010) 13- (Gill et al. 2004) 14- (Kuriyama et al. 2005) 15 - (Pereira, de Souza and Dorta 2013) 16-(Mynster Kronborg et al. 2016) 17-(Viberg, 
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Fredriksson and Eriksson 2003) 18 -(De Saeger et al. 2005) 19 -(Lee et al. 2010) 20- (Tseng et al. 2006) 21- (Zhou et al. 2001) 22- (Johnson-
Restrepo, Adams and Kannan 2008) 23- (Covaci et al. 2006b) 24- (Zhang et al. 2008) 25- (Du et al. 2012) 26-(Yamada-Okabe et al. 2005) 27-
(Abdallah, Harrad and Covaci 2008a) 28- (Kitamura et al. 2002), 29- (Abdallah and Harrad 2011a) 30 - (Antignac et al. 2008) 31 -(Harrad, 
Brommer and Mueller 2016) 32-(Kademoglou et al.) 33-(Li et al. 2017) 34-(Tilson et al. 1990, Umezu et al. 1998) 35-(Liu, Ji and Choi 2012) 
36-(Butt et al. 2014b), 37- (Ni, Kumagai and Yanagisawa 2007) 38-(Liu et al. 2012) 39-(Wang et al. 2013) 40 -(Dishaw et al. 2011) 41- (Kojima 
et al. 2013) 42-(Fautz and Miltenburger 1994, Esa, Warr and Newcombe 1988) 43 -(Veronesi, Padilla and Newland 1986) 44-(Chen et al. 2012) 
45 -(Abou-Donia 1981) 46- (Jonsson and Nilsson 2003) 47-(Auletta, Weiner and Richter 1998) 48- (Kojima et al. 2013) 49- (Schindler et al. 
2014)  50-(Kucharska et al. 2015a) 51-(1984) 52-(Kojima et al. 2013) 53-.(Liu et al. 2012) 54-(Hammel et al. 2016) 55-(Alves, Covaci and 
Voorspoels 2017) 56-(Liu et al. 2016) 57- (Abdallah, Zaky and Covaci),  58-(Saunders et al. 2015),59-(Mankidy et al. 2013) 60-(Lyubimov, 
Babin and Kartashov 1998) 61-(Egloff et al. 2011) 62-(Patisaul et al. 2013b) 63- (Zhou et al. 2014), 64-(Usenko et al. 2016), 65-(Yamaguchi et 
al. 1988b) 66-(Yamaguchi, Kawano and Tatsukawa 1988a) 67-(Hamers et al. 2006, Suzuki et al. 2008, Yamaguchi et al. 1988b), 68-(Chu et al. 
1987), 69-(Khalaf et al. 2009), 70-(Nakari and Huhtala 2010). 71- Simonsen et al.72-(Liang et al. 2014) 73-(Li et al. 2013) 
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1.2: Routes of Human Exposure to FRs 
While it is established that the diet (consumption of contaminated food) constitutes and 
important source of non-occupational exposure to BFRs, it appears that ingestion of indoor 
dust, dermal contact with dust/consumer products and inhalation of indoor air could also be 
substantial pathways of exposure (Abdallah et al. 2008a, Frederiksen et al. 2009, Watkins et 
al. 2011). Contact with indoor dust has been highlighted as an important contributor 
especially for young children because they spend a large portion of their time on the floor 
exploring their environment and they tend to place their hands or other objects or dust in their 
mouth. However, there remains uncertainty about how such contact with dust occurs. The 
principal pathway highlighted to date is oral ingestion. Various studies have reported on 
levels of different FRs in various environmental and human matrices (Covaci et al. 2011b, 
Covaci et al. 2009, Harrad et al. 2010b, Law et al. 2014, van der Veen and de Boer 2012b). 
Studies from North America report indoor dust (via ingestion or dermal contact) as the major 
exposure pathway for all age groups to PBDEs contributing 70-80% to the average overall 
daily exposure (Trudel et al. 2011b, Lorber 2007). In contrast to PBDEs, only a few studies 
are available that address human exposure to NBFRs and PFRs (Covaci et al. 2011b, 
Stapleton et al. 2011, Ali et al. 2012c). Ingestion of FRs is observed particularly more in 
toddlers and young children while other exposure pathways make substantial contributions to 
the overall adult intake of BFRs (Abdallah et al. 2008a, Harrad et al. 2010b, Harrad et al. 
2008).Furthermore, the observed association between BFRs in dust and body burdens may at 
least partly arise because BFRs in dust are an indicator of (an)other exposure hazard that 
influences body burdens. Specifically, body burdens may be influenced by dermal uptake via 
direct contact with materials containing FRs. Hence, furthering understanding of dermal 
uptake of FRs from dust and FR-treated materials is an important research gap. 
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Current thinking about exposure via dust ingestion for FRs is that although we think there is a 
correlation between FRs in indoor dust and human body burdens, we do not yet know the 
exact mechanisms(s) via which FRs transfer from dust into the body (e.g. whether it is 
ingestion or dermal uptake, most attention to date has focused on ingestion), or indeed 
whether dust is just an indicator of the levels in consumer materials and the "real" link is 
between such materials and body burdens. This paucity of information was evident in the EU 
risk assessment reports on TBBPA (EU Risk Assessment Report 2006) and BDE-209 (EU 
Risk Assessment Report 2002) where the lack of experimental data has led to the assumption 
of dermal absorption efficiencies based on consideration of compound-specific 
physicochemical properties and extrapolation from data available for PCBs. Furthermore, 
several authors have discussed the absence of experimental data on dermal absorption of 
various FRs and highlighted the potential inaccuracies of current estimates of human 
exposure to these FRs owing to a general lack of knowledge on the percutaneous route 
(Boyce, et al.2009;U.S EPA 1992) (Garner and Matthews 1998, Trudel et al. 2011b). 
Therefore, the lack of experimental information on human dermal uptake of FRs from dust 
and source materials represents an important research gap that hampers accurate assessment 
of human exposure to FRs. However, efforts to fill this gap are hindered by several 
difficulties including: ethical issues encountered with human studies, inter-species variation 
in dermal structure and uptake that cast doubt on the accuracy of extrapolation or allometric 
scaling of animal data to humans, and tighter regulations on in vivo tests involving 
animals.(Gibbs et al. 2013, Kandarova et al. 2013, Tornier et al. 2010) 
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Fig 1.4: Major pathways of human exposure to FRs. 
 
 
1.3: The skin as a barrier for systemic exposure to xenobiotic chemicals.  
Skin is multi-layered and is the largest body organ with a surface area of ~ 2 m2 and weighing 
about 5 kg in adult humans (Godin and Touitou 2007). It protects the body from the 
surrounding environment, thus forming an efficient barrier for hazardous chemicals. Human 
skin is formed of 3 main layers, namely: the epidermis, dermis and hypodermis (Figure 1.2). 
The epidermis is the outermost layer and is a non-vascular layer with a protective role as a 
barrier to penetration of chemicals to the underlying vascular dermis. The healthy human 
epidermis is further classified into 4 layers (stratum corneum, stratum granulosum, stratum 
spinosum and stratum basale) separated from the dermis by the basement membrane 
(Breitkreutz et al. 2013).The barrier properties of the skin lie mainly within the stratum 
corneum (SC), which has about 16 layers and takes about two weeks to completely 
desquamate (Hoath and Leahy 2003). The SC is linked to the protein-enriched corneocyte 
layers and the intercellular membrane lipids, mostly composed of ceramides, cholesterol, and 
free fatty acids (Proksch, Brandner and Jensen 2008). This highly hydrophobic layer is 
composed of differentiated non-nucleated cells, corneocytes, which are filled with keratins 
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and embedded in the lipid domain. Percutaneous penetration of molecules through the SC 
occurs mainly via passive diffusion but may also occur via sweat glands and hair follicles 
directly to the dermis. Although little is known about the expression and function of influx 
transport proteins in human skin and their role in dermal uptake of xenobiotics, the role of 
organic anion transporting polypeptides (OATP) in mediating the active transport process of 
large organic cations via human keratinocytes has been highlighted (Schiffer et al. 2003). 
Chemical residues limited to the epidermis will be eliminated from the exposed skin by 
desquamation and will not be available for systemic distribution (Aggarwal et al. 2014). 
                                  
                                            Fig 1.5: Anatomy of the human skin. 
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1.4: Significance of dermal absorption as a pathway of human exposure to FRs.  
While numerous studies have highlighted the importance of indoor dust ingestion as a 
pathway for human exposure to various FRs, few reports have discussed human dermal 
exposure to such contaminants (Stapleton et al. 2012a, Stapleton et al. 2008b, Watkins et al. 
2011). Watkins et al. 2011 reported a strong positive correlation between PBDE levels on 
hand wipes (assumed to result from hand contact with contaminated dust or flame-retarded 
products) and PBDE concentrations in serum from American adults. While concentrations of 
PBDEs in indoor dust were strongly correlated with those in hand wipes, and infrequent 
hand-washers had 3.3 times the levels of PBDEs in their hand wipes than the frequent hand-
washers; correlation could not be established directly between PBDE concentrations in 
indoor dust and their levels in serum. Similarly, Stapleton et al. 2014 (Stapleton et al. 2014) 
found that PBDE residues measured on children’s hand wipes were a strong predictor of 
serum PBDE levels. Carignan, et al. 2013 (Carignan et al. 2013), reported 2-3 times increase 
of median concentrations of penta-BDE, EH-TBB, and BEH-TEBP in paired hand wipe 
samples of 11 gymnasts before and after practice. In a more recent contribution, significant 
associations between concentrations of TCEP, TCIPP, TDCIPP, HBCD, EH-TBB, and BEH-
TEBP in children’s hand wipes and house dust were observed (Stapleton et al. 2014). This 
opens up the possibility that FRs in dust may also be an indicator of another exposure 
pathway, such as direct dermal uptake of FRs present in treated goods (e.g. games consoles, 
remote controls, and fabrics). A pivotal issue for risk assessment studies is the influence of 
indoor contamination with FRs on human body burdens. Understanding of this remains 
incomplete. One approach is that of Lorber (2008), who used a simple pharmacokinetic (PK) 
model to predict the body burdens of PBDEs in American adults using intake data from 
different exposure pathways. Predicted body burdens were compared with measured data and 
the relationship between external and internal exposure discussed. Since then, a few studies 
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have applied similar PK models with slight adjustments to further understanding of the 
relationship between concentrations of PBDEs, HBCD and TBBP-A in the environment and 
human body burdens (Abdallah and Harrad 2011b, Johnson-Restrepo and Kannan 2009, 
Trudel et al. 2011b). As well as identifying various research gaps including the 
bioavailability of FRs following ingestion of indoor dust and the elimination half-lives of 
these compounds in human, one major outcome of such PK studies is the highlighted 
potential importance of dermal contact with indoor dust and/or FR-containing items as a 
pathway of exposure to BFRs. To illustrate, dermal uptake was reported as the 2nd most 
important contributor (following dust ingestion) to PBDE body burdens of Americans. This 
was despite a very conservative assumption – made in the absence of experimental data for 
PBDEs - that only 3 % of PBDEs with which dermal contact occurred (via adherence of 
indoor dust to the skin) were absorbed (Lorber 2008a). Moreover, a recent PK model reported 
ingestion of diet and dust, as well as dermal exposure to dust to constitute the major factors 
influencing human body burdens of PBDEs in both Americans and Europeans. Once again, 
these conclusions were founded on low assumed values of dermal absorption efficiency (2.5-
4.8%) (Trudel et al. 2011b). Neither study considered potential dermal absorption following 
contact with FR-treated items and assumed percutaneous penetration fractions based on 
values reported for dermal absorption of dioxins and PCBs from soil in laboratory animal 
models (Trudel et al. 2011b, Lorber 2008a). Boyce et al. (2009) applied a Monte Carlo-based 
mathematical approach for assessment of human exposure to TBBPA, DBDPE and BDE-209 
via indoor dust ingestion and dermal contact. Based on physicochemical properties, analogy 
with data for PCBs and the absence of any chemical-specific studies, dermal absorption 
values of 10%, 0.1% and 1% were used for TBBPA, DBDPE and BDE-209, respectively. 
Results revealed dermal contact with indoor dust made significant contributions (15 - 40%) to 
estimates of overall human exposure to these BFRs in North America and Europe. The 
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authors highlighted that at such significant contribution levels; inaccuracies in the dermal 
absorption factors applied could have dramatic effects on exposure assessments (Boyce, et al. 
2009).  
1.5: Transdermal metabolism of xenobiotics. 
In the past few years, the cutaneous metabolic activity of skin has been identified and 
widely studied. Evidence shows that active enzymes in viable skin tissues have a capacity for 
bio-transforming topically applied compounds, with a consequence of an altered 
pharmacological effect (Zhang and Michniak-Kohn 2012). The SC, which contains a mixture 
of cholesterol, fatty acids, and ceramides not only act as epidermal barrier but also help in 
xenobiotic metabolizing. There is increasing evidence that xenobiotic metabolizing enzymes 
and transport proteins function as a second biochemical barrier of the skin (Gundert-Remy et 
al. 2014, Esser and Gotz , Wiegand et al. 2014) 
Extensive literature exists on the capacity of human skin to metabolise various chemical 
compounds, however, very little is known about the transdermal metabolism of flame 
retardant chemicals. Human skin cells express at least five different esterases which act on 
simple ester bonds in organophosphate compounds (e.g. paraoxon and bis (4-nitrophenyl) 
phosphate). Recent findings indicate that human skin possesses not only multiple cytochrome 
P450 isoenzymes, but also influx and efflux transporter proteins. While the pattern of 
cytochrome P450 isoenzymes in the skin differs from the pattern in the liver. It seems likely 
that the skin can participate in both Phase I (e.g. oxidation, reduction and hydrolysis) and 
Phase II (e.g. glucuronidation and acetylation) metabolic reactions (Gundert-Remy et al. 
2014, Merk 2009).Garner and Matthews confirmed extra hepatic dermal metabolism of 
mono- to hexa- PCBs in F-344 male rats (Garner and Matthews 1998). Similarly, Hughes, et 
al. 2001 reported in vitro dermal metabolism of BDE-209 and TDCPP in adult female mice. 
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The literature suggests that dermal biotransformation may play an important role in the 
ultimate fate and bio-availability of FRs in the skin.  
1.6: In vivo dermal bioavailability studies 
Human dermal uptake of environmental contaminants (e.g. polycyclic aromatic 
hydrocarbons, phthalates and pesticides) from soil and sediment has been reviewed (Spalt et 
al. 2009), however very little is known about the uptake of flame retardants via skin (Table 
1.5). In this regard, Schmid et al. 1992 studied the dermal absorption of PCBs in one human 
volunteer (52 year old male, 65 kg body weight) (Schmid, Bühler and Schlatter 1992). The 
volunteer was exposed to a mixture of 8 tetra- to hepta- 13C-PCBs for different time spans 
using cotton cloth and aluminium foil as carrier materials to mimic real life situations of skin 
contact with PCB-contaminated clothes or metal surfaces. After exposure the skin was 
washed subsequently with water and ethanol. Non-absorbed 13C-PCBs were determined in 
the washing solvents and in the carrier materials, while the bioavailable fraction was 
measured in plasma samples collected at 0.5-6 days post-exposure. Results revealed low 
percutaneous absorption (PA) of target PCBs equivalent to 6 % of the absorption after oral 
intake of the same amount. The absorption rate was largely dependent on the site of 
administration, on the carrier material (higher from the aluminium foil than the cotton cloth) 
and almost not on the duration of exposure where the percentage uptake remained constant at 
long (8 hours) and short (10 min) exposure times.  
Assessment of human dermal absorption of FRs involving human volunteers is 
limited due to ethical issues (Jakasa and Kezic 2008). In this regard, animal models are used 
when human volunteers are not available. In vivo animal models especially rats have long 
been used by different industrial and regulatory institutions to provide data on various 
toxicokinetic and toxicodynamic parameters, as well as dermal absorption (Zendzian 2000).  
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Table 1.5: Summary of in vivo and in vitro methods applied for studying dermal absorption of FR chemicals. 
Compound 
Skin  
Type 
Study type Dosing 
Exposure 
time 
Absorption (% of administered 
dose) 
Ref. 
BDE-47 
Female 
C57BL/6 
mice 
In vivo 
1 mg/kg bw applied to 2 cm2 
of skin 
5 days 62% 
(Staskal, et 
al. 2005) 
BDE-209 and 
TDCPP 
female 
mice 
(SKH1) 
In vitro 
6, 30 and 60 nmol in THF 
for BDE-209; 20, 100 and 
200 pmol in acetone for 
TDCPP 
24 hrs 
2–20% in skin, 0.07-0.34% in 
receptor fluid for BDE-209. 39–
57% in skin and 28–35% in 
receptor fluid for TDCPP 
(Hughes, et 
al. 2001) 
BDE-47 
Human 
and rat 
skin (350–
410 μm) 
In vitro 
10 mg/cm2 applied in 
acetone. 
24 hrs 
2-15% in 0.9% NaCl receptor 
fluid; 57% and 33% remained in 
cells for human and rat skin, 
respectively. 
(Roper, et al. 
2006) 
BISPHENOL-A 
(Precursor to TBBP-
A) 
Pig Ear 
Skin and 
Human 
skin 
In vitro 
50, 100, 200, 400 and 800 
nmol were applied 
in 60 µL ethanol/phosphate 
buffer (pH 7.4) 
24, 48 
and 
72 h 
Human skin (45.6 ± 6.2%),  pig 
skin (65.3 ± 8.2%)  
BPA–glucuronide formed in 
human skin , corresponding to 7 
± 2, 16 ± 3 and 30.± 3 nmol at 
24, 48 and 72 h, respectively. 
(Zalko, et al. 
2011) 
TBBPA 
Human 
skin & rat 
skin 
In vitro  
 
100 nmol/cm2 C-14 
TBBPA in 10 µL acetone 
24 h 
0.2 % penetrated,3.4 % 
absorbed into the  Human skin 
3.5% penetrated,9.3% absorbed 
(rat skin) 
(Knudsen et 
al. 2015) 
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 Rat  In vivo  
100 nmol/cm2 & 1000 
nmol/cm2 -[14C]-TBBPA 
(100 µL/Kg ) in acetone 
24 h 
 
 
 
72 h  
 7.7 % penetrated,13.6 % 
absorbed (~ 100 nmol/cm2) 
5.3 % penetrated,5.1  % 
absorbed (~ 1000 nmol/cm2) 
30% penetrated,40 % absorbed  
(~ 1000 nmol/cm2) 
(Knudsen et 
al. 2015) 
EH-TBB 
 
Human & 
rat skin 
In vitro 
100 nmol/cm2 –[14C] EH-
TBB in toluene ((5µL) 
24 h 
0.2 % penetrated,24 % 
absorbed, Flux = 11.0 pmol-
eq/cm2/h -human skin 
 2 % penetrated, 51% absorbed, 
Flux = 102 pmol-eq/cm2/h-Rat  
 
(Knudsen et 
al. 2016b) 
  Rat In vivo 
100 nmol/cm2 [14C] EH-
TBB in toluene (5µL) 
24 h 
27.5 % absorbed and 13% 
reached systemic circulation 
(Flux= 464 pmol-eq/cm2/h) 
(Knudsen et 
al. 2016b) 
BEH-TEBP 
Human & 
rat skin 
In vitro 
100 nmol/cm2 [14C] BEH-
TEBP in toluene (5µL) 
24 h 
Penetration <0.01 % in both  
12 % absorption in humans (0.3 
pmol-eq/cm2/h) 
41 % in rats (1.0 pmol-
eq/cm2/h) 
 
(Knudsen et 
al. 2016b) 
 Rat  In vivo  
100 nmol/cm2  [14C]-BEH-
TEBP in toluene ((5µL) 
24 h 
27% absorption, 1.2% reached 
systemic circulation (16.0 pmol-
eq/cm2/h) 
(Knudsen et 
al. 2016b) 
TBP-DBPE 
Human 
skin 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
Receptor fluid = <0.1%  
Epidermis = 11% 
Dermis = 1.6 % 
(Frederiksen 
et al. 2016) 
EH-TBB 
Human 
skin 
(0.8 mm ) 
N =5 F 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
Receptor fluid = 0.2%  
Epidermis = 10 % 
Dermis = 0.6 % 
Kp = 0.16-2.5 * 10-4cm/h 
-do- 
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BTBPE 
Human 
skin 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
Receptor fluid = 0.1 %  
Epidermis = 10 % 
Dermis = 0.7 % 
Kp = 0.16-2.4 * 10-4cm/h 
-do- 
DBDPE 
Human 
skin 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
Receptor fluid = <0.5 %  
Epidermis = 10 % 
Dermis = 1.0 % 
Kp = 0.11-2.2 * 10-4cm/h 
-do- 
BEH-TEBP 
Human 
skin 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
 Receptor fluid = 0.04 %  
Epidermis = 9.5 % 
Dermis = 0.5 % 
Kp = 0.13-1.4 * 10-4cm/h 
-do- 
syn-DP 
Human 
skin 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
Receptor fluid = <0.1 %  
Epidermis = 8.4 % 
Dermis = 0.5 % 
Kp = 0.11-1.9 * 10-4cm/h 
-do- 
anti-DP 
Human 
skin 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
Receptor fluid = 0.2 %  
Epidermis = 7.9 % 
Dermis = 0.8 % 
Kp = 0.16-1.8 * 10-4cm/h 
-do- 
α-HBCD 
Human 
skin 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
Receptor fluid =  0.1 %  
Epidermis = 11 % 
Dermis = 1.0 % 
Kp = 0.22-2.7 * 10-4cm/h 
-do- 
β-HBCD 
Human 
skin 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
Receptor fluid = <0.1 %  
Epidermis = 11 % 
Dermis = 0.8 % 
Kp = 0.17-2.5* 10-4cm/h 
-do- 
γ-HBCD 
Human 
skin 
In vitro 
10-100 and 50-300 ng/cell 
(500 µL ethanol with 20% 
isooctane residue) 
72 h 
Receptor fluid = 0.1 %  
Epidermis = 10 % 
Dermis = 0.8 % 
Kp = 0.15-2.3 * 10-4cm/h 
-do- 
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Similarly, Mayes, et al. 2002 reported PA values of 3.4-4.5 % in Rhesus monkeys exposed to 
PCB-contaminated soil for 24 h. 
The difference between the calculated PA values for PCBs from soil in this study and the 
14% dermal absorption factor used by the USEPA (U.S. EPA 1992) was attributed mainly to 
soil organic content in addition to particle size, skin residence time and contaminant “aging” 
in the soil. The percutaneous absorption of 14C-Aroclor 1260 in test monkeys was determined 
by measuring the radioactivity in excreta (equation 1) (Mayes et al. 2002). 
 
An important point is that the model used in equation 1 and in all in vivo studies in humans or 
surrogate species where the animal is not sacrificed, cannot account for any test compounds 
sequestered within the skin (Mayes et al. 2002, Spalt et al. 2009). This may lead to substantial 
underestimation of the actual dermal uptake of persistent lipophilic compounds which would 
eventually (within days) be systemically absorbed from the skin depot of the exposed 
organism. For such compounds, for which the outcome of concern is typically not acute 
toxicity, inclusion of skin burden is necessary (Spalt et al. 2009). While adjustment for 
excretion following intravenous administration may be employed, this has associated 
uncertainty and presumes no difference in the excretory pattern associated with dermal and 
intravenous administration used as a reference. The importance of this concept of 
contaminant skin depot was confirmed by (Garner and Matthews 1998). These authors 
applied 0.4 mg/kg body weight of a mixture of radiolabelled mono- to hexa- PCBs in acetone 
to a 1 cm2 hairless skin area at the back of adult male F-344 rats. Distribution of radioactivity 
in the dose site and selected tissues was determined by serial sacrifice at time points up to 2 
weeks. Results revealed the dermal penetration of test compounds to vary inversely with 
degree of chlorination and at 48 h ranged from ca. 100 % for mono-PCB to ca. 30 % for 
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hexa-PCB. Although the maximum internal exposure to mono-PCB was at 4 h (37 % of the 
dose present in tissues), only 0.2 % of the absorbed dose remained in the tissues after 2 
weeks. In contrast, tetra-PCB internal exposure was the greatest with ca. 85 % of the total 
absorbed dose present in tissues 72 h post administration. Furthermore, hexa-PCB 
equivalents in tissues continued to rise through 2 weeks postdose (~15 % of absorbed dose) 
since systemic absorption from epidermis depots was still incomplete when the study was 
terminated. While rat skin favoured the rapid absorption of lower chlorinated PCBs; their 
relatively rapid metabolism and elimination, suggests lower body burdens of the less 
chlorinated congeners compared to higher molecular weight PCBs which penetrate less 
rapidly, but persist at the site of exposure and slowly enter the systemic circulation (Garner 
and Matthews 1998). In another contribution, (Garner, Demeter and Matthews 2006a) used 
the same animal model to study the disposition of mono- to hexa- PCBs following dermal 
administration. Results confirmed higher chlorinated PCBs to be slowly absorbed and 
accumulated in the adipose and skin. Interestingly, excretion and metabolic profiles following 
dermal dosing tended to differ from profiles following equivalent intravenous doses. This 
was attributed to first pass metabolism occurring at the dermal dose site. The study further 
suggested that the rate of absorption, and consequently disposition of PCBs following dermal 
exposure, may be mediated, either in part or fully, by transdermal metabolism (Garner et al. 
2006a). 
The dermal absorption of the flame retardant resorcinol bis-diphenylphosphate (RDP) was 
investigated in rats and monkeys. Sprague-Dawley rats and cynomolgus monkeys were 
dermally exposed to 100 mg of 14C-RDP spread over a shaved area representing about 20 % 
of the animal’s surface area. Results revealed ~ 20 % of the dermal dose was absorbed in rats, 
whereas primates absorbed only 10 % of the applied dermal dose (Freudenthal et al. 2000). 
Very little is known about the dermal absorption of BFRs. In an early report, Ulsamer et al. 
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studied the dermal absorption of the banned flame retardant tris (dibromopropyl) phosphate 
(TRIS) in rabbits. The test animals were exposed to radiolabelled 14C-TRIS via sections of 
fabric (10 x 12 cm) placed in contact with skin for 96 h. Results revealed that up to 17 % of 
the applied dose was absorbed when the fabric was wetted with urine. Only 6 % of the dose 
was absorbed when the cloth was wetted with simulated sweat, which was slightly higher 
than the absorption (4 %) from a dry cloth (Ulsamer, Porter and Osterberg 1978). A more 
recent study used a female C57BL/6 mice model to assess the dermal bioavailability of BDE-
47. Test animals were exposed to 1 mg/kg body weight of 14C-BDE 47 in acetone applied to a 
hairless 2 cm2 skin patch. Results revealed ~62 % absorption of the administered dose after 5 
days while 15 % remained at the site of application where skin and adipose were reported as 
the major depot tissues (Staskal et al. 2005). Though the animal models have substituted 
human volunteers but, ethical and technical issues arising from them their use has been 
discouraged (Jakasa and Kezic 2008). 
1.7: Paradigm shift – in vivo to in vitro dermal bioavailability studies 
Due to the ethical and technical issues arising from the use of lab animals in toxicology 
studies, the use of in vivo animal models is strongly discouraged (Jakasa and Kezic 
2008).Therefore, much more emphasis is given to finding an alternative. In vitro test methods 
provide a better platform for development of predictive pharmacokinetic models. Several 
guidance documents for conducting in vitro skin absorption studies (OECD 2004; U.S. EPA 
2004; WHO 2006) are currently available. Various types of diffusion cells and different types 
of skin are used, for example, human excised skin from surgery or from cadavers (ex vivo 
skin) or animal (e.g. pig) skin. Similarly, Hughes, et al. 2001 used skin from adult hairless 
female mice (SKH1) mounted in flow-through diffusion cells to study the absorption of 14C-
BDE-209 and 14C-TDCIPP at 3 concentration levels. HEPES ((4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid))-buffered Hanks’ balanced salt solution (pH 7.4) with 10 % 
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fetal bovine serum was used as receptor fluid. Following 24 h exposure, the skin patches 
were washed with solvent prior to analysis of receptor fluid, skin wash and skin for chemical-
derived radioactivity. BDE-209 showed low penetration (0.3 %) into the receptor fluid while 
up to 20 % of the dose remained in skin after 24 h. TDCIPP displayed higher penetration 
(39–57 %) to the receptor fluid, while 28–35 % of administered dose remained in the skin. 
This was mainly attributed to its lower molecular weight and KOW than BDE-209 (Hughes et 
al. 2001). The dermal absorption of BDE-47 was studied using in vitro split-thickness skin 
membranes (350–410 μm, stratum corneum uppermost) of human and rat skin exposed to a 
single dose of ca. 10 mg/cm2 of 14C-BDE-47 for 24 h. The skin patches were mounted in 
flow-through cells while receptor fluid (NaCl, 0.9 %, w/v in water) was pumped through the 
receptor chambers at ca. 1.5 ml/h (Roper et al. 2006).The dose recovered from the receptor 
fluid was 2 % and 15 % of administered BDE-47 to human and rat skin, respectively. The 
difference between the results of this in vitro study (Roper et al. 2006) and the higher (62 %) 
sorption observed in an in vivo study of dermal absorption in mice (Staskal et al. 2005) 
(Table 1.5) may be attributed mainly to the use of 0.9% NaCl solution in water as a receptor 
fluid, as this may greatly reduce diffusion of the lipophilic BDE-47 to the receptor fluid 
(Wilkinson and Williams 2002) and does not accurately mimic actual biological conditions. 
Possible evidence of this is provided by the high residual levels of BDE-47 detected in the 
cells (57 % and 33 % for human and rat skin, respectively) that appeared not to diffuse to the 
receptor fluid (Roper et al. 2006). While no data exists on dermal absorption of TBBP-A, a 
recent in vitro study reported on the percutaneous bioavailability of its precursor, bisphenol A 
(BPA) from human and pig skin (Zalko et al. 2011). Viable human and pig skin patches (500 
µm thickness) were maintained at the air/liquid interface using Transwell inserts while 
dermal/epidermal feeding was achieved via diffusion of nutrients from a modified 
Dulbecco’s Eagle culture medium which kept the cells alive during 72 h exposure 
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experiments. BPA was efficiently absorbed (65 % and 46 % from pig and human skin, 
respectively) and metabolised by the cultured skin indicating the trans-dermal route 
contributes substantially to human exposure to BPA (Zalko et al. 2011). However, it should 
be noted that TBBP-A has a much higher molecular weight and consequently, different 
physicochemical properties (e.g. water solubility, partition co-efficient and vapour pressure) 
than BPA. Furthermore, the lack of halogen atoms in BPA is likely to enhance the rate of its 
percutaneous absorption compared to its tetra-brominated derivative (Garner and Matthews 
1998). 
Given the growing evidence that suggest dermal absorption to be a potentially significant 
pathway of human exposure to FRs, the paucity of data on dermal bioavailability of such 
ubiquitous contaminants may be attributed to a combination of ethical, technical and 
economic issues. One alternative method with the potential to overcome such difficulties is 
the use of 3D human skin equivalent (HSE) models which provide a relatively cheap, 
commercially available, ethical, and reliable method for dermal absorption studies that is 
capable of producing data of relevance to human exposure. 
1.8: Human Skin Equivalent models (HSE)  
1.8.1 Rationale. Although the Organisation for Economic Co-operation and Development 
(OECD) and the European Centre for Validation of Alternative Methods (ECVAM) describe 
methods for assessing dermal absorption using excised in vitro human and animal skin, the 
lack of correlation in transdermal permeation of chemicals across species imparts a high 
degree of uncertainty when extrapolating results from animal models to humans. This is 
mainly due to variations in the stratum corneum thickness, intercellular subcutaneous lipids 
and/or between-species differences in metabolic enzymes and their activity (Schafer-Korting 
et al. 2006). Therefore, excised in vitro human skin is preferable to animal skin (e.g. rat or pig 
skin) for dermal absorption testing, but is clearly less available. To overcome this shortage, 
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HSE models have been developed to provide an alternative to human skin in testing of 
compounds for transdermal permeability (Mertsching et al. 2008). A protocol was developed 
and validated according to the OECD guidelines for percutaneous absorption by using 
commercially available HSE models (Table 1.6). The permeability of tested HSE models 
were compared to that of excised human epidermis, pig skin and bovine udder skin, using 9 
compounds widely varying in physicochemical characteristics, including the OECD 
standards: testosterone, caffeine and benzoic acid. Results revealed HSE models closely 
mimic the histological and physiological character of viable human skin, allowing their use 
for in vitro skin penetration studies (Hartung et al. 2004, Schafer-Korting et al. 2008). 
Consequently, several validated methods using HSE models have been approved by OECD 
and ECVAM for testing skin absorption, phototoxicity, corrosion and irritation by xenobiotic 
chemicals.(Ackermann et al. 2010, Buist et al. 2010) 
1.8.2: Composition. HSE models can be generally classified into 2 main types: 
1- Reconstructed Human Epidermis (RHE):  RHE is a human skin tissue obtained 
from human keratinocytes cultured on an inert polycarbonate medium. One key advantage is 
that it permits growth of donor epidermal cells in a serum-free culture environment. After 
rapidly proliferating preparative keratinocyte cultures have been obtained, the epidermal cells 
yielded are seeded on inert filter substrates, which are then raised to the air-liquid interface in 
a humidified-air incubator. A fully-defined nutrient medium feeds the basal cells through the 
filter substratum. After 14 days, a stratified epidermis is formed that closely resembles human 
epidermis in vivo (Boelsma et al. 2000) 
Morphologically, these cultures exhibit a well-stratified epithelium and cornified epidermis 
with significantly improved barrier function and metabolic activity (Boelsma et al. 2000). 
Differentiation markers such as suprabasal keratins, integrin b4, integrin a6, fibronectin, 
involucrinyt, filaggrin, trichohyalin, type I, III, IV, V, VII collagen and laminin
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Table 1.6: Characteristics of commercially available HSE models. 
Brand Name 
Scaffold 
material 
Source Dermis Manufacturer 
Episkin™ 
Collagen 
(0.38 cm2) 
Keratinocytes(Mammary/
Abdominal samples 
obtained from healthy 
consenting Donors during 
plastic surgery) 
NO 
L’Oréal, Nice, 
France 
Skinethic™ 
Polycarbonate 
membrane 
( 0.5 cm2 ) 
Keratinocytes (neonatal 
foreskin tissue or adult 
breast tissue) 
No 
L’Oréal, Nice, 
France 
EpidermTM 
Collagen coated 
Polycarbonate 
(9mm diameter) 
Human keratinocytes 
(neonatal foreskin adult 
breast skin) 
No 
MatTek 
Corporation, MA, 
USA 
EpidermFT™ Collagen 
Human keratinocytes 
(neonatal foreskin adult 
breast skin) human 
fibroblasts (neonatal skin, 
adult skin) 
Yes 
MatTek 
Corporation, MA, 
USA 
EST-1000 
Polycarbonate 
membrane 
Keratinocytes (neonatal 
foreskin) 
No 
Cell Systems, 
Troisdorf 
Germany 
AST-2000 Collagen Human Keratinocytes Yes 
Cell Systems, 
Troisdorf 
Germany 
Phenion® FT 
Model 
Bovine, cross 
linked, 
lyophilized 
collagen 
(1.3 cm dia) 
Primary human 
keratinocytes (neonatal 
foreskin), human 
fibroblasts (neonatal 
foreskin) 
Yes 
Henkel, 
Duesseldorf, 
Germany 
StrataTest® 
Collagen I 
(0.6 cm2 ) 
immortalized, human 
NIKS® keratinocytes 
dermal fibroblasts 
Yes 
Stratatech 
Corporation 
Madison WI, 
 41 
 
USA 
Epistem ® 
LSE 
Collagen 
Primary human 
keratinocytes and dermal 
fibroblasts. 
Yes 
Epistem limited, 
Manchester, UK. 
StratiCell® 
EPI/001 
Polycarbonate 
membrane 
Primary human 
keratinocytes 
No 
Straticell 
Corporation, 
Gembloux, 
Belgium. 
StratiCell® 
Mel/001 
Polycarbonate 
membrane 
Primary human 
keratinocytes and 
melanocytes. 
No 
Straticell 
Corporation, 
Gembloux, 
Belgium. 
 
sulfate and membrane-bound transglutaminase are expressed similar to those of the human 
epidermis. 
1.8.3: Evaluation of 3D-HSE Skin models.  
1.8.3.1: Barrier function: The evaluation of permeability potential of chemicals or cosmetic 
formulations is a critical step in risk assessment or product development. The 3D-HSE 
models replaced in-vitro keratinocytes in culture as these models closely resemble the skin 
morphology. A validation study (Schafer-Korting et al. 2008) was performed to assess 
whether the RHE models like EPISKIN, Epiderm and SkinEthic were suitable for 
percutaneous permeability testing. The study tested the permeability of 9 compounds with a 
wide range of physicochemical properties and the results were compared with the 
recommended ex-vivo human epidermis and pig skin by OECD test guideline 428. Some of 
the main outcomes of this validation work are given below: 
 The lag-times of the studied drugs for the HSE models were in the order of minutes to 
few hours, the maximum being 2 h whereas the lag-times were high (4.47 h with 
nicotine to 11.05 h with digoxin) 
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 For testosterone, the following order of permeability (PAPP) was found: SkinEthic 
RHE >Epiderm >EPISKIN, however for caffeine, SkinEthic and EPISKIN exceeded 
in permeability than the Epiderm model, ex vivo human skin and pig skin. 
 Flufenamic acid and nicotine showed the highest permeability as compared to the 
other compounds which could be due to its low molecular weight 281.2 and moderate 
lipophilicity (4.80). A very lipophilic clotrimazole permeated through HES and pig 
skin less than flufenamic acid and nicotine where as the hydrophilic compound, 
Mannitol permeation was non-homogenous. The integrity and the barrier function of 
HSE models were well verified with high molecular weight compounds (>500) and 
the results indicated that ivermectin did not permeate at all whereas digoxin’s 
permeability was very low. This suggested that there were no differences between the 
RHE models and the OECD approved skin preperations with respect to the molecular 
weight cut-off. 
Permeation through the HSE model was two fold higher for testosterone and 10 fold higher in 
case of clotrimazole as compared to the pig skin at infinite concentrations. However, at finite 
dosing, the results were comparable for the distribution of testosterone and caffeine between 
donor, skin and receptor fluid. Thus the validation results support the use of RHE models as 
an alternative means for human and animal skin for dermal absorption and permeability 
testing. 
1.8.3.2: Characterising Metabolising Enzymes or activities:  
It is imperative to measure the levels of phase I and phase II enzymatic activities in skin 
models that are used in safety evaluation studies. Many studies have assessed the suitability 
of epidermal models for studies involving biotransformation by comparing the profiles of 
metabolising enzymes with the human skin. (Table 1.7 & Table 1.8) 
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EPISKIN Phase I enzymes activates the lipophilic compounds by adding a polar group to the 
compound and thus making it more hydrophilic. Then phase II enzymes like UDP-
glucuronosyl transferases, glutathione-S-transferases and sulfotransferases which add 
conjugate groups (glucuronosyl, thiol and sulfate respectively) to the intermediate 
hydroxylate compounds to increase their polarity and excretable. 
(Luu-The et al. 2009)  compared the mRNA expression of Phase I and Phase II enzymes in 
Episkin and FTM with the human epidermis, dermis and total skin using real time PCR. The 
data indicated that CYP450 & FMOs were expressed at low levels and phase II metabolizing 
enzymes like glutathione- S-transferase P1 (GSTP1), catechol-O-methyl transferase (COMT), 
steroid sulfotransferase (SULT2B1b) and N-acetyl transferase (NAT5) at much higher levels. 
These data strongly supports that the Episkin and FTM represent reliable and valuable 
alternative in vitro models to study the function of phase I and II metabolizing enzymes in 
xenobiotic metabolisms. 
1.9: General Protocol for in vitro percutaneous absorption studies. (Fig: 1.7) 
Each HSE model is supplied with its respective receptor/culture fluid and its percutaneous 
absorption protocol. Generally, the protocol involves mounting the fully-developed skin 
patches at the air-liquid interface of a permeation device (e.g. Franz-cell type diffusion cells, 
Mattek® permeation device) while in contact with the receptor fluid. The test compound is 
then applied to the surface of the stratum corneum and incubated for the required exposure 
time (usually 24 h). The receptor fluid is sampled and replaced at fixed time intervals. At the 
end of the exposure period, the skin surface is washed/wiped clean of any residual 
contaminant remaining, prior to collection of the receptor fluid and cell culture for chemical 
analysis. 
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Table 1.7: Representative CYP & non –CYP –xenobiotic –metabolizing enzyme activities^ in human skin and human reconstructed skin 
models (^ = Constitutive; number after slash: induced (highest reported induced activity) 
Activity Human Skin Skin microsomes EpiskinTM EpiDermTM Units/Abbreviations Reference 
CYP1 Family 
 
0.24-1.35* (AHH) 
BLQ-35*   (EROD) 
3.0 ± 1.2$ 
 
7.8 ± 0.4$ 
  FTM -2.6 ± 0.3$ 
 BLQ/ 1.7 ± 0.8# 
 
 
*pmol/min/mg microsomal protein 
$ = pmol of products/6 h/mg 
protein (sum of 7,500g supernatant 
+ medium) 
# = pmol/min/mg intact model 
protein 
AHH = Aryl hydrocarbon 
hydroxylase  
EROD = 7-ethoxyresorufin O-
dealkylase 
(Oesch et al. 
2014) 
CYP3A 
BLQ-76 ± 41* 
(BQOD) 
 BLQ 
94 ± 13*/5.5 ± 
0.9# 
*pmol/min/mg microsomal protein  
# = pmol/min/mg intact model 
protein 
BQOD = benzyloxyquinoline O-
dealkylase 
 
(Oesch et al. 
2014) 
CYP2C9 
0.46 ± 0.05e$ 
(Tolbutamide 4 
 
~≤ 0.5 
(MFCOD) 
               BLQ 
 
pmol/h/mg microsomal protein 
 
 45 
 
hydroxylation) MFCOD = 7-methoxy-4 
trifluoromethylcoumarin O 
dealkylase 
CYP1A2    
BLQ/0.7 ± 0.3@ 
< 0.16 
                0.7 ± 0.3 
@ = pmol/min/mg intact model 
protein 
 
CYP2E1 
2.83 ± 0.34 ** 
(Chlorzoxazone 6-
hydroxylation)  
< 0.11   
**  pmol/h/mg microsomal protein  
CYP3A4 
2.35 ± 0.23** 
(Mi|dazolam 1-
hydroxylation) 
< 0.23   
 
**  pmol/h/mg microsomal protein 
 
CYP3A5  < 0.08   ** pmol/h/mg microsomal protein 
 
Phase-II Enz     
  
GST-α 20 ± 6.8*d   307.99##   
NAT-1 
Slow =0.63 0.94*d 
Fast = 1.73-3.03*d 
  
 11.24 ± 4.15 
(microsome) 
 
 
nmol/min/mg protein 
  
   
(Jackh et al. 
2011) 
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UGT 
 
 
 
 
1.3  ± 0.2*d   
1.98 ± 0.17 
(microsome) 
 
 
nmol/min/mg protein 
 
 
(Jackh et al. 
2011) 
Non-CYP       
FMO    
5.95 ± 1.06 
(Benzydamine) 
(microsome) 
nmol/min/mg protein (Jackh et al. 
2011) 
COX 
23.5 ± 8.7# 
(ARACHIDONIC 
ACID) 
  3.6 ± 1.9d#/~8# 
# =  
pg prostaglandin E2 
formed/min/mg microsomal protein 
  Jackh, Blatz et 
al. 2011) 
NQR 
7-10h,~11h,I 
(Menadione) 
 ~ 11    ~ 3.6  
 
nmol/min/mg cytosolic protein 
 Jackh, Blatz et al. 
2011)  
GST 
~ 290*, 15 ± 3** 
(20 ± 6.8 )& 
CDNB 
 
~180-430 & 
51 ± 2 ** 
FTM = 112 ± 12** 
~ 410.-920& 
   (~62) & 
 
*= nmol/min/mg cytosolic protein 
(epidermis scrapped from skin 
surgical samples) 
** = pmol/min/mg protein (sum of 
7,500g supernatant + medium) 
& = nmol/min/mg cytosolic protein 
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CDNB =1-chloro-2,4 
dinitrobenzene 
 UGT 
(4-MU) 
1.3 ± 0.2c 
18 ± 11d 
 
 68 ± 3d 
 FTM = 54 ± 3d 
 ~ 1.8 -1.98 c 
C = nmol/min/mg microsomal 
protein 
d = pmol/min/mg protein (sum of 
7,500g supernatant + medium) 
 
 
NAT 
(PABA) 
33 ± 8 d 
 
 
21 ± 2 d 
FTM = 47 ± 3d 
  11.2 ± 4.1e 
d = pmol/min/mg protein (sum of 
7,500g supernatant + medium) 
e = nmol/min/mg S9 protein 
 
Para Toluidine 
-NAT 
0.63-3.03f   ~ 0.68f 
f  = nmol/min/mg cytosolic protein  
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Table 1.8 :  Expression profiles (copies/µg of total RNA)(x1000) of phase I and phase II 
metabolizing enzymes in human skin and the Episkin models (Luu-The et al. 2009) 
Genes 
profiling  
Total human 
skin (n=10) 
Human dermis 
(n= 6) 
Human epidermis 
(n =10) 
Episkin Model 
(n =6) 
FTM  (Episkin) 
     (n= 3-8)                                                          
Phase I      
CYP4B1 106 ± 21.61 55.57 ± 22.87 114.99 ± 25.14 137.36 ± 25.46 44.80 ± 2.90 
CYP26B1 65.84 ± 9.51 
151.22 ± 
102.21 
80.58 ± 17.01 7.42 ± 3.21 
36.16 ± 7.12 
CYP39A1 64.83 ± 7.12 13.60 ± 4.10 41.0 ± 7.69 14.67 ± 2.46 18.70 ± 7.06 
CYP2J2 44.66 ± 8.07 6.97 ± 1.01 45.35 ± 7.88 21.46 ± 7.18 42.70 ± 6.87 
CYP4FB 38.66 ± 18.65 31.23 ± 17.01 3.63 ± 0.57 7.53± 3.40 1.67 ± 0.82 
CYP4F12 36.33 ± 5.73 13.45 ± 8.76 29.33 ± 6.11 6.58 ± 3.59 18.74 ± 6.74 
CYP27A1 33.99 ± 6.30 52.51 ± 6.49 10.48 ± 1.32 ND ND 
CYP7B1 22.70 ± 3.02 20.18 ± 4.41 16.97 ± 4.60 27.61 ± 2.46 15.33 ± 2.46 
CYP2B6 18.47 ± 5.29 12.99 ± 3.47 3.98 ± 1.01 7.38 ± 6.81 3.98 ± 1.13 
CYP2D6 15.19 ± 3.15 7.88 ± 3.02 4.79 ± 0.76 9.39 ± 2.90 7.31 ± 2.71 
CYP2E1 14.10 ± 3.91 3.65 ± 2.76 7.50 ± 4.96 46.33 ± 21.44 11.44 ± 2.64 
CYP1A1 12.56 ± 7.28 2.81 ± 1.17 18.82 ± 11.07 10.13 ± 6.14 1.14 ± 0.26 
CYP1B1 6.58 ± 0.85 10.25 ± 3.85 7.85 ± 1.76 48.39 ± 24.41 5.56 ± 2.47 
CYP27B1 1.95 ± 0.26 1.95 ± 0.26 1.96 ± 1.32 50.25 ± 9.81 97.66 ± 20.9 
CYP46A1 6.49 ± 1.59 8.84 ± 3.94 1.59 ± 0.26 6.49 ± 2.94 1.18 ± 0.32 
CYP2C18 5.41 ± 0.94 1.33 ± 0.26 6.80 ± 1.76 27.89 ± 6.76 10.65 ± 6.8 
CYP2C8 4.34 ± 1.00 3.34 ± 2.97 6.96 ± 3.58 9.96 ± 3.88 12.93 ± 4.26 
CYP21A2 3.97± 0.88 13.70 ± 4.46 2.01 ± 0.50 4.01 ± 1.97 1.48 ± 0.85 
CYP2C9 3.34 ± 0.68 1.55 ± 1.47 1.40 ± 0.38 2.29 ± 0.68 0.94 ± 0.53 
CYP2F1 3.23 ± 0.62 3.97 ± 1.39 1.37 ± 0.33 4.57 ± 2.29 2.85 ± 1.11 
CYP4F2 3.25 ± 0.92 0.79 ± 0.34 1.51 ± 0.44 7.15 ± 3.18 5.39 ± 0.83 
CYP1A2 2.36 ± 1.5 0.68 ± 0.18 5.60 ± 1.32 0.68 ± 0.29 0.64 ± 0.26 
CYP3A5 2.4 ± 1.90 ND 7.71 ± 2.16 18.58 ± 7.98 2.63 ± 1.21 
CYP4F3 1.64 ± 0.74 1.32 ± 1.18 1.81 ± 1.13 1.36 ± 0.16 0.66 ± 0.15 
CYP3A7 1.49 ± 0.33 0.45 ± 0.11 1.74 ± 0.30 5.55 ± 2.27 0.68 ± 0.15 
CYP11A1 1.36 ± 0.21 2.95 ± 0.47 ND 0.57 ± 0.14 0.23 ± 0.13 
CYP26A1 0.93 ± 0.16 0.93 ± 0.43 ND ND ND 
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ADH1B 1500.0 ± 300.0 3000.0 ± 700 ND ND ND 
EPHX1 473.54 ± 70.5 
881.54 ± 
111.11 
91.42 ± 15.22 63.1 ± 12.35 
75.36 ± 67.48 
HADH2 
202.56 ± 
207.33 
245.96 ± 25.84 431.73 ± 36.46 576.73 ± 85.85 
893.71 ± 145.57 
EPHX2 210.71 ± 40.77 66.60 ± 21.25 226.24 ± 51.97 24.13 ± 4.88 78.98 ± 16.94 
AKR1C1 204.77 ± 28.42 354.36 ± 57.71 91.96 ± 11.77 814.62 ± 90.44 323.39 ± 41.34 
AKR1C2 193.65 ± 43.7 155.77 ± 39.33 98.36 ± 16.94 686.66 ± 91.87 422.24 ± 113.41 
DHRS8 88.94 ± 10.5 
215.85  ± 
27.85 
14.89 ± 6.60 10.2 ± 3.45 
11.18 ± 4.2 
FMO1 41.9 ± 8.18 11.37 ± 2.84 43.55 ± 9.62 0.59 ± 0.46 1.29 ± 0.42 
STS 17.93 ± 2.7 24.14 ± 6.21 12.73 ± 3.65 25.99 ± 6.60 40.98 ± 6.14 
FMO4 13.46 ± 2.42 10.16 ± 4.11 8.58 ± 1.90 6.37 ± 0.67 21.28 ± 2.39 
FMO5 12.89 ± 1.37 16.43 ± 6.0 15.63 ± 3.9 1.34 ± 0.39 7.13 ± 2.46 
FMO3 8.25 ± 1.58 13.90 ± 3.23 ND ND ND 
FMO2 5.9 ± 1.30 6.91 ± 0.70 44.46 ± 20.0 141.50 ± 11.48 141.15 ± 11.48 
NOS1 4.45 ± 1.30 1.96 ± 0.32 13.89 ± 2.88 5.15 ± 1.51 1.29 ± 0.32 
ADH7 1.35 ± 0.31 0.82 ± 0.42 1.28 ± 0.31 1.59 ± 0.35 2.54 ± 0.77 
NOS2A 1.10 ± 0.38 1.69 ± 0.42 1.02 ± 0.35 0.36 ± 0.35 BLQ 
AKR1CA 0.95 ± 0.49 BLQ ND ND ND 
Phase II      
GSTP1 
2833.43 ± 
507.22 
2249.79 ± 
550.48 
2579.28 ± 398.79 8825.94 ± 1175.6 
6593.73 ± 216.1 
SULT2B1b 
653.537 ± 
134.14 
107.787 ± 
94.309 
1242.21 ± 187.96 1937.9 ± 606.19 
2477.83 ± 
408.96 
COMT 
397.247 ± 
71.274 
271.551 ± 
31.708 
355.072 ± 60.164 716.641 ± 122.22 
1278 ± 115.0 
GST1 
305.177 ± 
80.758 
435.579 ± 
231.707 
198.773 ± 51.22 88.2553 ± 8.130 
227.874 ± 27.1 
SULT1A1 
216.636 ± 
38.752 
384.165 ± 
37.128 
26.4931 ± 6.504 21.12 ± 9.75 
111.149 ± 7.101 
GST M5 143.3 ± 28.99 
521.101 ± 
243.063 
10.04 ± 5.96 ND 
ND 
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NAT5 177.28 ± 29.81 
95.165 ± 
16.529 
130.446 ± 31.43 106.37 ± 30.81 
102.905 ± 
33.875 
SULT1E1 16.24 ± 5.20 2.12 ± 0.49 6.62 ± 1.25 9.6 ± 1.60 35.37 ± 8.35 
NAT1 11.23 ± 2.60 7.33 ± 1.527 3.21 ± 0.94 6.35 ± 0.99 7.50 ± 1.50 
UGT2B28 10.13 ± 8.91 2.87 ± 1.69 ND 0.99 ± 0.43 ND 
UGT2B4 4.82 ± 1.54 28.19 ± 16.71 0.48 ± 0.55 0.86 ± 0.35 0.47 ± 0.18 
UGT1A10 2.64 ± 0.80 1.94 ± 0.94 1.3 ± 0.57 1.45 ± 0.24 3.80 ± 1.32 
UGT2B17 1.25 ± 1.7 4.96 ± 5.94 ND 1.13 ±  0.94 ND 
UGT2B15 0.51 ± 0.22 1.42 ± 1.3 ND ND ND 
SULT1B1 0.36 ± 0.20 0.44 ± 0.28 ND 0.82 ± 0.63 0.41 ± 0.33 
SULT2A1 0.74 ± 0.35 0.43 ± 0.28 ND ND ND 
NAT2 ND ND 0.73 ± 0.37 ND ND 
Note – Values are extracted from the publication figures using using GetData software tool 
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Fig 1.6: General stages of development of HSE model.  
 
 
 
a) Keratinocytes and fibroblasts were pre seeded onto the scaffold/matrix before being assembled together using inserts. 
Ensuring that the agarose gel was sandwiched between the upper (keratinocyte) and bottom (fibroblast) layers. 
b) Then the entire construct was placed onto the plastic platform insert with sufficient medium added to each well to ensure 
an air-liquid surface. (Chau et al.2013)
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Fig 1.7 : General protocol for percutaneous absorption studies using in vitro 3D HSE 
models 
        Step-1                                             
    
       Step-2                                  
 
 
        Step-3                    
                                                                
                                                                                     
          Step-4               
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1.10: HYPOTHESIS and AIMS 
The overriding hypothesis that this work tests is that dermal uptake of FRs is a significant 
pathway of human exposure. To address these gaps, the aims of the current study are to: 
 Develop and validate  analytical methods for FRs using LC-MS/MS and GCMS 
 Assess the bioaccessibility of the studied FRs from indoor dust to synthetic 
sweat/sebum under physiological conditions. 
 Evaluate the validity of HSE models (EpiDermTM & EPISKIN TM) against human ex 
vivo skin samples for measuring human dermal exposure to FRs. 
 Develop and validate sampling and analytical methodology for determination of FRs 
in several samples like receptor fluid, cotton bud, skin tissue etc. 
 Understand the role of skin moisture and oiliness on dermal uptake of FRs from the 
dust 
 Conduct exposure experiments involving the application of consumer product 
samples like upholstered fabrics and plastics to 3D-HSE models under different 
exposure scenarios (dry, wet skin and in presence of moisturising cream) 
 Assess external and internal human exposure to target FRs via dermal exposure using 
the following data for all the age groups: 
- Bioaccessible fraction of FRs from indoor dust, plastics and fabrics to the human 
sweat/sebum on the skin surface.  
- Bioavailable fraction of FRs when the skin models are exposed to indoor dust, 
plastics and upholstered fabrics. 
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 CHAPTER II 
  ANALYTICAL METHODOLOGY AND VALIDATION 
 
 This chapter contains some material taken verbatim from Pawar, G., M. A. Abdallah, 
et al. (2016). Dermal bioaccessibility of flame retardants from indoor dust and the 
influence of topically applied cosmetics. J Expo Sci Environ Epidemiol 6 (10): 84. 
 
2.1: Instrumental analysis 
2.1.1: GC-NCI /MS Analysis for PBDEs 
Quantification of target PBDEs was performed using a TRACE 1310™ GC coupled to a 
ISQ™ Single Quadrupole mass spectrometer (Thermo Fisher Scientiﬁc, Austin, TX, USA) 
operated in negative chemical ionisation (NCI) (Harrad et al. 2008, Abdallah, Pawar and 
Harrad 2015b). Separation of target PBDEs was performed on Agilent DB-5 capillary 
column (15 m x 0.25 mm; 0.1 µm). The mass spectrometer was run in selected ion 
monitoring (SIM) with ion source, quadrupole and mass transfer line temperatures set at 230, 
150 and 300 °C, respectively. Helium was used as carrier gas at constant flow (1.0 mL/min) 
with methane as moderating (or reagent) gas. One μL of the extract was injected in solvent 
vent mode (injector temperature at 90 °C for 0.06 min, then increased at 700 °C/min to 305 
°C, vent time 0.04 min, vent flow 50 mL/min). The splitless time was 1.5 min. The GC 
temperature program started at 90 °C for 1.5 min, then ramped linearly at 15 °C/min to 295 
°C, which was kept for 15 min. Dwell times were 30 ms. Ions m/z 79 and 81, together with 
ions m/z 484.7/486.7 and 494.7/496.7 for BDE 209 and 13C12-BDE 209, respectively, were 
monitored for the entire run. Analyte identification was based on retention times relative to 
the respective internal standard used for quantification, ion chromatograms and intensity 
ratios of the monitored ions. A deviation of ion intensity ratios in sample peaks of more than 
20% of mean values observed in calibration standards was not accepted.
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Fig 2.1: GC-ECNI/MS chromatograms of all PBDE congeners (1 ng/µL of each in iso-octane) 
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2.1.2: LC-MS/MS Analysis for HBCDs and TBBP-A 
Separation of α-, β- and γ HBCDs and TBBP-A was achieved using a dual pump Shimadzu 
LC-20AB Prominence liquid chromatograph equipped with a SIL-20A autosampler, a DGU-
20A3 vacuum degasser and a Varian Pursuit XRS3 C18 reversed phase analytical column 
(150 mm × 2 mm i.d., 3 µm particle size) according to (Abdallah, Pawar and Harrad 2015). A 
mobile phase program based upon (a) 1:1 methanol/water and (b) methanol at a flow rate of 
150 µL min-1 was applied for elution of the target compounds; starting at 50% (b) then 
increased linearly to 100% (b) over 4 min, held for 7 min followed by a linear decrease to 
60% (b) over 4 min, held for 1 min and finishing with 100% (a) for 10 min. TBBP-A and the 
three HBCD diastereomers were baseline separated with retention times of 9.0, 10.6, 11.2 and 
11.7 min for TBBP-A, α-, β- and γ-HBCD, respectively. 
Mass spectrometric analysis was performed using a Sciex API 2000 triple quadrupole mass 
spectrometer operated in electrospray negative ionization mode. MS/MS detection operated 
in the MRM mode was used for quantitative determination based on m/z 640.679, m/z 
652.479 and m/z 657.779 for the native, 13C-labelled and d18-labelled HBCD 
diastereomers, respectively and m/z 540.879, m/z 552.879 for the native and 13C-
labelled TBBP-A, respectively. Specific instrumental calibration parameters are given in 
table 2.1 
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Table 2.1: Optimized MS/MS parameters* for the analysis of HBCDs and TBBP-A. 
Parameter Value (units) 
Curtain gas 35 (a.u.) 
Turbo gas temperature 500 (°C) 
Ion spray voltage - 4500 (V) 
Declustering potential -5 (V) 
Focusing potential -365 (V) 
Collision gas 5 (a.u.) 
Collision energy 40 (eV) 
Cell entrance potential -6 (V) 
Collision cell exit potential -10(V) 
 a.u. – arbitrary units 
Fig 2.2: Illustrative LC-MS/MS chromatogram of native and 13C-labelled HBCDs. 
 
                                                                                                     Time, min 
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2.1.3: GC-EI/MS Analysis for PFRs 
GC-EI/MS analysis of PFRs was performed using a Trace 1310 GC coupled to a ISQ mass 
spectrometer (Thermo Fisher Scientiﬁc, Austin, TX, USA) operated in electron ionization 
(EI) mode according to a previously described method (Abou-Elwafa Abdallah, Pawar and 
Harrad 2016). Separation of target analytes was performed on Agilent DB-5 capillary column 
(30 m x 0.25 mm; 0.25 µm) using helium as the carrier gas. One μL of purified extract was 
injected using cold split less injection. The injection temperature was set at 90 °C, hold 0.03 
min, ramp 700 °C/min to 290 °C. Injection was performed using a pressure of 1 bar until 1.25 
min and purge flow to split vent of 50 mLmin-1 after 1.25 min. The GC temperature program 
was 90 °C, hold 1.25 min, ramp 10 °C/min to 240 °C, ramp 20 °C/min to 310 °C, hold 16 
min. Helium was used as a carrier gas with a flow rate of 1.0 mL/min. The mass spectrometer 
was run in selected ion monitoring (SIM) mode. Dwell times ranged between 20 and 30 ms in 
different acquisition windows. The ion source, quadrupole and interface temperatures were 
set at 230, 150 and 300 °C, respectively, and the electron multiplier voltage was at 2200 V. 
TCEP, TCIPP and TDCIPP were quantified using the ions m/z 249, 277 and 381, 
respectively. 
           TnBP, TiBP, TEHP, EHDPP and TCP isomers analysis was conducted by a method 
developed on an Agilent 5975C GC/MS fitted with a 30 m DB-5 MS column (0.25 mm id, 
0.25 µm film thickness) (Brommer et al. 2012b). Helium was used as carrier gas with a 
constant flow rate of 1.0 mL/min. The injector temperature was set at 290 °C under splitless 
conditions and the MS operated with a solvent delay of 3.8 min. The ion source, quadrupole 
and interface temperatures were set at 230 °C, 150 °C and 300 °C respectively. The GC 
temperature programme was 90°C, hold for 1.25 min, ramp 10 °C/min to 170, ramp 5 °C/min 
to 240 °C, hold for 10 min, ramp 20 °C/min to 310 °C, hold for 10 min. Resulting total run 
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time was 46.75 min. The MS was operated in selected ion monitoring (SIM) mode. (Table 
2.2)  
Fig 2.3: GC-MS chromatogram of TCEP, TCIPP, TDCPP and TPhP-d15 (IS) at 1 ng/µL 
in Iso-octane. 
 
Fig 2.4: GC-MS chromatograms of TCP isomers. 
 
 
Table 2.2: Ions (m/z) monitored for some of the PFRs 
TPhP-d15 ToCP TmCP TpCP 
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Analyte Quantification Ion Identification Ion 
TnBP 211 155 
TiBP 211 155 
TCEP 249 251 
TCIPP 277 279 
TDCIPP 381 379 
EHDPP 251 250 
TEHP 211 99 
ToCP 368 367 
TmCP 368 165 
 TpCP 368 367 
d27- TnBP 103 167 
d15-TPhP 341 339 
                        
2.1.4: Determination of NBFRs  
GC-NCI /MS Analysis for NBFRs and other Flame retardants 
Quantification of target NBFRs was performed using a TRACE 1310™ GC coupled to a 
ISQ™ Single Quadrupole mass spectrometer (Thermo Fisher Scientiﬁc, Austin, TX, USA) 
operated in negative chemical ionisation (NCI).  Separation of target NBFRs was performed 
on an Agilent DB-5 capillary column (15 m x 0.25 mm; 0.1 µm). The mass spectrometer was 
run in selected ion monitoring (SIM) with ion source, quadrupole and mass transfer line 
temperatures set at 230, 150 and 280 °C, respectively. Helium was used as carrier gas at 
constant flow (2.0 mL/min) with methane as moderating (or reagent) gas. One μL of the 
extract was injected in solvent vent mode (injector temperature at 90 °C for 0.06 min, then 
increased at 700 °C/min to 305 °C, vent time 0.04 min, vent flow 50 mL/min ). The splitless 
time was 1.5 min. The GC temperature program started at 100 °C for 2.0 min, then ramped 
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linearly at 25 °C/min to 270 °C, which was kept for 5 min and then ramped at 5°C/min to 
270°C and finally at 20 °C/min to 320°C for 19 min. Dwell times were 30 ms. Ions m/z 79 
and 81 for α-TECH,β-TBECH together with ions m/z 356.8/358.8, 420.7/421,464.0/464.7, 
484.6/486.6,499.0/499.7, 653.8/655.8 for BTBPE,EH-TBB,TBPH, DBDPE,PBEB and DP, 
respectively, were monitored for the entire run. Analyte identification was based on retention 
times relative to the respective internal standard used for quantification, ion chromatograms 
and intensity ratios of the monitored ions. A deviation of ion intensity ratios more than 20% 
of mean values of calibration standards was NOT accepted. 
 
Fig 2.5: GC-MS chromatograms of syn-Dechlorane plus and anti-Dechlorane plus 
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Fig 2.6: GCMS chromatograms of NBFRs.    
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2.2: METHOD VALIDATION AND QA/QC CRITERIA  
2.2.1 Identification and Quantification  
Target compounds were identified and confirmed by specific retention time (tR) for each 
compound by injecting 2 ng pure standard on column. A full 5 point calibration was 
conducted for each of the studied compounds in a concentration range of 20-5000 pg/µL to 
assess the linearity of MS response. To compensate for the MS instrumental fluctuations and 
matrix effect, 13C- labelled isomers were used as internal standard for each of the compound. 
Excellent linearity (R2>0.99) was observed for each of the target compounds. Based on the 5 
point calibration, relative response factors (RRF) for each compound were calculated. The 
RRF is the instrument response for a unit amount of the target compound relative to the same 
amount of the internal standard (IS).The relative response factor (RRF) was calculated, using 
equation (2.1) for each calibration standard and for each compound 
………………………………….. (2.1) 
RRFN refers to the relative response factor of the native compound, ANAT is the peak area of 
the native in the calibration standard, AIS is the peak area of the IS in the calibration standard, 
MIS is the mass (ng) of IS added to the calibration standard and MNAT is the mass (ng) of 
native analyte added to the calibration standard. An average of the calculated RRFN of the 
five calibration standards was taken for the final RRF value of each analyte. The %RSD for 
each compound did not exceed 15%. The calculated RRFs were then used in equation (2.2) to 
calculate the concentration of the analyte (ng g-1) in the sample. 
……………………………………………..(2.2) 
Where ANAT refers to the analyte peak area in the sample, AIS is the peak area of the internal 
standard in the sample, MIS is the mass of IS added to the sample and SM is the sample mass 
extracted. For a given compound’s chromatograph the signal to noise ratio (S/N) must exceed 
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3:1.The bromine isotope ratios must be within ± 20% of the average for the 2 calibration 
standards run at the start and at the end of the sample batch. The relative retention time 
(RRT) of the peak in the sample must be within the ± 0.2% of the average value determined 
for the same analyte in the 2 calibration standards ran before and after the sample batch. 
2.2.2: Recovery Determination standard (RDS) 
To compensate for any losses during the sample processing i.e. extraction and clean-up, 
internal standards (IS) were added prior to extraction and a recovery determination standard 
(RDS) was added to the final sample extract just before injection on the GCMS or LC-
MS/MS. Calculation of the recoveries of IS were carried out. The RRF for each IS was 
calculated from the calibration standards using equation (2.3). 
………………………………………………………………………………………(2.3) 
ARDS is the peak area of the recovery determination standard (RDS) in the calibration 
standard and MRDS is the mass of RDS added to the calibration standard (ng). Again an 
average of the RRFIS from all five calibration standards was calculated for the final, average 
RRF value of each IS used in equation (2.4) to calculate the % recovery of the IS. 
 …………………….....................(2.4) 
AIS is the peak area of the IS in the sample, ARDS is the peak area of the RDS in the sample, 
MRDS is the mass of RDS added to the sample (ng) and MIS is the actual mass of IS added to 
the sample (ng).For 13C-α, β, and γ-HBCDs, average recoveries ranged from 71 to 92 % in 
bioaccessibility experiments (Table 2.3), while for 13C-TBBPA, PBDE 77 and PBDE 128 
average recoveries ranged > 85% in dust samples (Table 2.4). 
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 Table 2.3:  Representative table showing the % recovery of IS for the samples generated from Bioaccessibility experiments 
Sample type 13C-α-HBCD 13C-β-HBCD 13C-γ-HBCD 13C-TBBP-A d15-TPhP 
100% sweat 86.29   ±     6.50 87.32  ± 1.22 91.85 ±  3.22 90.33 ± 3.14 89.23 ± 8.16 
99:1 sweat:sebum 89.36 ± 5.90 81.30 ± 4.59 92.24 ± 7.27 88.82 ± 2.50 80.41 ±   6.12 
95:5 sweat:sebum 78.68 ± 4.03 78.18 ± 5.67 91.52 ± 10.03 90.40 ± 1.58 76.43 ± 5.18 
9:1 sweat:sebum 89.75 ± 3.26 83.29 ± 6.88 79.49 ± 1.82 81.30 ± 3.60 79.76 ± 9.52 
8:2 sweat:sebum 88.77 ± 7.07 84.73 ± 7.57 82.36 ± 1.32 83.34 ± 7.80 88.99 ± 8.82 
1:1 sweat:sebum 86.15   ± 8.46 74.92 ± 8.94 72.79 ± 7.22 91.17 ± 6.35 70.94 ± 7.43 
100% sebum 79.18 ± 18.03 83.74 ± 3.32 92.14 ± 2.50 78.88 ± 1.23 73.32 ± 5.72 
Dust/SSSM (1:1)/ Moisturising Cream 72.84 ± 6.01 85.86 ± 7.96 88.28 ± 7.12 73.25 ± 4.70 70.84 ± 6.12 
Dust/SSSM (1:1)/Body Spray 71.18 ± 8.76 73.36 ± 1.34 80.24 ± 11.95 81.94 ± 6.40 76.37 ± 5.64 
Dust/SSSM (1:1)/Sun Screen Lotion 83.97 ± 13.09 78.34 ± 8.65 70.60 ± 5.71 88.03 ± 5.70 70.67 ± 5.70 
Dust/SSSM (1:1)/Shower Gel 72.09 ± 1.48 75.30 ± 2.15 76.31 ± 1.23 85.83 ± 1.56 80.28 ± 7.29 
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Table 2.4: Summary of recoveries (expressed as %) of 13C-labelled internal standards 
added to the studied dust samples.  
Compound 
Dust samples 
Average SD 
13C-α-HBCD 88 9 
13C-β-HBCD 85 5 
13C-γ-HBCD 86 12 
13C-TBBP-A 88 10 
BDE-77 84 7 
BDE-128 87 6 
 
2. 3:  ACCURACY AND PRECISION  
2.3.1: Matrix spike method  
Matrix spiking is a technique that is used to assess the performance of analytical procedures 
when testing a specific analyte in a matrix like dust or any other biological samples. 
 The NIST dust standard reference material (SRM) 2585 was analysed on a regular basis. 
Certified PBDE concentrations are published for this SRM, while only indicative HBCD 
concentrations are available. Due to the lack of an appropriate reference material for HBCDs, 
this SRM was analysed with concentrations compared to the indicative values. One SRM was 
analysed with every 20 samples as an ongoing method performance check. The mean 
concentration ± standard deviation (SD), %RSD, certified PBDE and indicative HBCD 
values are listed in Table 2.5. As the % RSDs are below 20%, the repeatability of the method 
is acceptable. Good recoveries (83 ± 9%) of the labelled IS was obtained. None of the target 
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analytes were detected in method blanks (n=3) consisted of sodium sulphate (~0.1 g) treated 
as a dust sample. Furthermore, our results compared favourably to previously reported 
concentrations of the target PFRs in SRM 2585 (Table 2.5, Chapter V). 
Good recovery was obtained in case of the bioaccessibility experiment (Chapter III) for the 
sweat and sebum matrices at 3 different concentration levels. HBCDs, TBBPA & PFRs were 
ranged from 80-92% (Table 2.7) and the PBDEs recovery ranged from 87-93% (Table 2.8) 
Method performance under the applied experimental conditions was tested via matrix spikes 
of the EPISKIN™ tissues, ex-vivo skin, receptor fluid at 3 different concentration levels of 
the target FRs  (Table 2.9, 2.10, 2.11, Chapter IV). 
ERM-EC 590 (low density polyethylene; LDPE) and ERM-EC 591 (Polypropylene; PP) were 
used in determining the method accuracy in the Episkin-microplastic bioaccessibility and 
bioavailability experiments (Chapter VI) Five replicate analyses of each CRM were 
conducted before the analysis of any bioaccessibility and skin exposure samples. Satisfactory 
recovery data was obtained with %RSD below 20% in compliance with EC Directive 
2002/657/EC. (Table 2.12) 
No known SRM or CRM is available for PFR-treated textiles or fabrics. To the author’s 
knowledge, there are no studies conducted or published analyses on the same materials. 
However the fabrics were spiked with 13C-labelled analytes that were satisfactorily recovered 
(80-92%) (Chapter VII). 
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Table 2.5: Mean ± standard deviation of BFRs in SRM 2585, %RSD and Certified and 
Indicative values (* Indicative values from (Abdallah, Harrad and Covaci 2008b), ** 
indicative values from (Brandsma et al. 2013), # certified values from NIST SRM-2585, 
## indicative values from (Ali et al. 2012b) 
Target compound  This study (n=5) 
Certified Values/Indicative 
Values 
Average     ± SD Average  ± SD 
α-HBCD 22.3 3.4 20 * 3.1 
β-HBCD 4.4 0.8 4.3* 0.5 
γ-HBCD 127.2 21.1 121.0* 19.0 
TBBP-A 234.2 9.4 NM NM 
         TCEP 711 56 792.0** 170 
         TCIPP 788 109 844.0** 100 
         TDCIPP 1928 124 1556.0** 280 
BDE -28 48.3 6.0 46.9# 4.4 
BDE -47 465.0 36.0 497.0# 46 
BDE -99 858.3 31.3 892.0# 53 
BDE-100 141.8 11.7 145.0# 11 
BDE- 153 115.0 15.0 119.0# 1.0 
BDE- 154 85.3 13.5 83.5# 2.0 
BDE- 183 46.0 6.6 43.5# 3.5 
BDE- 209 2345.9 18.0 2510.0# 190 
         EH-TBB 35.8 3.6 40.0## - 
         BTBPE 41.2 7.4 32.0## - 
 
Table 2.6: Standard addition method results for TBBP-A in SRM 2585. 
 
Mass added (ng) Mass recovered 
(ng) 
Recovery  
(%) 
RSD (%)  
(n=5) 
10 8.5 85 2.8 
40 37.3 92.5 3.2 
80 79.1 98.8 3.1 
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Table 2.7: Summary of standard addition “matrix spike” analysis results for target FRs 
in different formulations of skin surface film liquid (SSFL) (Pawar et al. 2016). 
 
Spiking  
Level 
Congener 
100% sweat 1:1 sweat:sebum 100% sebum 
Recovery 
 (%) 
RSD*  
(n=5) 
Recovery 
 (%) 
RSD  
 (n=5) 
Recovery 
 (%) 
RSD  
 (n=5) 
10 ng BFRs, 
100 ng PFRs 
α-HBCD 88.4 5.1 83.2 4.3 83.4 5.4 
β-HBCD 85.3 4.0 81.4 5.2 80.7 3.9 
γ-HBCD 83.6 6.3 85.6 6.7 81.2 6.2 
TBBP-A 85.9 4.2 88.2 3.9 84.5 5.8 
TCEP 92.4 4.3 81.9 4.6 82.8 6.1 
TCIPP 92.6 4.3 80.2 6.1 80.5 4.6 
TDCIPP 86.5 5.2 84.2 5.2 82.3 4.9 
40 ng BFRs, 
 400 ng PFRs 
α-HBCD 91.0 5.8 87.3 5.5 84.8 6.1 
β-HBCD 81.2 4.1 88.9 4.8 82.4 4.5 
γ-HBCD 88.7 4.3 83.5 3.6 87.6 3.8 
TBBP-A 89.3 5.6 85.8 4.4 85.8 5.3 
TCEP 82.2 5.9 90.4 5.1 87.2 5.8 
TCIPP 88.1 6.6 91.6 4.9 83.1 6.7 
TDCIPP 81.6 5.3 86.7 6.2 85.6 6.8 
80 ng BFRs, 
 800 ng PFRs 
α-HBCD 83.8 6.2 83.5 3.9 91.3 5.6 
β-HBCD 89.6 5.3 87.3 4.1 86.2 6.4 
γ-HBCD 86.4 5.9 87.8 5.3 87.1 5.4 
TBBP-A 87.5 6.7 84.9 4.7 88.9 4.9 
TCEP 91.8 6.0 82.1 6.1 90.4 5.2 
TCIPP 90.2 5.3 88.3 5.9 85.7 6.1 
TDCIPP 88.4 6.4 85.4 5.6 89.2 6.4 
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Table 2.8: Summary of standard addition “matrix spike” method results for PBDEs in 
formulation of skin surface film liquid (SSFL). 
Mass added (ng) Congener Mass recovered (ng) Recovery (%) RSD (%) (n=5) 
 
 
50 
BDE-28 42.1 88.2 6.3 
BDE-47 41.0 87.0 4.2 
BDE-99 43.5 89.0 4.3 
BDE-153 46.0 90.3 5.3 
BDE-183 43.8 89.1 4.3 
BDE-209 41.7 88.7 5.2 
500 
BDE-28 435.0 89.4 5.8 
BDE-47 461.0 92.2 4.1 
BDE-99 455.0 93.0 4.3 
BDE-153 428.9 87.7 5.6 
BDE-183 475.0 89.0 5.3 
BDE-209 420.0 86.0 6.2 
1000 
BDE-28 889.0 88.0 8.3 
BDE-47 860.8 93.1 5.9 
BDE-99 870.0 87.5 8.3 
BDE-153 897..7 89.7 9.4 
BDE-183 877.8 92.8 10.3 
BDE-209 899.0 85.9 8.6 
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Table 2.9: Summary of standard addition “matrix spike” method results for PBDEs in 
Receptor fluid. (Abdallah et al. 2015b) 
Mass added (ng) Congener Mass recovered (ng) Recovery (%) RSD (%) (n=5) 
50 
BDE-1 44.6 89.1 5.1 
BDE-8 44.9 89.8 4.0 
BDE-28 44.1 88.2 6.3 
BDE-47 43.5 87.0 4.2 
BDE-99 44.5 89.0 4.3 
BDE-153 45.2 90.3 5.3 
BDE-183 44.5 89.1 4.3 
BDE-209 44.3 88.7 5.2 
500 
BDE-1 447.0 89.4 5.8 
BDE-8 461.1 92.2 4.1 
BDE-28 465.0 93.0 4.3 
BDE-47 438.7 87.7 5.6 
BDE-99 466.0 93.2 5.9 
BDE-153 443.8 88.8 6.6 
BDE-183 445.0 89.0 5.3 
BDE-209 430.2 86.0 6.2 
1000 
BDE-1 879.5 88.0 8.3 
BDE-8 930.8 93.1 5.9 
BDE-28 864.8 86.5 9.7 
BDE-47 907.0 90.7 7.8 
BDE-99 875.1 87.5 8.3 
BDE-153 896.7 89.7 9.4 
BDE-183 927.8 92.8 10.3 
BDE-209 859.3 85.9 8.6 
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Table 2.10: Representative table of standard addition “matrix spike” method results for 
PFRs. (Abou-Elwafa Abdallah et al. 2016) 
Mass added (ng) Matrix Congener Recovery (%) SD  (n=3) 
50 
EPISKIN™ 
TCEP 96.1 5.1 
TCIPP 91.8 4.0 
TDCIPP 93.2 6.3 
Ex vivo skin 
TCEP 87.5 4.2 
TCIPP 89.0 4.3 
TDCIPP 90.3 5.3 
Receptor fluid 
TCEP 97.1 4.3 
TCIPP 98.7 3.9 
TDCIPP 94.7 5.2 
500 
EPISKIN™ 
TCEP 98.6 5.8 
TCIPP 94.2 5.4 
TDCIPP 93.0 4.8 
Ex vivo skin 
TCEP 88.7 5.6 
TCIPP 93.2 5.9 
TDCIPP 90.8 7.6 
Receptor fluid 
TCEP 96.2 5.7 
TCIPP 98.1 6.3 
TDCIPP 95.4 6.6 
1000 
EPISKIN™ 
TCEP 92.8 8.3 
TCIPP 93.1 5.9 
TDCIPP 91.2 9.7 
Ex vivo skin 
TCEP 90.7 7.8 
TCIPP 87.5 8.3 
TDCIPP 89.4 8.4 
Receptor fluid 
TCEP 92.8 9.3 
TCIPP 95.1 7.8 
TDCIPP 91.9 8.6 
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Table 2.11: Matrix spike method for PFRs in cotton bud for skin experiments. 
Mass added (ng) Mass recovered 
(ng) 
Recovery  
(%) 
RSD (%)  
(n=5) 
TCEP 
             50 43.4 86.8 3.7 
            100 83.6 83.6 4.9 
            1000 800.0 80.0 2.7 
TCIPP 
             50             46.5 93.0 2.7 
            100             91.3 91.3 2.2 
            1000 825.0 82.5 4.1 
TDCIPP 
             50             39.8 79.6 3.7 
            100 85.6 85.6              1.9 
            1000 861.8 86.18 2.1 
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Table 2.12: Recovery (%) and RSD (%) for PBDE congeners from ERM-EC590 & 
ERM-EC591. 
Target compound  
This study (n=5) Certified Values (gkg-1) 
 
% RSD 
Average 
(ppm)    ± SD 
Average 
(ppm) ± SD 
 
ERM-EC590 (LDPE) 
BDE -47 0.177 0.06 0.23 0.04 1.34 
BDE -99 0.285 0.09 0.30 0.030 4.67 
BDE-100 0.056 0.01 0.063 0.005 4.11 
BDE- 153 0.046 0.01 0.047 0.006 15.32 
BDE- 154 0.023 0.003 0.026 0.0026 4.44 
BDE- 183 0.10 0.009 0.13 0.012 16.0 
BDE- 209 0.63 0.10 0.65 0.10 18.9 
ERM-EC591 (PP) 
BDE -28 0.191 0.05 0.0025 0.0006 20.0 
BDE-47 0.258 0.08 0.25 0.023 1.76 
BDE -99 0.294 0.07 0.32 0.04 6.8 
BDE-100 0.0056 0.001 0.066 0.007 0.29 
BDE- 153 0.0422 0.003 0.044 0.006 18.42 
BDE- 154 0.021 0.008 0.026 0.004 13.0 
BDE- 183 0.069 0.02 0.087 0.008 14.0 
BDE- 209 0.73 0.15 0.78 0.09 20.0 
 
Table 2.13: Average recoveries (expressed as percent) of the internal (surrogate) 
standards. 
Internal standard Average recovery (%) ± SD 
Fabric-E 92 ± 9 
Fabric-C 87 ± 11 
Fabric-O 81 ± 17 
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2.3.2: Limit of detection (LOD) and limit of quantification (LOQ) 
Instrumental limits of detection (LOD) were calculated for each of the studied compounds 
based on a 10:1 signal to noise ratio (Table 2.14). 
LOQ =   LOD x FEV    x              100               ……… …………………………(2.5) 
               VFEI X SS           % IS RECOVERY  
Where FEV = final extract volume; VFEI = volume of final extract injected; SS = sample 
size (g or L); and % IS Recovery is % recovery of internal standard used to quantify the 
target. For dust method blanks 0.2 g of pre-extracted Na2SO4 was used). None of the studied 
compounds were above the limit of detection (LOD) in the field blank samples. 
A “field” blank, comprising a skin tissue exposed to solvents only (omitting the dust, 
reference material plastics and the upholstered fabrics) and treated as a sample, was 
performed with each sample batch (n= 9). Blank values were subtracted from samples in the 
same batch if the blank contamination was more than 5% of the sample concentration. 
2.4: Statistical analysis 
Statistical analysis of the data was conducted using Excel (Microsoft Office 2003) and SPSS 
version 13.0. In all instances, where concentrations were below the LOQ, concentrations 
were assumed to equal half the LOQ. The results revealed concentrations in all data sets to be 
log-normally distributed. Hence, further ANOVA and t-tests were performed on log 
transformed concentrations. Levene test of homogeneity of variances and the F-test were 
performed on log-transformed data to evaluate statistical significance of the differences in 
variance between the tested data sets. The differences in means among the studied data sets 
were statistically evaluated using the suitable posthoc test (e.g. Bonferroni test if equal 
variances assumed). Confidence limits were preset to 95% while the significance levels in 
SPSS were set at 0.05. 
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Table 2.14: LOD (ng on coloumn) and LOQ (conc) values of HBCDs (LC-MS/MS), 
TBBPA (LC-MS/MS), PFRs (LC-MS/MS), PBDEs (GCMS) and NBFRs (GCMS) 
Analyte 
LOD 
(ng on 
coloumn) 
Method LOQs 
Dust 
(ng/g)  
SSFL  
(ng/mL) 
Skin 
(ng/cm2) 
Receptor 
fluid  
(ng /mL) 
ERM-
EC590/591 
(ng/g) 
Fabrics 
(ng/g) 
α-HBCD 0.027 3.40 0.06 0.034 0.071 NM NM 
  β-HBCD 
γ-HBCD 
TBBPA 
TCEP 
TCIPP 
TDCIPP 
0.030 
0.029 
0.07 
0.006 
0.004 
0.008 
3.80 
3.6 
8.92 
15.30 
10.20 
20.40 
0.07 
0.07 
0.18 
0.30 
0.20 
0.40 
0.035 
0.036 
0.041 
9.18 
6.10 
12.24 
0.078 
0.076 
0.18 
0.32 
0.21 
0.42 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
4.7 
3.16 
6.32 
BDE-28 0.078 0.17 0.003 0.10 0.003 0.13        NM 
BDE-47 0.10 1.60 0.03     0.96 0.033 1.24 NM 
BDE-99 0.13 2.42 0.04 1.45 0.05 1.87 NM 
BDE-100 0.15 2.5 0.05 1.5 0.051 1.93 NM 
BDE-153 0.21 0.54 0.01 0.32 0.01 0.414 NM 
BDE-154 0.22 0.56 0.01 0.33 0.01 0.434 NM 
BDE-183 
BDE-209 
TPhP 
EH-TBB 
TBPH 
BTBPE 
DBDPE 
0.20 
0.24 
0.56 
0.49 
    0.95 
2.3 
4.8 
0.51 
0.61 
1.42 
1.25 
2.42 
5.86 
12.24 
0.01 
0.01 
0.028 
0.025 
0.048 
0.11 
0.24 
0.30 
0.36 
0.857 
0.75 
1.45 
3.52 
7.34 
0.01 
0.01 
0.02 
0.025 
0.05 
0.12 
0.25 
0.394 
0.473 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
 77 
 
                            CHAPTER III 
DERMAL BIOACCESSIBILITY OF FLAME 
RETARDANTS FROM INDOOR DUST 
This chapter contains some material taken verbatim from Pawar, G., M. A. Abdallah, et 
al. (2016). Dermal bioaccessibility of flame retardants from indoor dust and the 
influence of topically applied cosmetics. J Expo Sci Environ Epidemiol 6 (10): 84. 
 
3.1:  INTRODUCTION 
Concerns exist over possible adverse health impacts following numerous reports of exposure 
to BFRs through inhalation, dermal contact and ingestion of both diet and settled dust. 
Physiologically-based in vitro bioaccessibility tests have emerged as an alternative method to 
study the availability for dermal uptake of several xenobiotics including heavy metals 
(Stefaniak et al. 2014, Hedberg, Midander and Wallinder 2010, Kulthong et al. 2010, Duling 
et al. 2012, Hillwalker and Anderson 2014) and pesticides (Ertl and Butte 2012a). Such 
bioaccessibility tests have been incorporated in regulatory frameworks such as the European 
standard for the release of nickel in artificial sweat (BS EN 1811, 2011). Bioaccessibility may 
be defined as “the fraction of the total dose of a specific chemical/contaminant present in a 
matrix that becomes liberated into the body fluids and hence, is available for absorption” 
(Ruby et al. 1996). In other words, a combination of data on bioaccessibility and subsequent 
dermal uptake is required to determine the ability of a chemical (e.g. BFR) present in a matrix 
(e.g. dust), to be released from that matrix and be subsequently absorbed by an organ of the 
human body like the skin (Ertl and Butte 2012a). Bioaccessibility data from in vitro studies 
are considered conservative estimates, because not all the mass of a given chemical released 
into the body fluid (i.e. the bioaccessible fraction) will likely be absorbed through the 
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biological membrane (e.g. skin) to reach the systemic circulation (i.e. bioavailable) (Abdallah 
et al. 2012). Under physiological conditions, the outermost surface of the human skin, the 
stratum corneum, is covered with a skin surface film liquid (SSFL) mixture which consists of 
varying proportions of sweat and sebum (Buckley and Lewis 1960, Nicolaides 1974). Sweat 
is aqueous in nature and functions mainly to regulate the body temperature. It consists of 
electrolytes, organic acids, amino acids, vitamins and other nitrogenous substances. Sebum is 
a clear, oily substance secreted by sebaceous glands and forms a 0.5 to >4.0 µm thick layer to 
protect the skin from drying out. It mainly consists of squalene, wax esters and triglycerides, 
as well as free fatty acids, with a small amount of cholesterol and cholesterol esters 
(Stefaniak and Harvey 2008).  
Cosmetics (e.g. sunscreen creams) may contain certain ingredients (e.g. surfactants) which 
can remain on the skin and become incorporated within the SSFL. This in turn, may alter the 
lipid domain of the skin, by interacting with the proteins in the barrier, or hydration, thereby 
increasing partitioning of chemicals to the SC (Lane 2013). Previous studies have shown 
certain sunscreen lotions to act as inadvertent penetration enhancers for potentially harmful 
chemicals (Pont, Charron and Brand 2004, Walters et al. 1997). Therefore, it is important to 
investigate the effect of topically-applied cosmetics on the dermal bioaccessibility of FRs in 
indoor dust.  
Against this background, this chapter investigates the dermal bioaccessibility of selected 
organic FRs present in house dust in the presence of varying proportion of physiologically-
relevant mixtures of sweat and sebum and topically-applied cosmetic products. 
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Figure 3.1: Schematic illustration depicting the structure of the skin and the absorption 
process for FRs in indoor dust in the presence of sweat/sebum mixture and topically 
applied cosmetics. 
 
 
3.2: EXPERIMENTAL METHODOLGY 
3.2.1: CHARACTERISATION OF THE STUDIED HOUSE DUST 
SRM 2585 is intended for use in evaluating analytical methods for the determination of 
certified and indicative values of target FRs (organics in house dust, particle size < 100 µm 
and total moisture content =2.11 ± 0.06 %) was purchased from NIST (Gaithersburg, MD, 
USA).  Aliquots (n=5, ~0.1 g each) of SRM2585 were analysed for target FRs using 
previously reported methods by our research group (Abdallah et al. 2008b, Brommer et al. 
2012a). Results compared well with the indicative and reported levels of target FRs in this 
SRM. (Chapter 2 Section 2.2.3 Table 2.5) 
3.2.2: PREPARATION OF SYNTHETIC SWEAT/SEBUM MIXTURE 
Physiologically-simulated artificial sweat and sebum mixture (SSSM) was prepared 
according to a previously reported method and US patent (Stefaniak and Harvey 2008) using 
over 25 different chemical components given in table.3.1 
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We prepared 1 L of artificial sweat. To do so, initially 500 mL of fully aerated 18MΩ-cm 
distilled and deionized water were warmed to 32ºC to match human skin temperature and 
stirred continuously in an Erlen Meyer flask. Then the appropriate masses of electrolytes and 
other ionic constituents (given in table 3.1) were added followed by organic acids and 
carbohydrates.The pH was adjusted to that of normal human skin (5.3 ± 0.1) by adding 5 M 
NaOH dropwise using pH electrode, the volume was made up to 1 L and filtered through 0.2 
µM pore size filter and preserved at 4°C.  
 Sebum was prepared according to Stefaniak and Harvey (2008) by dissolving the following 
constituents: squalene, palmityl palmitate saturated, triolein unsaturated, cholesteryl oleate, 
free cholesterol in concentrations found in physiological conditions in 500 mL of hexane in a 
sterilized 1000 mL Erlen Meyer flask with a magnetic stirrer bar. Synthetic sweat and sebum 
were mixed in different physiologically-relevant proportions using Tween 80 to mimic the 
naturally secreted surface active agents in the SSSM. 
3.3: Dermal bioaccessibility in vitro test protocol  
Briefly, ~60 mg of NIST SRM2585 dust and (when tested) 6 mg of cosmetics (moisturising 
cream, shower gel, sun screen lotion, and body spray were each examined separately) were 
accurately weighed and transferred into a clean dry test tube. In the absence of definitive data 
on the dust to sweat ratio on human skin, which is greatly influenced by variations of sweat 
secretion and dust loadings, we adopted a previously reported method (Ertl and Butte 2012) 
to mimic “wet skin conditions” using 1:1000 w/v dust to sweat ratio (i.e. 6 mL of the SSSM 
applied for each 60 mg of dust). The mixture was then gently agitated on a heated magnetic-
stirrer plate maintained at physiological skin temperature (32°C). After 1 hour, phase 
separation was achieved by centrifugation at 3000 rpm for 15 mins. The dust (solid residue) 
and SSSM (supernatant) samples were analysed separately.  
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Table 3.1: Chemical composition of synthetic sweat and sebum mixture (SSSM) 
Sweat Ingredients  Measured Qty.          Company 
Electrolytes and Ionic Constituents    ( g/L)        ( µL/L)  
Sodium Sulfate 0.05826           Sigma Aldrich 
Copper Chloride anhydrous                         803           Merck 
Ammonium Hydroxide                         186           Fisher 
Iron sulfate Heptahydrate 0.00272           Fisher 
Sulfur 0.0737           Fisher 
Lead- Reference Solution 1000 ppm                      1243.0           Sigma Aldrich 
Manganese- Reference Solution 1000 ppm                       691.4           Sigma Aldrich 
Nickel- Reference Solution 1000 ppm                       1232.0           Sigma Aldrich 
Zinc - Reference Solution 1000 ppm                       0.77           Sigma Aldrich 
Sodium Bicarbonate 0.252           FSA  
Potassium chloride 0.4546           VWR 
Magnesium Chloride Hexahydrate 0.01667           Sigma Aldrich 
Sodium Phosphate Anhydrous Monobasic 0.04836           Sigma Aldrich 
Calcium Chloride Dihydrate 0.7654           Fisher 
Sodium chloride 0.05844           Fisher 
Organic Acids and Carbohydrates   
Acetic Acid 0.00781           Sigma Aldrich 
Butyric Acid                      0.22          Sigma Aldrich 
D(+) –Glucose 0.0306          Sigma Aldrich 
Lactic Acid                       2011          Sigma Aldrich 
 Essential Amino Acid Mix  0.01-0.1                              Sigma Aldrich 
DL-Alanine (C3H7NO2)   
L-(+)-Arginine (C6H14N4O2)   
L-(+)-Aspartic acid (C4H7NO4)   
L-(+)-Citrulline (C6H13N3O3) 
L-(+)-Glutamic acid (C5H9NO4) 
  
Glycine (C2H5NO2)   
L-Histidine (C6H9N3O2)   
L-Isoleucine (C6H13NO2) 
L-Leucine (C6H13NO2)L-(+)-Lysine MonoHCL 
(C6H14N2O2°HCl) 
|  
L-(+)-Omithine Hydrochloride (C5H12N2O2°HCl)   
L-Phenylalanine (C9H11NO2)   
L-Threonine (C4H9NO3)   
L-(-)-Tryptophan (C11H12N2O2)   
L-Tyrosine (C9H11NO3)L-Valine (C5H11NO2)   
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Nitrogenous Substances   
Ammonium Chloride 0.00992              Fisher  
Urea 0.6006             Sigma Aldrich 
Creatinine                      1357.0             Sigma Aldrich 
SEBUM   
Squalene 0.5151            Sigma Aldrich 
Palmityl Palmitate (saturated) 0.9718             Sigma Aldrich 
Triolein (Unsaturated) 0.5345             Sigma Aldrich 
Cholesteryl Oleate 0.0972            Sigma Aldrich 
 
Figure 3.2: In vitro Dermal Bioaccessibility experimental configuration 
 
 
3.4: Extraction and Clean-up 
3.4.1: Determination of HBCDs & TBBPA  
All solvents and reagents were purchased from Sigma-Aldrich (Poole, UK) of the highest 
available quality (e.g., analytical grade). Native α-, β-, and γ- HBCD, TBBPA, isotope-
labelled 13C- and d18-α-, β-, and γ-HBCDs, 13C -TBBPA were purchased from Wellington 
Laboratories (Guelph, ON, Canada).  
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Dust/SSSM/cosmetic samples were spiked with 30 µL of 13C-isotopically labelled α-HBCD, 
β-HBCD, γ-HBCD and TBBPA (1ng/µL), prior to extraction with 3 mL of hexane: ethyl 
acetate (1:1 v/v) using a QuEChERS-based method.  
Sample tubes were vortexed on a multi-positional mixer for 5 mins, followed by ultra-
sonication for 5 mins and centrifugation at 3000 rpm for 5 mins. The extraction cycle was 
repeated twice before the pooled supernatant was collected in a clean tube and evaporated to 
~ 1 mL under a stream of N2. The crude extract was washed with ~ 2 mL of 95 % H2SO4 to 
remove lipids. The organic layer and washings were combined and evaporated to incipient 
dryness under N2. Target analytes were reconstituted in 150 µL of methanol containing 50 pg 
/µL of d18-α-HBCD used as recovery determination standard (RDS) prior to LC-MS/MS 
analysis using previously reported methods. (Abdallah et al. 2014a) 
3.4.2: Determination of PFRs 
Native TCEP, TCIPP and TDCIPP and d15-triphenyl phosphate (d15-TPHP) were purchased 
from Wellington Laboratories (Guelph, ON, Canada). Dust/SSSM/cosmetic samples were 
spiked with 30 µL of d15-TPHP (10 ng/µL) used as internal (surrogate) standard prior to 
extraction with hexane: ethyl acetate (1:1 v/v, 3 mL) using the same procedure applied for 
HBCDs. The crude extract (~1 mL) was cleaned up by loading onto a Florisil SPE cartridge 
(pre-conditioned with 6 mL of hexane). Fractionation was achieved by eluting with 8 mL of 
hexane (Fraction 1 (F1), discarded) followed by 10 mL of ethyl acetate, Fraction 2 (F2). F2 
was evaporated to incipient dryness under N2. Target PFRs were reconstituted in 100 µL of 
isooctane containing 13C-BDE-100 used as RDS prior to GC/MS analysis according to a 
previously reported method. (Abdallah and Covaci 2014a).  
3.4.3: Determination of PBDEs and novel BFRs 
Native PBDE congeners, TBB, BTBPE, 13C-BDE-47, and 13C-BDE-153 were purchased 
from Wellington Laboratories (Guelph, ON, Canada). Dust/SSSM were spiked with 30 µL of 
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13C-BDE-47 & 13C-BDE-153 (1 ng/µL) used as internal (surrogate) standards prior to 
extraction with hexane: ethyl acetate (1:1 v/v, 3 mL) and subjected to agitation on a multi-
positional vortex mixer for 5 mins. Extraction of target BFRs was achieved via ultra-
sonication of the samples for 5 mins and centrifugation at 3000 rpm for 5 minutes. The 
resulting supernatant liquid was aliquoted to clean test tubes. The extraction steps were 
repeated twice using fresh solvent mixture every time. The pooled supernatant fluid was 
subjected to evaporation under N2 stream until ~ 2 mL.Two mL of 95 % of H2SO4 were 
added to remove the lipid content with a slightly manual agitation and the resulting 
supernatant liquid transferred to a clean tube. The sulfuric acid phase was washed twice with 
1 mL of hexane and pooled them with the previous one. The clean extract was subjected to 
complete dryness under N2 stream and reconstituted in 150 µL of the correspondent RDS 
containing 50 pg/µL of 13C-BDE-100 and analysed by GC-MS. 
3.5: Assessment of dermal bioaccessibility 
In this study, bioaccessibility is expressed as fbioaccessible, calculated (equation 3.1) as the 
percentage of each target FR present in the dust that was found in the supernatant at the end 
of each bioaccessibility experiments (all experiments were carried out in triplicate, hence 
average values were used)  
fbioaccessibile (%) =                                                                   x 100 … ……………………(3.1) 
  
3.6: RESULTS  
3.6.1: Dermal bioaccessibility of HBCD, TBBPA and PFRs 
In general, ƒbioaccesssible of HBCDs and TBBPA increased with increasing sebum content of the 
SSFL (Table 3.3). At 100% sweat, the ƒbioaccesssible of γ-HBCD (1.4 ± 0.1%) was less than that 
of β–HBCD (1.6 ± 0.6%) and α-HBCD (2.3 ± 0.2%). However, the reverse trend was 
observed at 100% sebum, where the fbioaccesssible was highest for γ-HBCD (67.2 ± 3.37%), 
followed by β–HBCD (60.4 ± 10.1%) and α-HBCD (50.5 ± 7.0%). This behaviour is 
Average mass of FR in supernatant  
 Average mass of FR in dust 
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consistent with the lower water solubility of the γ-isomer (2 µg/L) compared to that of β–
HBCD (15 µg/ L) and α-HBCD (49 µg/ L) (Abdallah et al. 2012).We recorded ƒbioaccesssible 
values for TBBPA of 3.5 ± 0.5 % and 55.7 ± 8.5 % in 100% sweat and 100% sebum, 
respectively. Compared to HBCDs, the higher ƒbioaccesssible value for TBBPA in 100% sweat is 
likely attributable to the higher water solubility of TBBPA (1.26 x 103 µg/L). Compared to 
the aqueous-based sweat, the substantially higher bioaccessibility of the studied BFRs in 
sebum can be attributed to the enhanced solubility of these lipophilic chemicals in the oily 
sebum.  
In general, PFRs were more bioaccessible in sebum than sweat. In 100 % sweat, ƒbioaccesssible 
values for the studied PFRs were 16.0 ± 1.2% (TCEP), 12.4 ± 4.4% (TCIPP) and 11.9 ± 3.6% 
(TDCIPP); while in 100% sebum, the corresponding values were 22.3 ± 2.3% (TCEP), 26.9 ± 
6.4% (TCIPP), and 28.1 ± 0.6 % (TDCIPP). This concurs with the physicochemical 
properties of our target PFRs (Table 3.2). In particular, the water solubility of TCEP, TCIPP 
and TDCIPP was reported as 7 x 103, 1.6 x 103 and 1.5 mg/L, respectively (van der Veen and 
de Boer 2012a).  
Compared to the studied BFRs, PFRs show higher bioaccessibility in sweat and lower 
bioaccessibility in sebum (Table 3.3), which can be attributed to the differences in log Kow 
and water solubility among these two classes of FRs (Table 3.2). Overall, under the more 
physiologically abundant SSFL composition (1:1 sweat: sebum) studied here, BFRs showed 
higher dermal bioaccessibility than PFRs, which may be attributed to increased partitioning 
of the more lipophilic BFRs from dust to the oily sebum.  
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Table 3.2: Physicochemical properties of target FRs relevant to dermal exposure 
(KEMI 2008, EU Risk Assessment Report 2006, van der Veen and de Boer 2012a). 
Full name Acronym Water Solubility 
(µg/L, 25oC, pH=7) 
Log Kow 
Tetrabromobisphenol- A TBBPA 1.26 x 103 4.50 
1,2,5,6,9,10- 
hexabromocyclododecane 
HBCD 48.8  α-HBCD 
14.7 β-HBCD 
2.1 γ-HBCD 
66 ΣHBCDs 
5.07 ± 0.09 α-
HBCD 
5.12 ± 0.09 β-
HBCD 
5.47 ± 0.10 γ-HBCD 
Tris(2-chloroethyl)phosphate TCEP 7 x 106 1.44 
Tris(chloroisopropyl)phosphate TCIPP 1.6 x 106 2.59 
Tris(1,3-dichloro-2-
propyl)phosphate 
TDCIPP 1.5 x 103 3.80 
 
3.6.2: Effect of cosmetics on the dermal bioaccessibility of HBCD, TBBPA and PFRs in 
indoor dust 
To investigate the influence of commonly applied cosmetics on the dermal bioaccessibility of 
FRs in indoor dust, we determined ƒbioaccesssible values of target FRs from reference dust into 
1:1 sweat: sebum mixture, in the presence of (separately) moisturizing cream, sunscreen 
lotion, body spray, and shower gel. Results for each target compound were compared to a 
control group comprising reference dust exposed only to 1:1 sweat: sebum mixture without 
any surfactant or cosmetics. Except for TBBPA, statistically significant differences (P<0.05; 
ANOVA) were observed between ƒbioaccesssible values of target FRs in the presence of various 
cosmetics compared to the control group (Figure 3.3).
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Table 3.3: Effect of the composition of SSFL on the bioaccessibility (fbioaccessible) of target FRs from indoor dust 
 fbioaccessible (%) for different SSSM compositions 
Compound 100% Sweat 
99:1 
sweat: sebum 
95:5 
sweat: sebum 
9:1 
sweat: sebum 
8:2 
sweat: sebum 
1:1 
sweat: sebum 
100% Sebum 
α-HBCD 2.3 ± 0.2 2.4 ± 0.2 12.0 ± 6.0 20.0 ± 2.8 36.1 ± 2.7 40.9 ± 2.9 50.5 ± 7.0 
β-HBCD 1.6 ± 0.6 3.6 ± 0.7 10.1 ± 1.3 14.5 ± 5.7 29.7 ± 0.6 46.9 ± 3.4 60.4 ± 10.1 
γ-HBCD 1.4 ± 0.1 4.1 ± 1.8 11.4 ± 2.2 19.0 ± 5.4 23.2 ± 6.5 49.6 ± 5.8 67.2 ± 3.37 
Σ-HBCD 1.8 ± 0.2 3.3 ± 0.89 11.47± 4.1 18.7 ± 4.0 30.0 ± 4.2 45.2 ± 4.1 58.5 ± 5.7 
TBBPA 3.5 ± 0.5 4.8 ± 1.9 9.6 ± 4.2 25.2 ± 7.1 32.4 ± 5.4 39.5 ± 4.3 55.7 ± 8.5 
TCEP 16.0 ± 1.22 15.8 ± 0.8 14.8 ± 0.9 12.2 ± 1.0 11.2 ± 1.4 10.4 ± 1.8 22.3 ± 2.3 
TCIPP 12.4 ± 4.4 15.4 ± 2.8 20.6 ± 3.2 8.4 ± 2.2 11.9 ± 1.9 17.4 ± 2.7 26.9 ± 6.4 
TDCIPP 11.9 ± 3.6 12.0 ± 0.5 13.0 ± 0.4 10.5 ± 0.4 12.4 ± 0.3 18.6 ± 0.8 28.1 ± 0.6 
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Interestingly, the presence of cosmetics seems to decrease the bioaccessibility of HBCDs 
from indoor dust (Figure 3.3). This is in agreement with the reported slight decrease in 
dermal bioaccessibility of PCBs from house dust in the presence of skin cream (Ertl and 
Butte 2012b), which was attributed to possible retention of the lipophilic chemicals by skin 
cream lipids. Our results also show that while shower gel and sunscreen lotion enhanced the 
bioaccessibility of target PFRs, body spray significantly decreased the ƒbioaccesssible value of 
TDCIPP from indoor dust (Figure 3.3). To summarise, our results agree with previous reports 
that cosmetics contain various ingredients that can alter the composition of the SSFL and 
affect the availability of dust-bound FRs for dermal uptake. However, it is also evident that 
the nature and magnitude of this effect is substance-specific and highly dependent on the 
composition of the cosmetic preparation. The effect of surfactants - that are common 
ingredients of most cosmetics - on the dermal absorption of various chemicals has been 
previously highlighted (Pont et al. 2004, Walters et al. 1997). In addition, we hypothesize that 
the lipid content, ionic strength and skin contact period of these cosmetics can also influence 
the bioaccessibility of FRs from indoor dust. Detailed studies are required to test this 
hypothesis and fully investigate the factors affecting the bioaccessibility of FRs and 
ultimately their dermal uptake in the presence of various cosmetic preparations.  
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Figure 3.3: Effect of applied cosmetics on the bioaccessibility (fbioaccessible %) of target FRs from indoor dust. 
 
 
* Denotes a statistically significant difference (P < 0.05) from the control group. 
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3.6.3: Dermal bioaccessibility of PBDEs 
In general, ƒbioaccesssible of PBDEs increased with increasing sebum content of the SSFL (Table 
3.5). At 100% sweat, the ƒbioaccesssible of BDE-209 (0.04 ± 0.01%) was found to be lowest 
which could be due to its low water solubility (<0.0001 mg/L) as compared to other 
congeners. (Table 3.5).However, the reverse trend was observed at 100% sebum, where the 
fbioaccesssible was highest for BDE-209 (98.5 ± 7.78%), followed by BDE-28 (98.2 ± 7.08%) 
and BDE-47 (87.18 ± 3.13%). At the most abundant physiologically relevant proportion i.e. 
1:1 sweat sebum mixture, fbioaccesssible was highest for BDE-209 (79.37 ± 7.66%). The results 
show no negative correlation between the degree of congener bromination and the fbioaccesssible. 
This could be due to the equal proportion of aqueous and lipid content of the SSFL. 
Compared to the aqueous-based sweat, the substantially higher bioaccessibility of the studied 
BFRs in sebum can be attributed to the enhanced solubility of these lipophilic chemicals in 
the oily sebum.  
3.6.4: Effect of cosmetics on the dermal bioaccessibility of PBDEs in indoor dust 
The dermal bioaccessibility of PBDEs in presence of cosmetics, when compared to a control 
group comprising reference dust exposed only to 1:1 sweat: sebum mixture without any 
surfactant or cosmetics indicated that the presence of cosmetics seems to decrease the 
bioaccessibility of PBDEs from indoor dust (Table 3.6) which could be attributed to possible 
retention of the lipophilic chemicals by skin cream products like moisturising cream, sun 
screen lotion and shower gel. Interestingly there was no significant decrease in the 
bioaccessibility of PBDEs in presence of body spray which could be due to the gaseous form 
of the formulation. 
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Table 3.4: Physicochemical properties of PBDEs relevant to dermal exposure 
       Mol. wt.  Water 
Solubility 
(mg/L) 
Log Kow 
BDE-28 406.8 0.07 5.94 
BDE-47 485.8 0.002 6.81 
BDE-99 564.7 0.0024 7.32 
BDE-153 643.6 0.0009 7.9 
BDE-183  722.5 0.0015 8.27 
BDE-209 959.2 <0.0001 10.3 
 
Table 3.6: Effect of applied cosmetics on the bioaccessibility (fbioaccessible %) of target FRs 
from indoor dust. 
PBDEs Control Dust/SSSM (1:1)/ 
Moisturising 
Cream 
Dust/SSSM(1:1)/ 
Body Spray 
Dust/SSSM(1:1)/ 
Sun screen Lotion 
Dust/SSSM(1:1)/ 
Shower Gel 
BDE-28 73.5 ± 8.9 65.0 ± 13.0 72.0 ± 8.5 68.0 ± 15.0 72.0 ± 11.2 
BDE-47 72 ± 11.9 63.5 ± 8.0 71.0 ± 6.0 59.0 ± 16.3 70.0 ± 20.0 
BDE-99 63.16 ± 11.28 58.0 ± 5.0 61.0 ± 6.2 55.0 ± 2.8 56.0 ± 13.2 
BDE-100 71.9 ± 8.9 66.0 ± 8.5 70.0 ± 2.8 63.5 ± 19.3 60.0 ± 2.2 
BDE-153 67.98 ± 10.8 64.0 ± 2.3 62.5 ± 2.6 59.5 ± 18.2 61.0 ± 11.8 
BDE-183 50.8 ± 10.11 45.0 ± 11.0 50.0 ± 3.8 47.0 ± 12.0 43.0 ± 15.0 
BDE-209 79.37 ± 7.66 70.0 ± 17.0 77.0 ± 18.0 68.0 ± 13.7 66.0 ± 10.0 
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Table 3.5: Effect of the composition of synthetic sweat and sebum mixture (SSSM) on the bioaccessibility (fbioaccessible) of target FRs from 
indoor dust. 
 
 fbioaccessible (%) for different SSSM compositions 
Compound 100% Sweat 
99:1 
sweat: sebum 
95:5 
sweat: sebum 
9:1 
sweat: sebum 
8:2 
sweat: sebum 
1:1 
sweat: sebum 
100% Sebum 
BDE-28 3.1 ± 1.6 13.0  ± 3.4 33.5  ± 9.85 46.2 ± 19.72 58.9  ± 4.19 73.5 ± 8.9 98.2 ± 7.08 
BDE-47 3.25  ± 0.04 3.97 ± 0.5 58.73  ± 11.8 63.59 ± 7.3 88.26  ± 19.35 72 ± 11.9 87.18  ± 3.13 
BDE-99 4.44  ± 2.09 4.04  ± 1.07 26.15  ± 11.54 49.69 ± 6.96 60.51   ±  13.76 63.16 ± 11.28 69.61  ± 6.06 
BDE-100 6.1 ± 1.6 13.4 ± 9.35 42.94 ± 7.11 58.36  ±  5.13 66.3  ± 3.18       71.9 ± 8.9 75.39 ± 10.58 
BDE-153 1.5 ± 0.92 4.4 ± 0.92 36.75  ± 3.26 48.6  ± 23.24 64.64 ± 18.48 67.98 ± 10.8 74.75  ± 16.11 
BDE-183 0.89  ± 0.17 2.79 ± 1.84 4.04 ± 1.21 12.42 ± 5.24 17.54 ± 7.8 50.8 ± 10.11 79.37 ± 7.66 
BDE-209 0.04 ± 0.01 0.17± 0.07 0.19 ± 0.17       1.7 ± 0.15 4.84 ± 3.39 79.37 ± 7.66 98.5 ± 7.78 
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3.7: Comparison of digestive and dermal bioaccessibility 
Despite the vast differences between the digestive and dermal body fluids in terms of both 
composition and function, it is instructive to compare our results to previously reported 
bioaccessibilities of target FRs via the oral route. This can shed some light on the relative 
importance of dermal uptake versus ingestion as pathways of human exposure to FRs in 
indoor dust.  Abdallah et al. (Abdallah et al. 2012) reported on the gut bioaccessibility of 
HBCDs and TBBPA from indoor dust using a colon enhanced-physiologically based 
extraction test (CE-PBET). On average, fbioaccessible values of 92%, 80%, 72% and 94% were 
reported for α-, β-, γ-HBCDs and TBBPA, respectively. These are almost twice the dermal 
ƒbioaccesssible values for the same BFRs in our study (Table 3.3) 
The gut bioaccessibility of PFRs following ingestion of indoor dust was also studied using a 
modified version of the CE-PBET mentioned above (Fang and Stapleton 2014). Mean 
fbioaccessible values for TCEP, TCIPP and TDCIPP from 17 house dust samples were 80%, 82% 
and 85%, respectively, which are substantially higher than the corresponding dermal 
fbioaccessible values for the same PFRs (Table 3.3). 
The substantially higher gut bioaccessibility of FRs may be attributed to several factors. 
These include the strong acidic medium in the stomach (pH = 1), the bile salts and digestive 
enzymes in the small intestine, the presence of carbohydrates to simulate the fed status, 
coupled with the long contaminant residence time in the models used (~13 - 21.5 hours) 
(Abdallah et al. 2012, Fang and Stapleton 2014) compared to the 1 h dermal exposure period 
used in this study. More research is required to fully understand the influence of prolonged 
dermal exposure times on the bioaccessibility of FRs from indoor dust and examine the 
kinetics of the release of various FRs from indoor dust to the sweat/sebum mixture. (Abou-
Elwafa Abdallah et al. 2012) reported the % of  bioaccessibility to be 58 ± 3.7,41 ± 3.4, 53 ± 
2.2, 48 ± 2.3, 32 ± 2.5, 44 ± 2.9, 14.0 ± 1.3 for BDE-47, BDE-99, BDE-100, BDE-153, BDE-
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154, BDE-183 and BDE-209 respectively using a colon enhanced-physiologically based 
extraction test (CE-PBET). Another study by Fang et al (Fang and Stapleton 2014) carried 
out the bioaccessibility assessment for organophosphate flame retardants and PBDEs from 
dust however their study lacked a colon compartment in their model but they used tenax as a 
sink which resulted in an increase in the bioaccessible fraction.  
These value ranged from ~ 60% for low molecular weight congeners to ~ 25% for BDE-209 
Interestingly these values are lower than that of our dermal bioaccessibility results at 1:1 
seat/sebum mixture. The substantially higher dermal bioaccessibility of PBDEs may be 
attributed to several factors. These include the presence of both the aqueous and lipid phase 
of sweat/sebum formulation, in addition to the electrolytes and salts that might have 
contributed to enhanced dissolution and partitioning of all the PBDE congeners from dust to 
the simulated biological fluid. More research is required to fully understand the influence of 
prolonged dermal exposure times on the bioaccessibility of FRs from indoor dust and 
examine the kinetics of the release of various FRs from indoor dust to the sweat/sebum 
mixture.  
3.8: Assessment of human dermal exposure to FRs in indoor dust  
The results of dermal bioaccessibility experiments obtained in this study (Table 3.3 & Table 
3.4) were used to gain some insight on the internal dose of the target FRs arising from dermal 
exposure to contaminated indoor dust. Results revealed ƒbioaccesssible values for the studied FRs 
in indoor dust were significantly influenced by the presence of various cosmetic preparations. 
However, incorporation of our data into risk assessment models is hampered by the current 
lack of reliable information on the exact amount of cosmetics remaining on the skin after 
application and on the skin residence time of such formulations. Therefore, exposure 
assessment estimations were performed without such data.
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Human dermal exposure to our target FRs was estimated using the general equation: 
                        
……………………….. (3.2)                                                                                                     
Where DED = Daily exposure dose (ng/kg bw/day), C = FR concentration in dust (ng/g), 
BSA = Body surface area exposed (cm2), DAS = Dust adhered to skin (mg/cm2), FA = 
fraction absorbed by the skin (unitless), IEF = indoor exposure fraction (hours spent over a 
day in an indoor environment) (unitless), BW = Body weight (kg). 
We estimated the dermal exposure of 2 age groups (adults and toddlers) using three exposure 
scenarios. We used data previously reported by our research group on the minimum, median 
and maximum concentrations (Table 3.8 & 3.9) of target FRs in indoor dust from several UK 
microenvironments (Brommer 2014, Abdallah et al. 2008b) & (Tao, Abdallah et al. 2016) to 
estimate low, average and high exposure, respectively. 
The parameter FA in equation 3.2 was replaced by the experimental values of ƒbioaccesssible 
obtained in this study for each target FR at the most physiologically abundant sweat: sebum  
 
Table 3.7: Parameters used in dermal exposure assessment of target FRs in indoor dust 
(USEPA 2011). 
Parameter Adult Toddler 
Age >18 years 2-3 years 
Body weight 70 Kg 15 Kg 
Body surface area 1.94 m2 0.6 m2 
Skin surface exposed  4615 cm2 (head, forearms, 
hands 
 and feet) 
2564 cm2 (head, extremities 
including hands and feet) 
Dust adhered to skin 0.01 mg/cm2 0.04 mg/cm2 
Indoor exposure fraction 
(Abdallah et al. 2008b) 
  
House 63.8% 86.1% 
Office 22.3% - 
Car 4.1% 4.1% 
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mixture (1:1) (Table 3.5). Values for other parameters in equation 2 were obtained from the 
USEPA exposure factors handbook (USEPA 2011) and summarized in table 3.6 
Our dermal exposure estimates (Table 3.10 & 3.11) highlight the potential importance of the 
dermal route as a pathway of human exposure to FRs in indoor dust. The average scenario 
estimate of dermal exposure of UK adults and toddlers to the target BFRs ranged from (99-
110%) and (44-59%) respectively, of their estimated exposure via dust ingestion (Abdallah et 
al. 2008b) (Figure 3). For PFRs, the estimated average dermal exposure corresponded to (26-
42%) and (28-45%) of previously reported exposure via dust ingestion (Brommer 2014). 
However, it should be noted that our dermal exposure estimates assume a fixed body area 
undergoing constant exposure to FRs in indoor dust for a constant period daily at a fixed 
absorbed fraction derived from 1 h dermal contact time with indoor dust. Such rigid 
assumptions are likely unrealistic and introduce uncertainty to our estimates of dermal 
exposure. A further significant caveat is that our estimates account only for bioaccessibility – 
i.e. the efficiency of release of FRs from dust into sweat/sebum. While this is important, 
reliable data are not yet available on the subsequent dermal transfer of the studied FRs from 
sweat/sebum across the epidermis to the systemic circulation. Such transfer will very likely 
be <100%, and thus the true influence of dermal exposure to dust will likely be appreciably 
lower than the values shown in Table 3.10. While noting this caveat, we also note that our 
estimates of exposure via dust ingestion assume 100 % efficiency of transfer from dust into 
gut fluids and thence across the gastro-intestinal tract. 
In a risk assessment context, an extensive survey of the available literature revealed a No 
Significant Risk Level (NSRL) of 5.4 µg/day for TDCIPP listed as a carcinogen under the 
State of California safe drinking water and toxic enforcement act of 1986, PROPOSITION 65 
(OEHHA 2015). No other health based limit values (HBLVs) of legislative standing for our 
target FRs were found in the literature. However, based on a chronic no observed adverse 
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effect level (NOAEL) divided by an uncertainty factor of 1,000, HBLVs of 22,000 and 
80,000 ng/kg bw/day were derived for TCEP and TCIPP respectively (Ali et al. 2012a). Our 
worst-case scenario exposure estimates for dermal exposure of adults and toddlers fall far 
below these HBLV values even under our high-end dermal exposure scenario. However, as 
noted by Ali et al. (Ali et al. 2012a), the HBLV values cited here were based on relatively old 
toxicological studies and it is possible that future research may erode the margin of safety.    
Table 3.11 summarises the exposure estimates of UK adults and toddlers to the studied 
PBDEs via dermal exposure via indoor dust. It is instructive to compare our estimated 
exposure values with currently available health-based limit values (HBLVs) for PBDEs. US 
EPA recommended HBLV values for BDE-47 and BDE-99 as 0.1 µg/kg/d (IRIS 2008a, b).  
Our results for BDE-47 and BDE-99 were found to be below HBLV of 0.1 µg/kg/d. The 
reference dose (RfD) of daily oral exposure to BDE-209 of 7 μg/kg bw/day is considered to 
be without appreciable risk of deleterious effects (U.S. EPA, 2008). This comparison 
revealed the estimated exposures for BDE-209 via dermal exposure pathways fell below the 
HBLV values. It is obvious that the human skin poses an extra barrier to these hazardous 
chemicals, however the dermal pathway should definitely be considered, along with other 
routes, when assessing the overall human exposure to FRs and the potential risk arising from 
it. In conclusion, notwithstanding the various caveats noted above, the results of this in vitro 
bioaccessibility study provide some important first insights into human dermal exposure to 
various FRs present in indoor dust. The composition (i.e. sweat: sebum ratio) of skin fluids, 
as well as the presence/absence of commonly used skin cosmetics is demonstrated to exert a 
insignificant  influence on the efficiency with which our target FRs are released from dust 
and rendered available for dermal uptake. 
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Table 3.8: Concentrations of target FRs (ng/g dry weight) in UK indoor dust from 
different microenvironments (Brommer 2014, Abdallah et al. 2008b). 
 Homes* Offices$ Cars# 
FR Min Median Max Min Median Max Min Median Max 
α-HBCD 22 380 6600 15 220 2900 54 2000 8800 
β-HBCD 9 93 2600 11 84 1300 16 740 5200 
γ-HBCD 70 670 7500 36 470 3700 27 9600 56000 
TBBPA 0.03 62 382 0.03 36 140 0.03 2 25 
TCEP <60 810 28000 <60 870 160000 <60 1230 8700 
TCIPP 3700 21000 100000 3600 33000 230000 2400 53000 370000 
TDCIPP 60 710 14000 <30 480 51000 110 31000 740000 
* n = 35 for BFRs and 32 for PFRs. $ n = 28 for BFRs and 19 for PFRs. # n = 20 for BFRs and 21 for PFRs. 
Table 3.9: Concentrations of target PBDEs (ng/g dry weight) in UK indoor dust (Tao, 
Abdallah and Harrad 2016a) 
 Offices (n = 47) 
PBDEs Min Median Max 
BDE-28 <0.03 2.6 22.0 
BDE-47 7.1 37.0 660 
BDE-99 15.0 77.0 480 
BDE-100 1.9 12.0 120 
BDE-153 0.025 9.2 190 
BDE-183 0.065 9.8 220 
BDE-209 200 2700 110000 
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Table 3.10: Assessment of human dermal exposure (ng/kg bw/day) to FRs present in 
indoor dust upon contact with a skin surface film composed of 1:1 sweat: sebum 
FR/ 
Scenario 
       UK Adult     UK Toddler 
Low Average  High Low Average  High 
α-HBCD 0.1 1.0 14.1 0.1 1.1 16.9 
β-HBCD <0.1 0.3 6.7 <0.1 0.4 7.9 
γ-HBCD 0.2 3.0 25.8 0.2 3.3 29.7 
TBBPA <0.1 0.1 0.7 <0.1 0.1 0.9 
TCEP <0.1 0.1 3.7 <0.1 0.5 17.4 
TCIPP 0.3 0.5 6.4 3.9 4.7 46.8 
TDCIPP <0.1 0.1 2.2 <0.1 0.9 19.2 
 
Table 3.11: Assessment of human dermal exposure (ng/kg bw/day) to PBDEs present in 
indoor dust upon contact with a skin surface film composed of 1:1 sweat: sebum 
FR/ 
Scenario 
       UK Adult     UK Toddler 
Low Average  High Low Average  High 
BDE-28 0.000009 0.0008 0.0069 0.0001 0.0113 0.0957 
BDE-47 0.0022 00.0112 0.2005 0.0301 0.1566 2.7942 
BDE-99 0.0040 0.0205 0.1276 0.0556 0.2852 1.7781 
BDE-100 0.0006 0.0036 0.0365 0.0080 0.0508 0.5080 
BDE-153 0.000007 0.0026 0.0593 0.0001 0.0368 0.7597 
BDE-183 0.000014 0.021 0.0687 0.0002 0.0294 0.6597 
BDE-209 0.0667 0.9000 37.0 0.9291 12.5423 510.98 
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Fig 3.4: Comparison for (a) UK adults and (b) toddlers of exposure (ng/kg bw. day) to FRs in indoor dust via dermal contact (this study, 
average exposure scenario) and dust ingestion (Abdallah et al. 2008b, Brommer 2014) 
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CHAPTER IV 
Studies of dermal uptake of FRs applied as neat 
compounds to in vitro models 
 
Introduction 
This chapter reports the results of a series of experiments designed to study the dermal fate of 
a number of halogenated and phosphorus flame retardant chemicals applied as neat 
compounds (pure form of a chemical in a solvent) to in vitro 3D-HSE models. Results 
obtained using 2 commercially available 3D-HSE models were compared with each other and 
with those obtained from parallel experiments conducted using a commercially available ex 
vivo human skin model. 
4.1: NEAT COMPOUND APPLICATION TO 3D-HSE MODELS 
 4.1.1: MATTEK’S EpiDermTM  
The EpiDermTM EPI-212X-3D kit was obtained from MatTek Corporation (Ashland, MA). 
EpiDermTM EPI-212 tissue constructs are 0.26 cm2 human skin equivalents resembling the 
normal human epidermis (www.mattek.com). The kit includes maintenance medium (MM) 
which is a proprietary DMEM-based medium that allows acceptable differentiated 
morphology of the EpiDermTM EPI-212-X tissue for at least five days upon receipt (Figure 
4.1).  Fig 4.1: Microscopic view of MatTek EpiDermisTM 
         
Stratum Corneum 
Corneum Epidermis 
Microporous membrane 
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4.1.1.A: Storage & Equilibration: Upon receipt at Birmingham, sterile forceps were used to 
remove the tissues from the package, adhered agarose to the outside of the cell culture insert 
(if any) was removed by either  sterile forceps or directly wiped on the sterile gauze supplied 
with the kit. The 12 skin patches with the inserts were cultured overnight in 12-costar well 
plates containing 1 mL of MM media at 5 ± 1% CO2 and 37±1 °C before use in exposure 
experiments (Figure 4.2). 
                                                 Fig 4.2: EpiDermTM EPI-212X-3D kit 
 
                                   
4.1.1.B: Preparation of Epiderm for Percutaneous Absorption measurement: 
A MatTek Permeation device (MPD, part no. EPI-100-FIX, Figure 4.3) was used to mount 
the tissues directly with the inserts. The cell culture inserts which contain the Epiderm 
tissue with underlying microporous membrane were inserted between the 2 pieces of the 
device and the 4 screws/nuts tightened to create a seal between the bottom rim of the 
device’s inner annulus and stratum corneum. The MPD was reused after washing and 
sterilization by soaking in 70% ethanol for 30 minutes. 
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                                       Fig 4.3: Mattek Permeation Device 
 
                                     
4.1.1.C:  Experimental setup 
The donor solution volume for MPD device for mounting the EPI-212-X is 0.4 mL. 
Sufficient donor volume (typically 100µL) of dosing vehicle was used so that the donor 
concentration would not drop more than 5% throughout the course of the permeation 
experiment. Five mL of a DMEM-based culture medium was used as a receptor solution in a 
6 well plate (Figure 4.4). To comply with the OECD guidelines, 5% bovine serum albumin 
(BSA) was added to the receptor fluid (Table 4.1) to enhance the solubility of target analytes, 
while the levels of test compounds in the donor solution were chosen to ensure that the 
concentrations in the receptor fluid during the experiment did not exceed 10% of the 
saturation solubility. 
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Fig 4.4: Permeability Configuration using MatTek Permeation Device (MPD) 
illustrating exposure of donor solution to the surface of EpiDerm tissue and receptor 
compartment containing DMEM culture medium. 
 
 
 
4.1.1. D: Equilibration and dosing of neat compound 
Before dosing, the permeation device containing the tissue was equilibrated to the desired 
physiological temperature of 37°C in the incubator. According to  OECD guidelines (OECD, 
2004), the target compounds given in table below 4.1 were prepared in acetone  and  applied 
to each of the investigated skin tissues using an appropriate volume (100 μL) of dosing 
solution. The applied doses fall within the range of potential human exposure to the studied 
BFRs via contact with indoor dust (Abdallah et al. 2008a). Acetone was selected as the 
dosing vehicle on the basis of its ability to dissolve the test compounds at the desired levels 
and its minimal effect on skin barrier functions (Abrams et al. 1993). A previous study of the 
effect of organic solvents on the trans-epidermal water loss (TEWL) as an indicator of skin 
barrier revealed no significant differences in the behaviour  of acetone and hexane compared 
to that of water, while a mixture of chloroform and methanol [2:1 (v/v)] caused the most 
signiﬁcant increase in TEWL (Abrams et al. 1993). All experiments were performed in 
triplicate. 
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Table 4.1: Components of the modified DMEM (D0422, Sigma-Aldrich, UK) medium 
used as maintenance/receptor fluid for the investigated tissues. 
 
Component D0422 
Inorganic Salts g/L 
Calcium Chloride 0.2 
Cupric Sulfate • 5H2O 0.0000001 
Ferric Nitrate • 9H2O 0.0000001 
Magnesium Chloride • 4H2O 0.0000001 
Magnesium Sulfate (anhydrous) 0.0977 
Potassium Chloride 0.4 
Sodium Bicarbonate 2.2 
Sodium Chloride 6.8 
Sodium Phosphate Monobasic 
(anhydrous) 0.122 
Zinc Sulfate • 7H2O 0.0000002 
Amino Acids  
L-Alanine 0.09 
L-Arginine (free base) 0.05 
L-Asparagine • H2O 0.02 
L-Aspartic Acid 0.03 
L-Cysteine (free acid) 0.04 
L-Cystine 0.02 
L-Glutamic Acid 0.0445 
L-Glutamine — 
Glycine 0.05 
L-Histidine (free base) 0.015 
L-Isoleucine 0.05 
L-Leucine 0.075 
L-Lysine • HCl 0.08746 
L-Methionine 0.015 
L-Phenylalanine 0.025 
L-Proline 0.03 
L-Serine 0.01 
L-Threonine 0.04 
L-Tryptophan 0.01 
L-Tyrosine • 2Na • 2H2O 0.05045 
L-Valine 0.05 
Vitamins  
Ascorbic Acid • Na 0.00227 
D-Biotin 0.0005 
Calciferol 0.0001 
Choline Chloride 0.0015 
Folic Acid 0.001 
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Myo-Inositol 0.002 
Menadione (sodium bisulfite) 0.00001 
Niacinamide 0.001 
D-Pantothenic Acid (hemicalcium) 0.001 
Pyridoxal • HCl 0.001 
Retinol Acetate 0.0001 
Riboflavin 0.0001 
Thiamine • HCl 0.001 
DL-α-Tocopherol Phosphate • Na 0.00001 
Vitamin B12 0.0002 
Other  
D-Glucose 2 
Glutathione (reduced) 0.00005 
Methyl Linoleate 0.00003 
Phenol Red • Na 0.0107 
Pyruvic Acid • Na 0.025 
bovine serum albumin (BSA) 5% v/v 
Penicillin and streptomycin 
100 U penicillin and 100 μg 
streptomycin/Ml 
 
 
            Fig 4.5: Figure displaying the In vitro permeability set-up. 
(6-well plate containing the receptor fluid and the epidermis) 
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Fig 4.6:  Incubation – 37 °C at 5% CO2 and 98% relative humidity for 24 hr. 
 
4.1.1 E: Sampling  
At fixed time points (0.25, 0.5, 0.75, 1, 2, 4, 6, 10, 12, 18, 20, 24, and 30 hrs) depending on 
the compound studied, aliquots of receptor fluid (2.5 mL) were collected from the receptor 
compartment and immediately replaced with 2.5 mL fresh fluid. After 30 h, the entire 
receptor fluid was collected and the skin surface washed thoroughly with cotton buds 
impregnated in (1:1) hexane: ethyl acetate (5 times). The tissues were removed from the 
permeation devices and both the donor and receptor compartments were washed separately (5 
× 2 mL) with PBS. All samples were stored at −20 °C until chemical analysis. 
                                            Fig 4.7: Donor Compartment with the skin insert. 
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 Fig 4.8:  Skin wash with cotton bud. 
              
4.1.1 F:  Sample Extraction and Clean-up                
Each permeation assay generated five different types of samples comprising: receptor fluid, 
skin tissue, cotton buds (used to thoroughly wipe the skin surface), donor and receptor 
compartment washes. The receptor fluid, skin tissue and cotton buds samples were extracted 
according to a previously reported QuEChERs method (Abdallah et al., 2015). Briefly, each 
sample was spiked with 30 ng of isotopically labelled internal (surrogate) standards. 
Extraction was performed using 2 mL of (1:1) hexane: ethyl acetate mixture and vortexing 
for 2 minutes, followed by ultrasonication for 5 minutes and centrifugation at 4,000 g for 3 
minutes. This extraction cycle was repeated twice before the combined organic extracts were 
evaporated under a gentle stream of N2 and reconstituted into 100 µL of recovery (syringe) 
standard for QA/QC purposes. The donor and receptor compartment washes were spiked with 
30 ng of the 13C-labelled internal standard mixture prior to direct evaporation under a gentle 
stream of N2. Target analytes were reconstituted into 100 µL of methanol containing recovery 
(syringe) standard for QA/QC purposes. 
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4.1.1.G:   Modelling of percutaneous penetration using Epiderm® human skin 
equivalent 
For infinite-dose condition, the cumulative amount of chemical penetrating the skin, Q, as a 
function of time, may be modelled using the appropriate version of Fick’s second law; where 
Kp is the chemical’s permeability coefficient, tlag its lag time and Cv° its concentration in the  
 
Solution. At steady state, the exponential term is negligible  
                        
Thus the cumulative amount of chemical at steady state (Qss) is a linear function of time. The 
derivative as a function of time, defines the maximum flux, which is constant at steady state  
 
Jss is the flux (ng/cm
2/hr) for the chemical and determined by plotting the cumulative 
absorption versus the time profile. The slope of the regression line represents the flux. 
Steady-state conditions were indicated by a linear regression line [R2 ≥ 0.9; P ≤ 0.05.] 
When using inﬁnite-dose conﬁgurations, i.e., in which the donor concentration far exceeds 
the concentration in the receptor compartment (CD >> Cv°), Cv° can be replaced by CD 
 Permeation data was summarised by determining the lag time, steady state flux, and 
cumulative amount after 24 hr (Q24). Results are presented as the arithmetic mean of three 
replicates ± the standard deviation (SD). Statistical analysis was performed using SPSS 13.0. 
Differences in skin permeation were evaluated by the paired Student’s t test between two data 
sets. A Games−Howell test was used for analysis of variance (ANOVA) among several data 
sets with equal variances not assumed; p< 0.05 was regarded as indicating a statistically 
signiﬁcant difference. 
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Fig 4.9:  Flowchart of the algorithm applied for identification of the steady state range 
as described by Niedorf et al. (Niedorf, Schmidt and Kietzmann 2008b) 
 
 
 
 
 
 
 
 
 
 111 
 
4.2: NEAT COMPOUND APPLICATION USING 3D-HSE EPISKINTM MODEL 
 
Reconstructed skin models Episkin® 1.07 were provided by Skin Ethics (Lyon, France). 
Episkin is an in vitro reconstructed human epidermis from normal human keratinocytes 
cultured on a collagen matrix at the air-liquid interface. This model is histologically similar to 
the in vivo human epidermis. The human keratinocytes are obtained from healthy consenting 
donors during plastic surgery. HIV 1 & 2, B and C hepatitis tests are carried out on the donor 
blood as well as verification of the bacteriological & fungal sterility of the cells and absence 
of mycoplasma. (www.episkin.com). Episkin are provided as a kit consisting of 12 plastic 
insert where the epidermis patch is grown on a collagen matrix and kept firm in its place with 
the help of outer “o” ring. This feature is an extra value added advantage in Episkin model 
where the skin are ready to use immediately by placing the insert with the skin in a costar 
well plate containing the receptor fluid.  
 
                                                  Fig 4.10: Episkin set-up. 
                       
 
     
Insert 
    Epidermis 
Plastic ring  
 Collagen 
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12 reconstructed Epidermis placed in maintenance medium       Dosing of neat compound in acetone                                                                                                      
& incubated at 37°C with 5% CO2 and 98% RH for 24 hrs  
 
 
                                                                                                                 
                                                                                                                                                                                                             
Cotton buds soaked in hexane: ethyl acetate (3:1) and 
the surface of the skin was swept for residual quantity 
and walls of the well for non specific binding 
 
                                                                                                                                                                                                         
Skin Removed –Placed in hexane: ethyl 
acetate in clean test tubes 
  
 
       Collection of Receptor fluid every 4 hrs                                                                                                                                                                                                  
 
 
Extraction 
and Clean-up 
Analysis 
  Fig 4.11      EPISKIN® PROTOCOL 
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Table 4.2: Concentrations of target compounds applied on Episkin/Mattek Epidermis in 
acetone. 
Target Analyte M.Wt (g/mol)  
& Log Kow 
(unitless)  
3D-HSE SKIN 
MODEL 
Mass per unit 
area (ng/cm2)                 
Study 
Exposure    
Time (hr) 
     BDE-1 249.1 (4.28) Episkin™ 500,1000 24 
BDE-8 --------------- Episkin™ 
 
500,1000 24 
BDE-28 327.9 (5.94) 
 
Episkin™ 
 
500,1000 24 
BDE-47 485.8 (6.81) Episkin™ 
 
500,1000 24 
BDE-99 564.7 (7.32) Episkin™ 
 
500,1000 24 
BDE-153 643.6 (7.9) Episkin™ 
 
500,1000 24 
BDE-183 722.5 (8.27) Episkin™ 
 
500,1000 24 
BDE-209 959.2 (10.3) Episkin™ 
 
500,1000 24 
α-HBCD 641.7 (5.07) 
Episkin™ 
EpiDerm™ 212-X 500,1000 24 
β-HBCD 641.7 (5.12) Episkin™ 
EpiDerm™ 212-X 500,1000 24 
γ-HBCD  
641.7 (5.47) 
Episkin™ 
EpiDerm™ 212-X 500,1000 24 
TBBPA 543.9 (4.50) Episkin™ 
EpiDerm™ 212-X 500,1000 24 
TCEP  285.49 (1.44) Episkin™ 
EpiDerm™ 212-X 250,500,1000 24 
TCIPP 327.57 (2.59) Episkin™ 
EpiDerm™ 212-X 250,500,1000 24 
TDCIPP 430.91 (3.65) Episkin™ 
EpiDerm™ 212-X 
250,500,1000 24 
TPhP 326.29 (4.59) 
Episkin™ 
EpiDerm™ 212-X 250,500,1000 24 
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TBOEP 398.48 (3.75) Episkin™ 
 
500,1000 24 
TEHP 434.65 (9.49) Episkin™ 500,1000 24 
ToCP 368 (5.1) Episkin™ 
 
500,1000 24 
TmCP 368 (5.1) Episkin™ 
 
500,1000 24 
TpCP 368 (5.1) Episkin™ 
 
500,1000 24 
PBEB 550.65 (6.76) Episkin™ 
 
500,1000 24 
α/ β -TBECH 399.74 (3.73) Episkin™ 
 
500,1000 24 
β-TBECH 399.74 (3.73)  Episkin™ 
 
500,1000 24 
EHTBB 549.9 (7.73) Episkin™ 
EpiDerm™ 212-X 500,1250,2500 30 
BEHTEBP  706.2 (11.95) Episkin™ 
EpiDerm™ 212-X 
 
500,1250,2500 30 
BTBPE 687.6 (9.10) 
Episkin™ 
EpiDerm™ 212-X 
 
500,1000 24 
DBDPE 971.2 (11.1) Episkin™ 
 
500,1250 24 
Syn-DP 653.72(9.0) Episkin™ 
 
500,1000 24 
Anti-DP 653.72(9.0) Episkin™ 
 
500,1000 24 
HBB 551.49 (6.07)   Episkin™ 
 
    500,1000 24 
PBBz 472.59 (5.4)   Episkin™ 
 
    500,1000       24 
PBEB 500.64 (7.96)    Episkin™ 
 
    500,1000       24 
PBT 486.621 (5.87)    Episkin™ 
 
500,1000       24 
Note : Pure standards for all FRs investigated in this study were purchased from Wellington 
labs  
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4.3: Evaluation of 3D HSE Models using human ex vivo skin mounted on  Franz 
Diffusion cell 
The measurement of dermal absorption of chemicals for consumer products intended for 
application to the skin or the xenobiotics is an important part of risk assessment. In vitro -
Franz diffusion cells are applied to assess the skin permeability testing. (Bartosova and 
Bajgar 2012, Davies et al. 2015, Franz 1975). For the purpose of our skin permeation 
experiments, we procured custom-made Franz diffusion cells made of borosilicate glass 
components from the University of Birmingham professional glass-blower workshop. The 
cell comprises two compartments:  the donor compartment, which contains the sample to be 
tested and the receptor compartment containing the receptor fluid. The two compartments 
are separated by the mounted viable excised human skin, which acts as a conduit for 
diffusion. The effective diffusion area of the Franz cells was 0.2 cm2, receptor volume was 
5.0 mL with other dimensions shown in Figure 4.12. The receptor temperature was 
maintained at 37 °C to mimic the physiological temperature. Testing was conducted for 24 
hr, during which the receptor fluid was collected via the sampling port and replaced with an 
equal volume of fresh receptor fluid at each time point. Fresh excised human upper breast 
skin was obtained via Caltag Medsystems Ltd. (Buckingham, UK) from 3 consented female 
adults (aged 36, 33 and 37 years) following plastic surgery. Selection criteria included: 
Caucasian, no stretchmarks, no scars and no hair.  Full thickness skin without adipose tissue 
and an overall thickness of 550 ± 80 µm was used. Upon receipt, the ex vivo skin samples 
were equilibrated for 1 h with 3 mL of DMEM-based (Sigma-Aldrich, UK) culture medium 
(Table 4.1) at 5% CO2 and 37 ˚C before use in permeation experiments. The study protocol 
received the required ethical approval (# ERN_12-1502) from the University of 
Birmingham’s Medical, Engineering and Mathematics Ethical Review Committee. 
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Fig 4.12: Sketch of a typical custom-made Franz cell 
 
 
 
Fig 4.13: Histological comparison of excised human breast skin and 3D-HSE Episkin 
model. 
 
 
 
 
 
 
 
 
 
EPISKIN™ Human excised breast skin 
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4.4:  QA/QC  
All tissues were visually inspected and if physical imperfections were noted by the 
manufacturer or via the following end –use testing, then the respective tissue was excluded. 
Viability: Tissues are exposed to 1% Triton X-100 for 24 hours. The time of exposure 
required to reduce the tissue viability (ET-50) using the MTT (3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide) viability assay was determined for each tissue batch. 
Acceptable MTT results (i.e. Formazan concentration ≥1.5 mg/mL) were achieved following 
24 h of exposure.  
Functionality: Both positive and negative control experiments were carried out alongside 
each sample batch. Positive controls involved the exposure of the test tissue to Triton-X-100 
(0.01% solution in deionised water) which showed ~100% permeation (n = 5; 97 ± 4%), 
while negative controls showed 0% penetration of decabromodiphenyl ethane (0.01% 
solution in acetone) after 24 hour exposure.  
Integrity: The integrity of the skin membrane was tested using the standard trans-epidermal 
electrical resistance (TEER) and methylene blue (BLUE) standard methods (Guth et al. 2015) 
Furthermore, histological testing was performed randomly to evaluate the full differentiation 
of the human skin equivalent tissues (Figure 4.14). 
Fig 4.14: Evaluation of histology for Episkin model. 
 
  
 
Episkin-Stratum Corneum 
Episkin-Keratinocytes 
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Table 4.3: Summary of QA/QC tests for Epiderm® model. (Provided by the SkinEthics 
Lyon, France). 
 
Quality Control 
 
Test 
 
Specification 
 
Result 
 
 
 
 
 
Histology 
Scoring 
 
           ≥ 19.5 21.0 ± 0.3 
(CV =1.5%) 
 
 Satisfactory  
Well differentiated 
epidermis consisting 
of a basal layer, 
several spinous and 
granular layers and 
a thick stratum 
corneum 
MTT test (IC50)         ≥ 1mg/ml                              1.5 mg/ml 
Statistical Analysis: Histology – Probability 0.95 that 100% of the 
batch >20 
IC50:  probability 0.95 that IC50 ≥ 1.4 mg/ml  
 
BIOLOGICAL 
SAFETY 
 
On Blood of the same donors, verified ; 
The absence of HIV1 and 2 antibodies  
The absence of hepatitis C antibodies 
The absence of hepatitis B antigens HBs 
On Epidermal cells of the same donors, verified ; 
The absence of bacteria, fungus and mycoplasma 
 
The efficiency of the experimental approach was investigated using a mass balance exercise. 
% Recovery           =    MCotton Bud + Mskin +MRF + Mwell wash  
                                                               Initial Donor mass 
Where   
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MCotton Bud = Amount (ng) of Analyte remained on skin surface removed with the Cotton Buds 
soaked in Hexane    
Mskin = Amount (ng) of Analyte remained in the skin upto 24 hr 
MRF = Cumulative amount in the receptor fluid over 24 hr  
Mwell wash = Non-specific binding obtained after well wash with PBS after 24 hr 
4.5:  RESULTS 
4.5.1: Evaluation of 3D-Human Skin Equivalents (Abdallah et al. 2015) 
We have developed and applied a protocol for the evaluation of dermal absorption of HBCDs 
and TBBPA using 2 commercially available 3D-HSE models (EPISKIN™ and EpiDerm™) 
according to the OECD guidelines and subsequently the results were compared to the data 
obtained from ex-vivo skin. The results of the permeation experiments were grouped under 
three major compartments: the directly absorbed dose (cumulative concentration in the 
receptor fluid over 24 h + receptor compartment rinse), the skin (concentration in the skin 
tissue after 24 h) and the unabsorbed dose (concentration in the skin surface wipes after 24 h 
+ donor compartment rinse) (Table 4.5) .The results revealed the overall recoveries from the 
mass balance exercise exceeded 85% for all the tested chemicals for all the models. 
 Flux (Jss) of HBCDs ranged from 0.8–1.5 ng/cm2·h, 0.9–1.5 ng/cm2·h and 0.7–1.3 ng/cm2·h 
for the EPISKIN™, EpiDerm™ and human ex vivo skin, respectively. α-HBCD showed a 
consistently higher flux across skin than γ-HBCD at the studied doses. The Jss for TBBP-A 
was approximately the same value for both Episkin and Epiderm models (1.47 ng/cm2·h) but 
was slightly lower (1.29 ng/cm2·h) for the ex vivo model. 
The directly absorbed fraction was found to be 6.29 % in case of TBBP-A followed by α-
HBCD (5.81 %), β-HBCD (3.86 %) and γ-HBCD (3.42 %) when dosed at 500 ng/cm2. A 
similar trend was observed at the higher dosing level (1 µg/cm2). This could be attributed to 
the physicochemical properties of the tested compounds, where TBBP-A has a lower mass 
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and higher water solubility than HBCDs. Furthermore, a statistically significant correlation (P 
< 0.05) was observed between the 24 h cumulative absorbed dose and the log KOW (Table 
1.2) of the studied BFRs in all the tested in vitro models. This highlights the influence of 
physicochemical properties on the human dermal bioavailability of a chemical.  
The estimated Papp (Table 4.4) values showed greater resistance of human ex vivo skin to 
the penetration of target BFRs than the EPISKIN™ and EpiDerm™ models. However, 
this difference was not statistically significant. In addition, both 3D-HSE models and 
human ex vivo skin displayed increasing resistance to the penetration of BFRs in the same 
order of γ-HBCD > β-HBCD > α-HBCD > TBBP-A. The lag time for β-HBCD and α-HBCD 
was found to be approx. 1 hr or more than 1 hr in all the three models. The lag time for β-
HBCD was found to be similar for Episkin and Epiderm models (approx. 0.80 hr) and 0.85 hr 
for the ex vivo skin model. The lag time increased for TBBPA in the following order: 
Epiderm < Episkin <Human ex vivo. Higher permeation of all target compounds in the 
following order: EpiDerm™ >EPISKIN™ > Human ex vivo skin was observed at the 
two concentration levels studied. However, statistical analysis showed no significant 
differences (P > 0.05) between the levels of target analytes in the 3 major compartments 
of the examined tissues. Border line statistical significance values (P = 0.053 and 0.056) 
were observed between the results for human ex vivo skin and those for EpiDerm™ for β-
HBCD and EPISKIN™ for TBBPA, respectively. The EpiDerm™ model displayed the 
largest permeation difference from human ex vivo skin with a ~25% increase in the 
permeated dose of β-HBCD over 24 hours exposure. We investigated the potential effect of 
the acetone, 30% acetone in water, and 20% Tween 80 in water on the percutaneous 
penetration of BFRs for the human ex vivo and Episkin models. Results indicated higher 
levels of target compounds absorbed from 20% Tween 80, which was also evident for TBBP-
A and α-HBCD. Schafer-Korting et al. (Schafer-Korting et al. 2006) reported less penetration 
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of testosterone in pig and bovine skin (0.07 and 0.13 % of applied dose) compared to human 
skin (0.32 %), while EPISKIN™ and EpiDerm™ models showed higher permeations (0.53 
and 2.36, respectively). However, the EPISKIN™ and EpiDerm™ models used in this study 
are listed under the “enhanced barrier function” category, which is different from those used 
in the 2006 study.  
Table 4.4: Steady state flux, permeation coefficient and lag time values estimated for the 
target BFRs using different in vitro skin models. 
 
 
 Flux  
(ng/cm2.h) 
Permeation coefficient  
(cm/h) 
Lag time  
(h) 
EPISKIN™ 
α-HBCD 1.25 2.50 x 10-04 0.80 
β-HBCD 0.84 1.69 x 10-04 1.01 
γ-HBCD 0.78 1.56 x 10-04 1.21 
TBBPA 1.47 2.93 x 10-03 0.72 
EpiDerm™ 
α-HBCD 1.33 2.74 x 10-04 0.77 
β-HBCD 0.88 1.77 x 10-04 0.97 
γ-HBCD 0.85 1.72 x 10-04 1.13 
TBBPA 1.48 2.97 x 10-03 0.60 
Human ex vivo skin 
α-HBCD 1.08 2.16 x 10-04 0.85 
β-HBCD 0.74 1.47 x 10-04 1.17 
γ-HBCD 0.69 1.37 x 10-04 1.26 
TBBPA 1.29 2.58 x 10-03 0.79 
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Fig 4.15: Cumulative dose (ng/cm2) absorbed into the receptor fluid following exposure 
of (from top to bottom): (a) human ex vivo skin, (b) EPISKIN™ and (c) EpiDerm™ to 
1000 ng/cm2 of target BFRs over 24 h.  
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Table 4.5: Distribution of target BFRs (expressed as % of exposure dose) in different 
compartments of the in vitro diffusion system following 24 hour exposure to 500 ng/cm2 
of α-, β-, γ-HBCDs and TBBP-A in acetone.  
 α-HBCD β-HBCD γ-HBCD TBBP-A 
 EPISKIN™ 
Receptor fluid (24h) 5.81 ± 1.04 3.86 ± 0.78 3.42 ± 0.94 6.29 ± 0.65 
Receptor rinse 0.10 ± 0.02 0.07 ± 0.02 0.11 ± 0.02 0.41 ± 0.28 
Directly absorbed fraction 5.90 ± 1.06 3.94 ± 0.82 3.46 ± 0.96 6.70 ± 0.92 
Skin-Epidermis (Depot) 30.06 ± 2.42 27.18 ± 2.28 23.66 ± 3.16 24.18 ± 2.54 
Skin wash (unabsorbed) 44.34 ± 4.04 51.47 ± 3.72 56.82 ± 4.58 53.53 ± 3.46 
Donor rinse (unabsorbed) 5.13 ± 0.64 3.16 ± 0.82 2.38 ± 1.06 4.93 ± 2.08 
Total Recovery 85.43 ± 8.16 85.75 ± 7.64 86.32 ± 9.76 89.34 ± 9.02 
 EpiDerm™ 
Receptor fluid (24h) 6.35 ± 0.92 4.02 ± 1.04 3.74 ± 0.82 6.44 ± 0.59 
Receptor rinse 0.11 ± 0.04 0.10 ± 0.08 0.09 ± 0.04 0.34 ± 0.16 
Directly absorbed fraction 6.46 ± 0.94 4.13 ± 1.12 3.82 ± 0.86 6.78 ± 0.74 
Skin-Epidermis (Depot) 28.19 ± 3.18 24.39 ± 2.22 21.02 ± 3.52 23.79 ± 2.42 
Skin wash (unabsorbed) 45.73 ± 4.02 53.91 ± 3.44 58.84 ± 4.38 55.04 ± 4.29 
Donor rinse (unabsorbed) 5.07 ± 0.62 2.39 ± 0.52 1.97 ± 0.74 4.11 ± 1.27 
Total Recovery 85.45 ± 8.76 84.82 ± 7.30 85.65 ± 9.50 89.72 ± 8.72 
 Human ex vivo skin 
Receptor fluid (24h) 4.88 ± 1.44 3.21 ± 1.06 3.01 ± 1.02 5.37 ± 0.65 
Receptor rinse 0.07 ± 0.02 0.11 ± 0.02 0.06 ± 0.02 0.21 ± 0.28 
Directly absorbed fraction 4.95 ± 1.44 3.32 ± 1.06 3.07 ± 1.48 5.57 ± 0.92 
Skin-Epidermis (Depot) 30.59 ± 2.28 27.82 ± 2.38 24.16 ± 2.24 24.71 ± 2.96 
Skin wash (unabsorbed) 47.05 ± 4.44 51.19 ± 4.68 56.48 ± 3.28 56.53 ± 4.46 
Donor rinse (unabsorbed) 5.23 ± 1.48 3.37 ± 1.02 2.07 ± 0.66 3.83 ± 2.08 
Total Recovery 87.82 ± 7.84 85.70 ± 6.28 85.78 ± 7.38 85.65 ± 10.42 
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Fig 4.16: A representative curve showing cumulative permeation (ng/cm2) of target 
BFRs in the EPISKIN™ model at the linear-range region (R2 ≥ 0.9). Error bars 
represent 1 standard deviation.   
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Figure 4.17: Cumulative permeation (ng/cm2) into the receptor fluid following exposure 
of human ex vivo skin to 500 ng/cm2 of target BFRs in (A) acetone, (B) 30% acetone in 
water, and (C) 20% Tween 80 in water for 24 h 
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4.5.2: Human dermal absorption of PBDEs and effect of bromine substitution.(Abdallah 
et al. 2015b)    
When Episkin was exposed to PBDE congeners at two different levels 500 ng/cm2 and 1000 
ng/cm2, results (Table 4.7 & 4.8) indicated that the degree of permeation was inversely 
proportional to the degree of bromination.BDE-1 was absorbed at 30% of the applied dose 
after 24 hrs of exposure whereas the environmentally abundant BDE-47 and BDE-99 showed 
absorption values of 3% and 2% respectively. All target PBDEs accumulated in the skin to 
varying degrees. The proportion of accumulation increased with the increase of bromine 
substitution from BDE-1 (~18%) to BDE-153 (~37%) and decreased steeply from BDE-183 
(~13) to BDE-209 (8%) (Fig 4.17).This behaviour could be due to the physicochemical 
properties of PBDEs i.e. more polar mono-PBDEs penetrated faster through the water-rich 
viable epidermis and octa-PBDEs were accumulated for longer in the lipid-rich stratum 
corneum prior to diffusion through the viable epidermis at a slower rate. Our results were in 
good agreement with a previously reported study (Garner, Demeter and Matthews 2006b) on 
PCBs  (in vivo rat model). The low dermal accumulation values for BDE-183 and BDE-209 
are due to their large molecular weight which hinders their partitioning to the stratum 
corneum and subsequent absorption by keratinocytes (Choy and Prausnitz 2011). Results also 
revealed a significant positive correlation (P<0.05) between the Papp values (Table 4.6) for 
mono to hexa PBDEs and water solubilities and vapour pressure of these congeners, with a 
significantly negative inverse relationship observed between Papp and both Log Kow and 
molecular weight of the studied congeners. Because of the slow penetration of BDE-183 and 
BDE-209, Papp values could not be calculated. The estimated lag times (tlag) varied between 
0.25 and 1.26 h for BDE-1 and BDE-153, respectively. This is due to the fact that less 
brominated congeners diffuse quickly through the dermal tissue while lipophilic (more 
brominated) congeners are likely to accumulate within the stratum corneum. This retained 
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BFR mass constitutes a depot that may be available for subsequent release into the receptor 
fluid (systemic circulation) provided there is no loss in the skin by metabolism, irreversible 
binding to keratinocyte proteins, evaporation or desquamation. 
 
Fig 4.18: Percent of applied dose (500 ng/cm2) of target PBDEs absorbed (present in the 
receptor compartment), un-absorbed (remaining in the donor compartment and on skin 
surface) and accumulated in the skin tissue following 24 h exposure.   
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Table 4.6: Steady state flux, permeation coefficient and lag time values estimated from 
exposure of EPISKIN™ to 500 ng/cm2 of target PBDEs for 24 h.  
 Flux (ng/cm2.h) Permeation coefficient (cm/h) Lag time (h) 
BDE 1 5.45 1.09 x 10-2 0.25 
BDE 8 2.42 4.84 x 10-3 0.42 
BDE 28 0.88 1.76 x 10-3 0.82 
BDE 47 0.63 1.26 x 10-3 0.90 
BDE 99 0.40 8.00 x 10-4 1.10 
BDE 153 0.20 4.00 x 10-4 1.26 
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Table 4.7: Cumulative levels (expressed as average percentage ± standard deviation of applied dose) of target PBDEs in the receptor 
fluid following exposure of EPISKIN™ to 500 ng/cm2 of target PBDEs. 
Time 
(hours) 
BDE-1 BDE-8 BDE-28 BDE-47 BDE-99 BDE-153 BDE-183 BDE-
209 
0.25 ND* ND ND ND ND ND ND ND 
0.50 0.25 ± 0.09 0.10 ± 0.04 0.07 ± 0.03 0.04 ± 0.01 ND ND ND ND 
1.00 1.06 ± 0.28 0.41 ± 0.05 0.20 ± 0.02 0.13 ± 0.02 0.08 ± 0.01 0.03 ± 0.01 ND ND 
2.00 1.98 ± 0.61 0.82 ± 0.07 0.31 ± 0.09 0.21 ± 0.09 0.07 ± 0.04 0.04 ± 0.01 ND ND 
6.00 5.07 ± 1.07 1.88 ± 0.65 0.46 ± 0.31 0.48 ± 0.32 0.43 ± 0.15 0.13 ± 0.05 ND ND 
10.00 10.20 ± 1.89 4.34 ± 1.72 1.59 ± 1.56 0.97 ± 0.82 0.57 ± 0.77 0.33 ± 0.03 ND ND 
12.00 14.24 ± 2.12 6.75 ± 2.24 2.19 ± 1.36 1.56 ± 0.89 0.86 ± 0.84 0.46 ± 0.02 0.03 ± 0.01 ND 
18.00 20.43 ± 2.54 8.68 ± 2.17 2.77 ± 1.43 2.23 ± 0.88 1.29 ± 1.07 0.68 ± 0.04 0.04 ± 0.01 ND 
24.00 24.92 ± 2.71 11.08 ± 2.43 4.23 ± 1.68 2.85 ± 1.09 1.96 ± 1.26 0.89 ± 0.11 0.05 ± 0.01 ND 
 
* Not detected (less than 0.02% of applied dose for all congeners, or 0.05% for BDE-209). 
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Table 4.8: Distribution of target BFRs (expressed as average percentage ± standard deviation of exposure dose) in different fractions of 
the in vitro diffusion system following 24 h exposure to 500 ng/cm2 of the studied PBDEs. 
 
 BDE 1 BDE 8 BDE 28 BDE 47 BDE 99 BDE 153 BDE-183 BDE-209 
Absorbed* 24.9 ± 2.71 11.0 ± 2.43 4.2 ± 1.68 2.8 ± 1.09 1.9 ± 1.2 0.89 ± 0.11 0.05 ± 0.01 ND$ 
Unabsorbed# 51.7 ± 3.93 58.1 ± 4.28 58.9 ± 5.16 56.6 ± 4.81 57.6 ± 4.7 56.0 ± 5.67 81.57 ± 5.41 85.35 ± 4.95 
Skin 17.6 ± 1.75 21.6 ± 1.83 27.2 ± 2.14 33.1 ± 1.87 33.9 ± 2.3 37.4 ± 2.18 12.78 ± 1.24 8.38 ± 1.31 
Sum 94.3 ± 7.52 90.7 ± 8.31 90.4 ± 8.91 92.6 ± 7.68 93.5 ± 8.2 94.3 ± 7.90 94.40 ± 6.62 93.73 ± 6.22 
 
* Comprises cumulative concentrations in the receptor fluid over 24 h + receptor compartment rinse. 
# Comprises concentrations in the skin surface wipes after 24 h + donor compartment rinse. 
$ Not detected (less than 0.02% of applied dose for all congeners, or 0.05% for BDE-209)
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4.5.3: Human dermal absorption of chlorinated organophosphate flame retardants 
(Abou-Elwafa Abdallah et al. 2016) 
Finite Dosing: Using human ex vivo skin for TCEP, the cumulative absorption detected in 
receptor fluid was found to be 28% of the applied dose (500 ng/cm2), with lower absorbed 
fractions of 25% and 13% observed for TCIPP and TDCIPP respectively (Table 4.9). 
Analysis of the skin tissues showed recoveries of 15%, 11% & 7% of the applied dose for 
TCEP, TCIPP, and TDCIPP respectively after 24 h exposure. Statistical analysis revealed a 
significant (P< 0.05) positive correlation between the absorbed fractions of PFRs and their 
water solubility but a significant negative correlation between the cumulative 24 hr 
absorption of target compounds and their log Kow. Similar results were obtained using the 
Episkin-HSE model. No statistically significant differences (P>0.05) were obtained between 
the two in vitro models. However, the Episkin™ tissues were more permeable to all target 
compounds than the human ex vivo skin. TCEP, TCIPP and TDCIPP showed respectively 
16%, 11% and 9% greater absorption in experiments using the Episkin model compared to 
those using the human ex vivo skin model (Fig 4.18 & 4.19). 
Infinite Dosing: Infinite dose application maximizes the concentration gradient and 
diffusion/penetration through the skin becomes the rate-limiting step, therefore it permits 
calculation of the permeability constant (Kp) for each compound. (OECD, 2004). 
In the first 8 h of exposure both TCEP and TCIPP showed a rapid increase in the absorbed 
dose and the rate declined until 24 hr but TDCIPP showed a slower and yet more consistent 
rate of absorption throughout the 24 hr exposure period. This behaviour could be attributed to 
the higher lipophilicity of TDCIPP (log Kow = 3.8) compared to TCIPP (log kow = 2.6) and 
TCEP (log Kow = 1.4), resulting in slower mass transfer rate across the lipophilic stratum 
corneum. 
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Results revealed a significant negative correlation between Kp and log Kow (Table 4.10) 
Differences in the barrier function (ΔKp) decreased with decreasing polarity in the order: 
TCEP (ΔKp = 0.8) > TCIPP (ΔKp = 0.6) > TDCIPP (ΔKp = 0.2). However, more studies 
covering a greater range of chemicals with a wider variety of physicochemical properties are 
required to confirm this observation. 
Effect of hand washing: After 6 hrs of finite dosing (500 ng/cm2) to ex vivo skin, the surface 
was washed thoroughly with a neutral detergent solution, while monitoring the absorbed dose 
in the receptor fluid continued until 24 h. Results (Fig 4.20) showed the absorption rate 
decreased markedly after washing, percutaneous penetration of the studied PFRs continues 
from the skin depot. A statistically significant difference (P<0.05) was observed in the 
absorption rate of TCEP and TCIPP with and without washing over a 24 h exposure period. 
The difference for TDCIPP was not significant (P =0.12). In general our results indicate that 
hand-washing reduce overall dermal absorption of PFRs, albeit to varying degrees depending 
on the physicochemical properties of the FRs. 
Effect of exposure vehicle: After 24 h exposure, results revealed an increase in the absorbed 
dose of the 3 target compounds from 20 % Tween 80 solution in water compared to acetone 
(Figure 4.20) but none of them showed a statistically significant difference (P>0.05) between 
the studied exposure vehicles. In general, a vehicle may hydrate the stratum corneum (SC), 
extract critical barrier components out of the skin, or damage the skin because it is a strong 
acid or base. Removing SC lipids may increase percutaneous absorption of the drugs. 
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Table 4.9: Distribution of target PFRs (expressed as average percentage ± standard 
deviation of exposure dose) in different fractions of the in vitro diffusion system 
following 24 h exposure to 500 ng/cm2 of the studied compounds. 
 
Human ex vivo skin TCEP TCIPP TDCIPP 
Absorbed* 28.3 ± 2.3 24.7 ± 1.4 12.7 ± 1.2 
Unabsorbed# 6.8 ± 1.1 10.8 ± 1.2 14.8 ± 1.4 
Skin 55.3 ± 3.5 53.1 ± 2.9 62.3 ± 4.3 
Sum 90.30 ± 6.9 88.61 ± 5.5 89.79 ± 6.7 
EPISKIN™ TCEP TCIPP TDCIPP 
Absorbed* 33.7 ± 2.5 27.7 ± 1.9 13.9 ± 1.5 
Unabsorbed# 6.8 ± 1.4 10.8 ± 1.0 14.8 ± 1.3 
Skin 49.3 ± 3.9 50.3 ± 3.2 61.5 ± 4.6 
Sum 89.7 ± 7.8 88.8 ± 6.1 90.2 ± 7.5 
* Comprises cumulative concentrations in the receptor fluid over 24 h + receptor 
compartment rinse.# Comprises concentrations in the skin surface wipes after 24 h + donor 
compartment rinse 
 
Table 4.10: Flux rates (Jss, ng/cm2 h), permeability constants (Kp, cm/h), lag times 
(tlag,h) and linear ranges (h) estimated from infinite exposure of human ex vivo skin and 
EPISKINTM to 1000 ng/cm2 of target PFRs for 24 h. 
 
 
Human ex vivo skin EPISKIN™ 
 
Jss Kp x 10-2 tlag Range R2* Jss Kp x 10-2 tlag Range R2 
TCEP 21.9 2.2 0.28 0.5 – 8 0.97 30.1 3.0 0.21 0.5 – 8 0.98 
TCIPP 15.5 1.6 0.29 0.5 – 10 0.98 21.7 2.2 0.23 0.5 – 10 0.96 
TDCIPP 5.4 0.5 2.9 4 – 22 0.96 7.4 0.7 2.9 4 – 22 0.98 
* R2 is the linearity coefficient. A minimum value of 0.9 combined with a P-value < 0.05 was 
required to express linearity (Niedorf, Schmidt and Kietzmann 2008a).  
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Fig 4.19: Distribution of the studied PFRs applied as finite dose (500 ng/cm2) to: (a) ex 
vivo human skin and (b) EPISKIN™ tissues following 24 h exposure. Error bars 
represent 1 standard deviation (n=3). 
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Fig 4.20: Cumulative absorbed dose of the target PFRs following 24 h exposure of: (a) 
human ex vivo skin and (b) EPISKIN™ to 1000 ng/cm2 of the tested compounds (infinite 
dose). 
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Fig 4.21: Cumulative absorbed dose of (a) TCEP, (b) TCIPP and (c) TDCIPP applied to 
ex vivo human skin at 500 ng/cm2 each (finite dose). The skin surface in 3 cells was 
washed with detergent after 6 h (red line), while the other 3 cells were not washed (blue 
line). 
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Fig 4.22: Distribution of: (a) TCEP, (b) TCIPP and (c) TDCIPP following 24 h exposure 
of human ex vivo skin to 500 ng/cm2 of each compound in (i) acetone and (ii) 20% 
Tween 80 solution in water. Error bars represent 1 standard deviation (n=3).  
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Fig 4.23: Linear cumulative permeation range (ng/cm2) of target PFRs following infinite 
exposure of EPISKIN™ to 500 ng/cm2 for 24 hours.  
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Fig 4.24: Linear cumulative permeation range (ng/cm2) of target PFRs following infinite 
exposure of human ex vivo skin to 1000 ng/cm2 for 24 hours. Error bars represent 1 
standard deviation. 
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4.5.4: Other PFRs  
4.5.4.1 TEHP & EHDPP 
Tri-ethylhexyl phosphate (TEHP and 2-ethylhexyl-diphenyl phosphate (EHDPP) were 
applied at 1000 ng/cm2 & 500 ng/cm2 in acetone in triplicate to Episkin. The 24 h cumulative 
absorption values for TEHP and EHDPP across the Episkin model at 37 °C and 1000 ng/cm2 
dosing level were 0.50 ± 0.15 ng/cm2, 62.1 ± 7.2 ng/cm2 and 36.44 ± 3.4 ng/cm2 respectively. 
A similar trend was observed for the 500 ng/cm2 dosing level (Table 4.11). The results 
indicate that the absorption was highest in case of EHDPP and the least for TEHP. This 
behaviour could be attributed to the differences in the molecular weight and log Kow values 
among these 3 target compounds. TEHP has the highest molecular weight of 434.65 g/mol 
and Log Kow of 9.49. The transport of highly lipophilic chemical like TEHP occurs 
predominantly due to lipid rich stratum corneum and subsequent transfer into the aqueous 
epidermis is very slow or it could remain largely in the stratum corneum. The molecular 
weight & Log Kow for EHDPP (362.4, 5.73) are lower than TEHP resulting in higher 
absorption across the skin. The amount remaining in the skin reservoir was higher for TEHP 
i.e. 750.43 ± 12.0 ng/cm2 and 278.0 ± 9.5 ng/cm2 for 1000 ng/cm2 and 500 ng/cm2 
respectively. This is followed by EHDPP (578.12 ± 12.7 for 1000 ng/cm2, 202.49 ± 7.0 for 
500 ng/cm2). Again this is due to high lipophilicity and molecular weight of TEHP. 
Significant amounts remained unabsorbed in all cases at both dosing levels. 
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Table 4.11: Distribution of target PFRs (expressed as ng/cm2 ± standard deviation of exposure dose) in different fractions of the in vitro 
diffusion system following 24 h exposure to 1000 ng/cm2 & 500 ng/cm2 of the studied PFRs. 
                       TEHP    EHDPP 
  1000 ng/cm2                        500 ng/cm2 1000 ng/cm2                 500 ng/cm2              
Receptor fluid (24h) 0.30 ± 0.1  0.22 ± 0.08        35.24   ±   2.5     47.25  ±  3.5 
Receptor rinse 0.20 ± 0.05 0.08 ± 0.02  1.20     ±  0.9      2.0      ±  1.2 
Directly absorbed 
fraction 
0.50 ± 0.15 0.30 ± 0.1 
           
36.44   ±  3.4     49.25   ±  4.7 
Skin-Epidermis (Depot) 750.43 ± 12.0 278.0 ± 9.5  578.12  ±  12.7   202.49 ± 7.0 
Skin wash (unabsorbed) 182.0 ± 6.0 197.63 ± 13.5        91.0     ±  14.0    99.0    ±  9.0 
Donor rinse 
(unabsorbed) 
ND ± ND ND ± ND 
 
 ND       ±  ND    ND     ±    ND 
Total Recovery 93.29 ± 17.56 95.17 ±  15.0   70.39     ±  1.2    70.0   ±  10.0 
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Table 4.12: Flux rates (Jss, ng/cm2 h), permeability constants (Kp, cm/h), lag times 
(tlag,h) and linear ranges (h) estimated from infinite exposure of EPISKINTM to 1000 
ng/cm2 of target PFRs for 24 h. 
 
 
Jss Kp  
TEHP 0.0042 4.4 ± 0.28 (10-6) 
EHDPP 1.30 2.29 ± 1.38 (x 10-3) 
 
 
4.5.4.2: TCP isomers  
The TCP isomers were dosed at infinite concentration (1000 ng/cm2) in acetone in triplicate 
using Episkin. The cumulative absorption profiles for the neat isomers across the Episkin at 
37 °C are shown in Fig 4.22 Each TCP isomer was found to continuously permeate for the 
full 24 h (i.e. steady state was not reached in 24 h). The cumulative amount in the receptor 
fluid was found to be 687 ± 15.25 ng/cm2, 679 ± 11.23 ng/cm2, 532 ± 19.7 ng/cm2 for ToCP, 
TmCP and TpCP respectively. Thus the cumulative amount of isomers permeated at 24 h 
follows the order of ortho = meta > para but there is no statistically significant difference in 
the permeation between the three isomers. The amount remaining in the skin reservoir was 
similar i.e. 140-143 ng/cm2 in case of ToCP and TmCP respectively. However, this amount 
was slightly higher for TpCP (163 ng/cm2). This could be attributed to the fact that the para 
isomer of tricresyl phosphate has a slightly lower water solubility and higher lipophilicity 
than the ortho and meta isomers. Therefore the partitioning of the para isomer to the lipid-
rich stratum corneum is expected to be higher than the others. The unabsorbed amount was 
found to be 78.56 ± 1.06 ng/cm2, 94.2 ± 3.70 ng/cm2, 90.63 ± 3.31 ng/cm2 for ToCP, TmCP 
and TpCP respectively. Flux values range from 22.14 ng/cm2.h for ortho to 17.58 ng/cm2.h 
for para isomer (Table 4.13). 
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The Kp (cm/hr) was found to be slightly similar i.e. for ToCP (2.22 cm/h); TmCP (2.14 
cm/h); TpCP (1.80 cm/h). This could be due to the similar molecular weight (368 g/mol) and 
log Kow (5.1) but the positioning of the methyl group on the benzyl ring may influence the 
permeability and toxicity of the different TCP isomers. Overall we achieved good recovery 
ranging from 75-87 % for all the isomers in the skin set up. However, a slight decrease in 
recovery for the TpCP isomer might be due to metabolism. It is therefore recommended to 
investigate potential dermal metabolism in future dermal exposure studies for each isomer. 
Table 4.13: Distribution of TCP isomers in different fractions of the in vitro diffusion 
system following 24 h exposure to 1000 ng/cm2 of the studied compounds. 
EPISKIN™ (ng/cm2) ToCP TmCP TpCP 
Receptor fluid 687 ± 15.25 679 ± 11.2 532 ± 19.7 
Receptor Rinse 18.0 ± 3.8 5.0 ± 1.8 6.0 ± 0.89 
Unabsorbed (Bud) 78.56 ± 1.0 94.2 ± 3.7 90.63 ± 3.31 
Skin 143 ± 6.0 140.0 ± 0.16 163 ± 
3.98 
Recovery (%) 86.0 ± 5.6 87.3 ± 5.1 75 ± 11.5 
 
Fig 4.25: Cumulative absorption of TCP isomers over 24 h 
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Table 4.14: Flux rates (J, ng/cm2 h), permeability constants (Kp, cm/h) and linear 
ranges (h) estimated from infinite exposure of EPISKINTM to 1000 ng/cm2 of TCP 
isomers for 24 h. 
Episkin 
J Kp x 10-2 R2 
ToCP 22.14 2.2 0.94 
TmCP 21.44 2.1 0.95 
TpCP 17.58 1.8 0.92 
 
 
Fig 4.26: Linear cumulative permeation range (ng/cm2) of TCP isomers following 
infinite exposure of Episkin to 1000 ng/cm2 for 24 hours.  
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4.5.5: Human dermal absorption of Fire master -550 components (TPhP, EHTBB and 
BEHTEBP) 
For TPhP and TBB the % absorption was higher at the lowest dosing concentration i.e. at 500 
ng/cm2 and lowest at the higher concentration i.e. at 2500 ng/cm2. The % of absorption was 
4.6, 9.6, and 18 (TPhP) and 0.37, 0.64, and 0.70 (EHTBB) at 2500 ng/cm2, 1250 ng/cm2 and 
500 ng/cm2 respectively. Kp was found to be constant at all the 3 dosing levels for TPhP i.e. 
0.23 cm/hr and for EHTBB approx. 0.06 cm/hr. Kp is higher for TPhP than EHTBB as it is 
lighter molecule (higher diffusion rate) than EHTBB and TPhP possesses a log Kow of 4.65 
which favours permeability according to LIPINSKI’s rule of FIVE. BEHTBP was not 
detected in either the receptor fluid, receptor rinse or skin after 30 h of exposure at 3 
concentration levels. This may be attributed to the high M.Wt (706 g/mol) and large 
molecular size of BEHTBP in addition to its high hydrophobicity. Further studies need to be 
carried out at lower dosing levels and for durations exceeding 30 hrs without losing the 
integrity of the skin. These studies are important as it may result in more substantial systemic 
circulation uptake especially for TPhP over chronic dermal exposure. 
Table 4.15: Distribution in different fractions of the in vitro diffusion system following 
12 h exposure for TPhP & 30 h exposure for EHTBB and TBPH at 2500 ng/cm2 & 500 
ng/cm2 
1200 ng/cm2 TPhP EHTBB BEHTEBP 
Absorbed* 4.6 ± 9.1 0.37 ± 0.15  ND  
Unabsorbed# 24.0 ± 3.6 71.0 ± 13.8 60.0 ±      15.0  
Skin 61.0 ± 14.5 18.0 ± 12.4 14 ±       10.0  
Sum 89.6 ± 6.0 89.37 ± 3.5 74   ±        6.0  
500 ng/cm2 TPhP EHTBB          BEHTEBP 
Absorbed 18.1 ± 5.0 0.70 ± 0.30  ND  
Unabsorbed 22.0 ± 16.5 69.0 ± 2.5 66.0 ±     12.0  
Skin 55.0 ± 13.0 12.68 ± 3.8 10.5    ±     5.6  
Sum 95.1 ± 7.5 92.38 ± 11.0 76.5 ±     17.0  
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4.5.6: Positive (2, 4, 6 TBP) and negative (DBDPE) controls  
The validity and suitability of permeability assays were confirmed by reference compounds 
for high and low absorption. In this study, 2, 4, 6-tribromophenol was used as a high 
permeability reference (positive control) since it is a brominated phenol with increased 
polarity in the structure which would help the molecule to diffuse across the polar domain i.e. 
the epidermis of the skin. We also used DBDPE as a low permeability reference (negative 
control) because of its high molecular weight and lipophilic nature. These controls were run 
with every batch of permeability experiments. 
When Episkin was dosed at 1250 ng/cm2 , the cumulative amount absorbed was found to be  
645.0 ± 8.3 ng/cm2  and 2.71 ± 1.5 ng/cm2 in case of 2,4,6 TBP and DBDPE respectively. The 
huge difference in this behaviour is due to differences in the physicochemical properties of 
these chemicals. For DBDPE the molecular weight is 971.22 g/mol and LogKow =11.1 
whereas 2, 4, 6-TBP is a polar compound having a mol wt = 330.799 g/mol and Log Kow = 
4.13. A higher amount i.e. 708.24 ± 112.58 ng/cm2 of DBDPE remained on the skin 
unabsorbed due to its inability to penetrate the stratum corneum layers as a result of its high 
molecular weight. The proportion found in the skin depot was found to be higher for 2, 4, 6-
TBP (201.0 ± 5.9 ng/cm2) as compared to DBDPE (34.61 ± 8.8 ng/cm2), while the flux for 2, 
4, 6-TBP was 375.0 ng/cm2.h and Kp was found to be 4.0 X 10-2 cm/hr. Due to the low 
permeability and inconsistency of cumulative absorption of DBDPE over 24 hr, the flux and 
Kp values could not be calculated. In study by Gabriel Knudsen et al (Knudsen, Sanders and 
Birnbaum 2016a) the potential dermal uptake of DBDPE was assessed using human and rat 
skin, with results revealing penetration to be 4% of the applied dose of 2.7 nmol/cm2 with a 
major proportion (~ 12%) of the DBDPE remaining in the dermis as a skin depot. Compared 
to this study, our results showed only 0.59% of the initial dose absorbed across the skin; this 
could be due to the fact that in the previous study the DBDPE was dermally applied in an 
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organic solvent – namely toluene - resulting in higher permeability, whereas in our study we 
dosed in acetone which has minimal effect on the skin integrity as it easily evaporates at skin 
temperature when applied on the skin leaving the penetrant chemical behind to diffuse. 
Table 4.16: Distribution in different fractions of the in vitro diffusion system following 
12 h exposure for 2, 4, 6-TBP & 24 h exposure for DBDPE at 1250 ng/cm2. 
1250 ng/cm2 2,4,6 TBP* DBDPE** 
Receptor fluid  
 
        645.0 ±   8.3      2.71      ±       1.5 
Receptor rinse         27.0    ±  4.1      4.71     ±       0.66 
Skin-Epidermis (Depot) 
      201.0 ±  5.9       34.61 ±               8.8
Skin wash (unabsorbed) 
       8.15 ±  1.6     708.24 ± 112.58 
Donor rinse 
(unabsorbed) 
      1.5 ±   0.6       ND ± ND 
Total Recovery 
      70.6 ±  4.1  60.02 ± 4.89 
                * 12 hr study   ** 24 hr study 
Fig 4.27:  Linear cumulative permeation range (ng/cm2) of 2, 4, 6 TBP following infinite 
exposure of Epikin to 1250 ng/cm2 for 12 hours.  
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4.5.7: Dermal absorption of emerging brominated flame retardants (PBEB, PBBz, PBT, 
HBB, α, β-TBECH, syn, anti-Dechlorane plus) 
The directly absorbed dose i.e. cumulative concentration in the receptor fluid over 24 hr (plus 
receptor compartment rinse) and the unabsorbed dose (skin surface wipes plus donor 
compartment rinse) were estimated for the following emerging flame retardants:  
pentabromoethylbenzene (PBEB), pentabromobenzene (PBBz), pentabromotoluene (PBT), 
hexabromobenzene (HBB), 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane and the 
chlorinated flame retardants syn and anti dechlorane plus (Table 4.5). The efficiency of the 
experimental approach was investigated using a mass balance exercise. The cumulative 
directly absorbed amount was found to be highest for α-TBECH and β-TBECH followed by 
PBEB, PBBz, PBT and HBB. The penta and hexa bromo series have slightly closer values 
i.e. 1.4-2.06 ng/cm2. Surprisingly, the syn and anti dechlorane plus showed no penetration 
across the skin layers at both the concentrations over 24 hrs. This could be attributed to the 
high lipophilicity of dechlorane plus (LogKow – 9.0) and molecular weight (653.72). In 
contrast to this behaviour, TBECH has a lower mass and higher water solubility than 
dechloranes and penta and hexa brominated compounds. TBECH isomers have molecular 
weight < 500 (399.74) and a Log Kow <5.0 (3.73) which aids easy diffusion through the 
polar layers of epidermis. A significant proportion remained in the skin as a depot for all the 
compounds studied, which could penetrate the deeper layers of the skin and ultimately reach 
the systemic circulation after a period of time. 
This highlights the influence of physicochemical properties on the human dermal 
bioavailability of a chemical. Flux (Jss) values ranged from 0.07–0.09 ng/cm2·h for α-
TBECH and β-TBECH respectively at 1000 ng/cm2 (Table 4.17). Flux values for other EFRs 
studied were: HBB (0.0342 ng/cm2·h), PBT (0.0583 ng/cm2·h), PBZ (0.034 ng/cm2·h) and 
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PBEB (0.067 ng/ cm2·h). A decreasing trend of Kp with the increasing Log Kow was 
observed. (Table 4.18) 
Table 4.17: Distribution in different fractions of the in vitro diffusion system following 
24 h exposure for EFRs at 1000 and 500 ng/cm2. 
 
 
PBEB 
  
                    PBBz 
  1000 ng/cm2                     500 ng/cm2 1000 ng/cm2                      500 ng/cm2 
Receptor fluid (24 
h) 
 2.06 ±   0.8 1.8 ± 0.9 1.95 ± 0.85 1.55 ± 0.9 
Receptor rinse ND ± ND ND ± ND ND ± ND ND ± ND 
Skin-Epidermis 
(Depot) 
699.0 ± 8.3 441.0 ± 10.5 592.3 ± 7.3 344.0 ± 4.17 
Skin wash 
(unabsorbed) 
81.76 ± 3.06 21.71 ± 8.67 203.5 ± 11.9 101.0 ± 9.0 
Total Recovery 78.28 ± 11.5 88.21 ±   9.5 79.78 ± 16.7 89.21 ± 9.5 
                 PBT               HBB  
 1000 ng/cm2                    500 ng/cm2 1000 ng/cm2                    500 ng/cm2 
Receptor fluid (24 
h) 
 1.70 ±    0.8 1.5 ± 0.5 1.4 ± 0.74 1.2 ± 0.4 
Receptor rinse ND ± ND ND ± ND ND ± ND ND ±  ND 
Skin-Epidermis 
(Depot) 
593.4 ± 8.3 345.0 ± 6.7 811.6 ± 17.4 379.0 ± 11.0 
Skin wash 
(unabsorbed) 
111.5 ± 1.29 90.0 ± 5.8 76.89 ± 12.8 48.75 ±   5.6 
Total Recovery 71.0 ± 4.0 87.3 ± 8.9 88.98 ± 13.0 85.7 ±  9.2 
                 α-TBECH  β-TBECH 
 1000 ng/cm2                    500 ng/cm2 1000 ng/cm2                    500 ng/cm2 
Receptor fluid 
(24h) 
1.97 ±   0.5 2.10 ±   1.2 1.80 ± 0.9 2.3 ± 1.2 
Receptor rinse 2.46 ± 1.2 3.0 ±   2.0 2.20 ± 1.4   2.8 ± 3.0 
Skin-Epidermis 
(Depot) 
682.2 ± 13.7 300.0 ± 5.6 589.0 ± 16.2 318.0 ± 5.6 
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Skin wash 
(unabsorbed) 
249.9 ± 6.97 88.41 ± 6.0 189.0 ± 14.5 90.0 ± 12.5 
Total Recovery 93.4 ± 7.0 78.63 ± 8.5 78.2 ± 19.0 82.6 ± 11.0 
             
 
Table 4.18: Flux rates (Jss, ng/cm2 h), permeability constants (Kp, cm/h) and linear 
ranges (h) estimated from infinite exposure of EPISKINTM to 1000 ng/cm2 of EFRs for 
24 h. 
Episkin 
Jss Kp * 10-5 R2 
PBEB 0.067 6.7 0.89 
PBBz 0.0340 3.40 0.80 
PBT 0.0583 5.8 0.99 
HBB 0.0342 3.42 0.89 
       α-TBECH 0.0705 7.05 0.74 
β-TBECH 0.0965 9.65 0.98 
Syn, Anti-Dechlorane 
Plus 
NM NM NM 
 
 
 
            Syn-DP                  Anti –DP 
 1000 ng/cm2              500 ng/cm2 1000 ng/cm2                    500 ng/cm2 
Receptor fluid (24h) 
ND 
±
  
 ND ND ± ND ND ± ND ND ± ND 
Receptor rinse ND ± ND ND ± ND ND ± ND ND ± ND 
Skin-Epidermis 
(Depot) 
517.0 ± 11.0 312.0 ± 8.5 482.0 ± 16.0 298.0 ± 6.0 
Skin wash 
(unabsorbed) 
188.2 ± 19.0 74.0 ± 9.0 176.0 ± 14.0 64.0 ±   7.0 
   Total Recovery 70.0 ± 16.0 77.2 ± 8.7 66.0 ± 17.0 72.4 ± 11.0 
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4.5.8: Summary  
Overall our neat compound application for all the FRs (with varying physicochemical 
properties) to the HSE models results showed a significant negative correlation between the 
permeability constant of FRs and their Log KOW values i.e. lower the molecular weight of the 
chemical (< 500 g/mol) and if the LogKow is within the ideal range (3-5), the dermal 
absorption would be higher. For some of the chemicals which have got high molecular 
weight and high lipophilicity like BDE 209, DBDPE and syn, anti DP we have observed no 
absorption or penetration through the skin where as other high molecular weight compounds 
like were found to be  highly accumulated in the stratum corneum layer with very low dermal 
absorption. 
 Fig 4.28:  Correlation between Log Kp and Log Kow values of the studied FRs. 
  (R2 = 0.7198 and P < 0.01) 
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CHAPTER V 
TOWARDS UNDERSTANDING THE ROLE OF SKIN 
MOISTURE AND OILINESS ON DERMAL UPTAKE 
OF FLAME RETARDANT CHEMICALS 
 
This chapter contains some material taken verbatim from Pawar, G., M. A. Abdallah, et 
al. (2016). Dermal bioaccessibility of flame retardants from indoor dust and the 
influence of topically applied cosmetics. J Expo Sci Environ Epidemiol 6(10): 84. 
 
5.1: INTRODUCTION 
 We spend the majority of our day indoors, where we are frequently exposed to flame 
retardants (FRs) due to the presence of such chemicals in consumer goods like furniture, 
electronics and building materials (van der Veen and de Boer 2012a).This is illustrated by 
numerous studies showing significant concentrations of HBCDs & PFRs in indoor dust 
(Abdallah and Covaci 2014a, Brommer and Harrad 2015, Abdallah et al. 2008b). 
Humans are exposed to FRs mainly via diet, dust inhalation/ingestion and dermal contact 
with dust or consumer products (Abdallah et al. 2008b, Frederiksen et al. 2009, Watkins et al. 
2011, Xu et al. 2016). Few studies have characterised the concentrations of HBCD isomers in 
indoor dust (Roosens et al. 2009),  human blood (Li et al. 2014, Xiao et al. 2011) and breast 
milk (Eljarrat et al. 2009). (Roosens et al. 2009) reported positive correlation of HBCD 
concentrations in human serum with those in indoor dust samples and also other studies 
(Johnson et al. 2010, Watkins et al. 2012) reported positive correlations for PBDEs (BDE 47, 
99 and 100).Wu et al. (Wu et al. 2007) reported correlations between breast milk and dust 
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concentrations of tetra-hexaBDEs.In contrast to these studies one study even (Cequier et al. 
2015) reported negative correlation between dust concentrations and serum levels where as 
the diet indicated a higher contributions to the body burdens compared to the indoor 
environment. However Roosens et al reported no such correlation for HBCDs dietary 
exposure. Despite highlighting the importance of the internal and external body burdens and 
the pathways of exposure like dust ingestion or diets contribution, previous studies have not 
provided conclusive evidence of how external exposure drives human body burdens of FRs. 
Other research findings (Stapleton et al. 2014, Stapleton et al. 2012b, Watkins et al. 2013) 
suggested that handwipes were a strong predictor of serum PBDE levels. In another study  
(Hoffman et al 2015) TDCIPP and TPhP were detected frequently in hand wipes and dust. 
One of the recent study analysed hand wipes which are more likely to reflect exposures for 
PFRs arising from contact with surfaces (Hammel et al. 2016). Such exposures may arise 
from hand-to-mouth contact and/or dermal absorption as concentrations of  PFRs on hand 
wipes were associated with concentrations of their metabolites in urine (Stapleton et al. 
2008a). Potential metabolites of PFRs have been studied in human biological matrices like 
urine. (Butt et al. 2014a, Meeker et al. 2013, Hoffman, Daniels and Stapleton 2014, Van den 
Eede et al. 2013, Van den Eede et al. 2015). These studies have correlated the concentration 
found in dust and its metabolites in urine, albeit little is known about the potential route of 
exposure. Even non-invasive samples like hair (Kucharska et al. 2015b) and nails (Liu et al. 
2016) were also found to be contaminated with PFRs.  
Recent studies have provided estimates of external human exposure to PFRs via inhalation 
(Bergh et al. 2011), ingestion of indoor dust (Abdallah and Covaci 2014b) and diet 
(Malarvannan et al. 2015). However, very little is known about the relative contribution of 
dermal exposure pathway to the overall human body burdens of these contaminants. 
Furthermore, pharmacokinetic modelling of the extensively studied PBDEs suggested the 
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potential significance of dermal contact with indoor dust as a pathway of human exposure to 
these FRs (Lorber 2008b, Trudel et al. 2011a). Despite this, as of now there remains a paucity 
of data testing the hypothesis that contaminants are transferred from dust to the skin and its 
subsequent absorption to reach the systemic circulation. 
We have studied the bioaccessibility (the amount of the chemical that is potentially available 
for absorption and is dependent on the rate of release from the dust particles and its solubility 
into the physiological fluids like sweat/sebum) and bioavailability (the amount of chemical 
absorbed and is available for physiological function) for HBCDs and PFRs compounds 
applied in “neat” form to shed some light on the importance of dermal exposure in risk 
assessment however this exposure will differ from the real life exposure scenario where 
contaminants are present not as standards in organic solvents but in “real-world” matrices 
like dust particles, fibres or hard plastic pellets etc. Exposure to standard chemicals can occur 
during handling the chemicals or at the work place but majority of the chemicals are exposed 
to humans via indoor dust or consumer goods. The uptake of the chemicals from the vehicle 
/organic solvent would be different from that of dust exposure because the chemicals 
adsorbed on the dust particles needs to partition first to the sweat or the sebum (oily phase) 
on the skin surface and then the stratum corneum. Also in case of neat compound application, 
the partitioning/diffusibility would be faster. The dust particles adhered to the skin surface 
could be the potential source of highly lipophilic flame retardants which could be absorbed 
by the skin. Another factor which prompted us to go beyond the neat application study is the 
presence of cosmetics on the skin surface. Cosmetics (e.g. sunscreen creams) may contain 
certain ingredients (e.g. surfactants) which can increase the oiliness of the skin, remain on the 
skin and become incorporated within the skin surface film liquid. This in turn, may alter the 
lipid domain of the skin thereby increasing the partitioning of chemicals to the stratum 
corneum. Furthermore, the presence of natural surface active agents in this human skin 
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surface film (sweat/sebum mixture) (Stefaniak, Harvey and Wertz 2010), may influence the 
dermal absorption of these PFRs.  
Against this background, the aim of this chapter is to mimic real life scenarios to study 
uptake of HBCDs and PFRs from indoor dust in the presence of sweat/ sebum and topically 
applied moisturising cream. 
Fig 5.1: Schematic diagram showing the concept of dermal exposure 
  
 
  
 
 
                               BIOACCESSIBILITY  
 
 
                                            BIOAVAILABILITY 
5.2: METHODOLOGY  
5.2.1: Dust  SRM2585 with the indicative values for HBCDs and OPFRs was used to study 
the dermal uptake of these compounds.  
5.2.2: Synthetic Sweat and Sebum formulation 
A synthetic sweat solution was prepared by dissolving electrolytes, organic acids, 
carbohydrates, amino acids, nitrogenous substances and vitamins in 500 mL of 18 MΩ-cm 
distilled and deionised water at 32 ºC to mimic the temperature of human skin. A synthetic 
sebum mixture was likewise prepared according to Stefaniak and Harvey (2008) by 
dissolving physiologically-relevant proportions of squalene, cholesterol oleate, triolein 
   Source  
 
Body Fluids 
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Available for 
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consumer products                                                                                 
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BARRIER 
Absorption 
Blood 
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(unsaturated), and palmityl oleate in hexane (quantity sufficient). The detailed composition of 
both the synthetic sweat and sebum mixtures are to be found in Chapter 2 Section 2.2.2. 
5.2.3: Episkin Dust Exposure 
Episkin was equilibrated in 12 co-star well plates in 2.5mL culture media at 37 °C. After 30 
mins equilibration, the skin surface was exposed to 50-60 mg of SRM-2585 dust uniformly 
with the help of a spatula and a brush under 4 different scenarios: (a) just dust; (b) dust in 
presence 100µL of (1:1 v/v) of sweat: sebum mix; (c) dust in presence of 100 µL of 20% 
Tween 80, and (d) dust in presence of 50 mg of moisturising cream. Each of the scenarios 
was examined in triplicates. (Fig 5.2). After 15 mins of gentle shaking the plate was 
incubated at 37°C with humidified air containing 5% CO2. In case of moisturising cream, 50 
mg of cream was weighed in a tared clean glass tube and then with the help of a spatula, the 
cream was applied on the surface of the skin before spreading or exposing the dry dust on the 
skin surface. For all the 12 wells at serial time points, the receptor fluid was collected up to 
termination of exposure at 24 hr by removing the dust from the skin surface with a cotton bud 
soaked in hexane. At termination, the skin patches were removed with forceps and subjected 
to tape stripping (n=5) (Fig 2) and receptor compartments were washed separately (5 × 2 mL) 
with PBS. All samples (Receptor fluid, skin, cotton buds, well wash and tape strips) were 
stored at −20 °C until chemical analysis. 
5.2.4: Extraction-Clean-up and Analysis 
Receptor fluid, well wash, tape strips, cotton buds and the epidermis (after homogenisation ) 
were spiked with 30 µL of 13C-isotopically labelled α-HBCD, β-HBCD, γ-HBCD and TPhP-
d15 (1 ng/µL), prior to extraction with 3 mL of hexane: ethyl acetate (1:1 v/v) mixed with 
200 µL acetone (protein precipitation) using a QuEChERS-based method. Sample tubes were 
vortexed on a multi-positional mixer for 5 mins, followed by ultra-sonication for 5 mins and 
centrifugation at 3000 rpm for 5 mins. The extraction cycle was repeated twice before the 
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pooled supernatant was collected in a clean tube. The receptor fluids  crude extracts were 
dried completely and reconstituted in 150 µL of methanol containing 50 pg/µL of d18-α-
HBCD and analysed later on LC-MS/MS. Target PFRs were reconstituted in 100 µL of 
isooctane containing 13C-BDE-100 used as RDS prior to GC/MS analysis according to a 
previously reported method (Abdallah and Covaci 2014b).  
Fig 5.2 Schematic Diagram Plate A: The first three skin patches were applied with 50 
mg of dry SRM-2585 dust to mimic “ dry” skin condition and other 3 skin patches were 
dosed with 100µL of sweat and sebum (1:1 v/v) mixture before applying 50 mg of SRM-
2585 dust uniformly. Plate-B:  50 mg of SRM -2585 dust was applied on the skin surface 
in presence of 20% Tween 80 (100µL) in triplicate and moisturising cream was applied 
uniformly with the help of spatula on skin surface and then 50 mg SRM-2585 dust was 
applied to cover the surface. 
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Fig 5.3: Tape stripping with the help of 3M adhesive tape (Pic 1-4).  
             
         
After terminating the exposure, the Episkin patch was dismantled from the Transwell “O” 
ring and with the help of clean forceps (rinsed in acetone between each stripping)  the upper 
stratum corneum surface (1 cm2) was placed towards the adhesive film for 2 mins and 
removed gently. In this way the stripping was carried out 5 times. After the sampling the 
tapes were placed in a clean test tube for further analysis. The tape strip contains the amount 
of corneocytes and the corresponding amount of penetrated target chemicals which were 
determined later by LC-MS/MS.                           
1 
2 
3 4 
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The crude extract of tape strips , cotton buds containing dust,  sebum, moisturising cream & 
20% Tween 80  (~1 mL) was cleaned up by loading onto a Florisil SPE cartridge (pre-
conditioned with 6 mL of hexane). Fractionation was achieved by eluting with 8 mL of 
hexane (Fraction 1:F1 for HBCDs) followed by 10 mL of ethyl acetate (Fraction 2: F2 for 
PFRs). F1 was washed with ~ 2 mL of 95 % H2SO4 to remove lipids. The organic layer and 
washings were combined and evaporated to incipient dryness under N2.Target analytes were 
reconstituted in 150 µL of methanol containing 50 pg/µL of d18-α-HBCD used as recovery 
determination (Abdallah et al. 2014b). Fraction F2 was evaporated to incipient dryness under 
N2. Target PFRs were reconstituted in 100 µL of isooctane containing 
13C-BDE-100 used as 
RDS prior to GC/MS analysis according to a previously reported method (Abdallah and 
Covaci 2014b). Further details of instrumental analysis are provided in Chapter 2.1.3 
5.3: QA/QC 
We evaluated the mass balance for each exposure experiment by dividing the sum of FR 
masses found in all skin compartments by the initial mass (ng) applied on the skin surface. 
We also checked for the level of PFRs in the 3M adhesive tapes before using it and the PFRs 
were not detected. The recovery of initially applied FR mass was between 60-95 % across all 
tested FRs and exposure scenarios. (Table 5.2) The reasons for the obtained recoveries might 
be due to the possible dermal metabolism, losses during extraction/clean-up steps and 
analytical variabilities. Statistical analysis of the data was conducted using Excel (Microsoft 
Office 2003) and SPSS version 13.0. ANOVA tests were performed on concentrations in the 
receptor fluids and the skin. (P ≤ 0.05, if differences are significant) 
5.4: RESULTS & DISCUSSION  
Concentrations of target FRs measured in all the compartments under all four exposure 
scenarios are shown in Figure 5.4 and Table 5.1. When dry dust was exposed to the Episkin, 
in 24 hrs time the cumulative absorption (receptor fluid plus receptor rinse) was found to be 
0.85 ± 0.14 ng/cm2, 0.079 ± 0.05 ng/cm2 & 0.408 ± 0.36 ng/cm2 for α-HBCD, β-HBCD and 
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γ-HBCD respectively. The absorption was higher in α-isomer followed by γ-isomer and then 
least for β-isomer. This behaviour could be due to lower water solubility of the γ-isomer (2 
µg/L) compared to that of β–HBCD (15 µg/ L) and α-HBCD (49 µg/ L) (Abdallah et al. 
2012). Surprisingly the absorbed amount is higher in γ-isomer as compared to the β isomer 
even though it has the lowest water solubility this may be due to the lesser concentration of β 
isomer than the γ-isomer in the SRM-2585 dust. This trend is more evident in the wet 
exposure scenario where in the presence of sweat/sebum mixture the amount absorbed was 
increased as compared to dry condition, it was found to be 5.19 ± 2.74 ng/cm2, 0.77 ± 0.40 
ng/cm2, 0.75 ± 0.30 ng/cm2 for α-HBCD, β-HBCD & γ-HBCD respectively. We also 
analysed the skin after removing the 5 outermost layers of the stratum corneum, the rationale 
behind performing only 5 stripping is that in the real life scenario these layers are considered 
as outside the body (not absorbed) and undergoes desquamation regularly. The rest of the 
contaminants in the stratum corneum layers can be considered as the “stored within the skin”. 
The amount remained in the skin layers for α-HBCD, β-HBCD & γ-HBCD are 4.13 ± 0.55 
ng/cm2, 2.56 ± 0.14 ng/cm2 & 4.40 ± 0.81 ng/cm2 respectively. This amount is slightly 
increased in presence of sweat and sebum mixture. The effect of exposure conditions had 
increased the permeability of the FRs from the dust but statistically not so significant (P 
>0.05). The cumulative absorption values in the presence of 20% Tween 80 were 10.55 ± 
6.48 ng/cm2, 1.43 ± 0.94 ng/cm2, 10.19 ± 5.73 ng/cm2 for α-HBCD, β-HBCD & γ-HBCD 
respectively. However this amount penetration decreased in presence of 50 mg applied 
moisturising cream (3.31 ±1.76 ng/cm2, 0.42 ± 0.27 ng/cm2 and 0.42 ± 0.24 ng/cm2 for α-
HBCD, β-HBCD & γ-HBCD respectively) due to the retention of lipophilic HBCDs in the 
moisturising cream’s lipids. 
In case of dry dust exposure the receptor compartment concentration was found to be 1.7 ± 
1.2 ng/cm2, 6.43 ± 3.45 ng/cm2, 4.43 ± 1.74 ng/cm2 for TCEP, TCIPP and TDCIPP 
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respectively. Interestingly we observed the cumulative absorption increased in case of wet 
scenario. The values were 9.98 ± 3.8 ng/cm2, 321.78 ± 18.03 & 130.52 ± 20.01 ng/cm2 for 
TCEP, TCIPP and TDCIPP. 
The amount remained in the skin layers also increased in wet condition due to the 
sweat/sebum effect. It increased from 142.91 ± 12.67 ng/cm2 to 344.64 ± 54.12 ng/cm2 
(TCEP), 114.0 ± 6.8 ng/cm2 to 518.5 ± 8.9 ng/cm2 (TDCIPP). These higher values may arise 
due to enhanced solubility or dissolution of these FRs in the presence of sweat and sebum. 
Alternatively and/or additionally, they may arise as a result of enhanced partitioning/ 
diffusion of sebum through stratum corneum layers and enhanced permeability of sweat 
through the epidermis, which in both instances could have enhanced the permeability of the 
chemicals. However this trend was not observed in TCIPP which could be due to metabolism 
or analytical variability. Interestingly the 20% Tween 80 and moisturising cream further 
decreased the penetration in comparison to the sweat/sebum mixture. In the presence of 20% 
Tween 80 the receptor fluid concentration was 5.46 ± 3.56 ng/cm2 (TCEP), 92.69 ± 24.2 
ng/cm2 (TCIPP) & 90.59 ± 6.95 ng/cm2 (TDCIPP) and in case of moisturising cream the 
concentration decreased to 3.0 ± 1.96 ng/cm2 (TCEP), 19.54 ± 9.43 ng/cm2 (TCIPP) & 42.62 
± 16.94 ng/cm2 (TDCIPP). 
In comparison to HBCDs, PFRs were found to be more absorbed in both the wet and dry 
scenarios. The first reason for this behaviour is due to higher water solubility for PFRs as 
compared to the HBCDs isomers which helps in higher solubility in sweat and then 
partitioning into the hydrophilic epidermis as compared to HBCDs. The second reason is that 
the PFRs have higher concentrations in the dust so the absorption rate is dependent on the 
concentration gradient for the chemical on the skin surface. Third, due to higher lipophilic 
nature of HBCDs, they were found to be stored in the skin preferentially in the epidermis 
layers resulting in prolonged release into the receptor fluid. PFRs showed higher absorption 
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in 24 hrs time as compared to the HBCDs in presence of Tween-80 and moisturising cream. 
This might be due to enhanced permeation of PFRs by Tween 80 or moisturising cream 
through the lipophilic stratum corneum layers. Whereas for HBCDs the viable epidermis 
would increase the resistance for permeation. 
The increase in the target compound recovered from the tape stripping and the epidermis 
demonstrated that artificial sweat-sebum mixture and 20% Tween 80 enhanced the transfer of 
flame retardants from the dust particles. 
5.5: Implications for human expsoure 
The results of dermal absorption and penetration of HBCDs and PFRs from the dust across 
the skin layers were used to assess the daily internal dose of the target FRs using the general 
equation: 
                                          
 
Where DED = Daily exposure dose (ng/kg bw/day), C = PFR concentration in dust (ng/g),    
BSA =Body surface area exposed (cm2), DAS = Dust adhered to skin (mg/cm2), FA = 
fraction absorbed by the skin (unitless), IEF = indoor exposure fraction (hours spent over a 
day in a certain indoor environment) (unitless), BW = Body weight (kg). 
We estimated the dermal exposure of 2 age groups (adults and toddlers) using three exposure 
scenarios i.e. dry expsoure, wet exposure and in presence of moisturising cream.  
We used the concentrations in SRM-2585 Dust (Chapter 2, Table 2.5) and the parameter FA 
in equation 1 was replaced by the experimental values obtained in this study for the uptake of 
each target HBCDs & PFR from the SRM-2585 dust using the Episkin model (Table 5.2). 
Values for other parameters in equation 1 were obtained from the USEPA exposure factors 
handbook (USEPA 2011) and summarized in Table Chapter 3, Table 3.7. 
When the adults and toddlers group were compared for the dry skin, wet skin and in presence 
of moisturising creams scenario the differences were found to be slightly higher in toddlers 
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group (Table 5.3), however the differences between them were not statistically significant 
(P>0.05). This may be attributed to more dust adhering to the toddlers’ skin and higher 
exposed skin surface area to body weight ratio compared to adults. We have also noticed that 
the daily dermal estimates for the FRs were found to be lower when we considered the data 
on the bioavailable fraction (subsequent dermal transfer of the studied FRs from sweat/sebum 
or in presence/absence of moisturising cream across the epidermis to the systemic circulation) 
as compared to the bioaccessible fraction of the FRs from the dust to the sweat/sebum 
mixture. This is obvious as the skin is the main barrier to the absorption and penetration of 
the FRs. Other important aspects of exposure is that of the applied moisturising creams, the 
daily dermal estimates in both the adults and toddlers were found to be lower than that of the 
dry and wet skin expsoure which could be due to the possible retention of the lipophilic FRs 
in the fatty formulation of cosmetics. Its worth to note that our dermal exposure estimates 
assume a fixed body area undergoing a constant exposure to FRs in indoor dust for a constant 
period of time and not for a chronic exposure. Such a rigid assumption may introduce 
uncertainty to our estimates of dermal exposure, more research is required to fully elucidate 
the toxicological implications of such exposure in both adults and toddlers. Our worst-case 
scenario exposure estimates for dermal exposure of adults and toddlers (Table 5.3) fall far 
below the HBLV values of  No Significant Risk Level (NSRL) of 5.4 µg/day for TDCIPP 
(OEHHA 2015). No other health based limit values (HBLVs) of legislative standing for our 
target FRs were found in the literature. Our estimates of daily dermal uptake of FRs from the 
dust shows that the composition (i.e. sweat: sebum ratio) of skin fluids, as well as the 
presence/absence of commonly used skin cosmetics is demonstrated to exert a substantial 
influence on the efficiency with which our target FRs are released from dust and rendered 
available for dermal uptake. 
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Table 5.1 Showing the cumulative absorption found in the receptor fluid, unabsorbed amount (cotton wipe), skin depot (both stratum 
corneum i.e. tape stripping and the epidermis) and receptor well rinse. (Note all results are in Mean ± SD ng/cm 2, Recovery in %
 
            
          α-HBCD 
       
       β-HBCD 
       
           γ-HBCD 
        
       TCEP 
 
     TCIPP 
 
     TDCIPP 
                                                      Dry Dust Exposure (SRM-2585) 
  
Receptor fluid (24hr) 0.68     ± 0.05 0.039 ± 0.02 0.0486 ± 0.15 1.20 ± 0.78 5.23 ± 2.9 3.23 ± 1.09 
Receptor rinse  0.17 ± 0.09 0.040 ± 0.03 0.36 ± 0.21 0.5 ± 0.42 1.2 ± 0.55 1.2 ± 0.65 
Tape Strip (S.Corneum) 0.019 ± 0.02 0.34 ± 0.17 1.29 ± 0.8 25.48 ± 13.09 91.53 ± 8.9 393.96 ± 12.42 
Skin-Epidermis (Depot) 4.13 ± 0.55 2.56 ± 0.14 4.40 ± 0.81 142.91 ± 12.67 192.0 ± 26.86 114.0 ± 6.8 
Cotton wipe  (unabsorbed) 11.52 ± 0.19 0.53 ± 0.30 106.97 ± 5.33 535.14 ± 20.56 420.56 ± 9.39 512.0 ± 8.4 
Total Recovery (%) 64.3 ± 2.45 84.7 ± 12.65 86.31 ± 7.43 94.0 ± 6.78 89.9 ± 6.7 60.61 ± 8.2 
                                                    Dust Exposure (SRM-2585) in presence of 1:1 v/v Sweat and sebum mixture 
   
Receptor fluid (24h) 5.06 ± 2.67 0.58 ± 0.36 0.6 ± 0.25 6.16 ± 1.8 316.88 ± 16.80 123.02 ± 17.21 
Receptor rinse 0.13 ± 0.07 0.19 ± 0.04 0.15 ± 0.05 3.82 ± 2.0 4.90 ± 1.23 7.5 ± 2.8 
Tape Strip (S.Corneum) 0.14 ± 0.05 0.07 ± 0.06 0.61 ± 0.22 19.42 ± 7.8 57.62 ± 18.9 84.32 ± 9.6 
Skin-Epidermis (Depot) 4.33 ± 0.03 2.27 ± 0.11 4.51 ± 0.58 344.64 ± 54.12 151 ± 8.36 518.5 ± 8.9 
Cotton wipe  (unabsorbed) 7.65 ± 3.45 0.46 ± 0.05 89.43 ± 14.5 183.61 ± 26.92 211.31 ± 67.0 314.32 ± 5.0 
Total Recovery (%) 82.42 ± 1.76 83.4 ± 3.56 73.0 ± 7.8 74.35 ± 11.3 93.88 ± 13.21 61.99 ± 13.43 
                                                                                                             Dust Exposure (SRM-2585) in presence of 20 % Tween 80 (aqueous) 
 
Receptor fluid (24h) 9.32 ± 5.61 1.23 ± 0.89 8.65 ± 5.0 3.05 ± 2.89 86.2 ± 21.0 89.25 ± 6.5 
Receptor rinse 1.23 ± 0.87 0.20 ± 0.05 1.54 ± 0.73 2.41 ± 0.67 6.49 ± 3.2 1.34 ± 0.45 
Tape Strip (S.Corneum)  1.34 ± 1.0 0.34 ± 0.22 16.54 ± 8.9 26.59 ± 11.68 51.09 ± 15.9 28.54 ± 5.6 
Skin-Epidermis (Depot) 5.2 ± 2.3 0.81 ± 0.45 23.56 ± 11.8 509.41 ± 45.6 256 ± 7.32 634 ± 11.8 
Cotton wipe  (unabsorbed)  0.87 ± 0.5 0.78 ± 0.56 37.9 ± 11.4 100.61 ± 36.7 314.7 ± 24 429.15 ± 6.7 
Total Recovery (%) 94.5 ± 16.43 78.1 ± 15.63 67.32 ± 18.9 85.6 ± 8.92 77.7 ± 11.2 64.67 ± 7.8x 
                                                                                                             Dust Exposure (SRM-2585) in presence of  moisturising cream  
 
Receptor fluid (24h) 2.64 ± 1.43 0.33 ± 0.26 0.32 ± 0.15 2.0 ± 1.2 15.87 ± 7.89 29.95 ± 11.34 
Receptor rinse 0.67 ± 0.33 0.09 ± 0.01 0.1 ± 0.09 1.09 ± 0.76 3.67 ± 1.54 12.67 ± 5.6 
Tape Strip (S.Corneum) 1.45 ± 0.82 0.56 ± 0.24 11.6 ± 5.8 3.5 ± 2.8 8.7 ± 1.67 128.45 ± 12.45 
Skin-Epidermis (Depot) 3.54 ± 1.45 0.84 ± 0.34 10.73 ± 6.7 34.0 ± 9.45 186 ± 6.89 125.8 ± 13.4 
Cotton wipe  (unabsorbed) 5.43 ± 2.5 1.83 ± 0.87 56.2 ± 15.6 498.2 ± 6.98 345.0 ± 12.89 789.67 ± 31.5 
Total Recovery (%) 72.2 ± 15.90 83.9 ± 7.4 60.2 ± 21.5 71.83 ± 16.59 70.7 ± 8.9 64.29 ± 5.6 
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Fig 5.4: Graph showing the cumulative amount absorbed after 24 hrs of Dry SRM-2585 exposure (Control) in presence of sweat/sebum 
(wet condition),20% Tween 80 and moisturising cream (Values are given in Mean ± SD , n=3 replicates , ng/cm2  P > 0.05 for all the 
groups). 
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Fig 5.5: Graph showing the amount remained in the skin (sum of amount in stratum corneum and the epidermis)  after 24 hrs of Dry 
SRM-2585 exposure (Control) in presence of sweat/sebum (wet condition),20% Tween 80 and moisturising cream (Values are given in 
Mean ± SD , n=3 replicates, (ng/cm2 ), P > 0.05 for all the groups). 
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Table 5.2: Assessment of human dermal exposure (ng/kg bw/day) to FRs present in 
SRM-2585 dust upon contact with a skin surface at three different scenarios i.e dry 
skin, wet skin and in presence of moisturising creams. 
Dermal 
exposure 
scenario 
Dry skin exposure Wet skin exposure 
In presence of  
moisturising creams 
  Adults       Toddlers Adults       Toddlers Adults          Toddlers          
α-HBCD 0.003             0.030  0.005          0.060 0.000036          0.00042 
β-HBCD 0.001              0.016 0.002           0.020 0.000007           0.00008 
γ-HBCD 0.0003            0.003 0.003           0.030 0.000058           0.00067 
TCEP  0.100             0.868  0.200          2.130 0.000193           0.0022 
TCIPP  0.100             1.194  0.247          2.840 0.001075           0.01236 
TDCIPP  0.060             0.707  0.340           3.910 0.000882           0.0105 
  
5.6: Summary  
 Results demonstrated the importance of bridging and simultaneously considering 
factors like role of sweat/sebum and cosmetics in the dermal exposure of hazardous 
FRs from indoor dust. It shed light on how the adsorbed FRs (HBCDs & PFRs) on the 
dust particles gets dissolved in the human sweat or sebum and subsequently available 
for the partitioning into the outermost dead cell layers i.e. stratum corneum layer of 
the skin.  
 For the first time we have mimicked the real life dermal exposure scenario by 
incorporating dry and wet conditions in our in vitro dermal experiment. The 
implication of this is to understand the type of skin i.e. dry skin and oily skin and it’s 
prone to the hazardous chemicals. Dust was applied to the skin surface to show that 
dust could be a potential source of dermal exposure for FRs which would contribute 
to the overall body burdens. Our results suggested that the sweat/sebum mixture 
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increased the absorption of the lipophilic chemicals like HBCDs & PFRs thus it 
indicates that the wet or oiliness of the skin increases the exposure level, however it 
was not statistically significant as compared to the dry exposure which could be due 
to the moisture content of the skin. 
 For the first time we developed a novel way of tape stripping method applied to the in 
vitro 3D-HSE skin. The results revealed that the substantial amount of the FRs 
remained in the skin. This bioaccumulation is important to know the behaviour of the 
chemicals and to correlate with the physicochemical properties of the substances 
accidentally exposed to the skin. Another importance is to understand the lag time of 
the chemicals to appear into the systemic circulations. We are in dermal contact with 
various cosmetics/personal care products on a daily basis and the oily fats of the 
formulations or the surfactants like Tween 80 may undergo retention on the skin 
surface. Due to the oiliness of the skin (which could be due to naturally secreting 
sebum or the intentionally applied skin creams) the dust particles might cling to the 
surface and the chemicals like FRs may act directly in the skin or be absorbed through 
the skin into the blood, accumulate in the body and exert toxic effects in various 
organs. It is important to monitor such exposure especially in toddlers group which 
are vulnerable due to their developmental status than is the general population.  
 However future studies needs to be carried out to work on some of the uncertainties in 
dermal risk assessment. First, the amount of the chemicals (if any) in the personal care 
products which would further facilitates the body burdens in addition to the chemicals 
exposed via dust. Second, skin contact area and the frequency of events. Third, 
duration of contact and intensity of contact. 
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CHAPTER VI 
DERMAL BIOACCESSIBILITY AND UPTAKE OF 
PBDEs FROM PLASTICS 
6.1: INTRODUCTION  
Plastics play an important role in the electrical and electronics (E&E) industry. E&E 
applications rely on thermo-plastics because of their unique features like light weight, 
resistance to physical, chemical, biological degradation and fire safety. Production of plastics 
for use in E&E applications grows globally and its demand reached 47.8 million tonnes/year 
in European countries according to Plastics Europe (Plastics 2016). Humans are likely to be 
exposed to many plastic products every day while using computers, laptops, TV-sets, fridges, 
cell phones, toys…etc. Moreover, plastics continuously degrade into smaller particles and 
highly increasing surface area is likely to become available for the desorption of persistent 
organic pollutants like PBDEs contained within the particles. Studies have suggested that  
plastics may also leach chemicals if they are scratched or heated and the chemicals can 
penetrate into cells, chemically interact with biologically important molecules and may 
disrupt the endocrine system (Teuten et al. 2009). PBDEs or other FRs may be present in 
plastic toys as contaminants during the manufacturing process or the chemicals could be 
transferred from indoor dust to the toy’s external surfaces or to the soft foams/fillings when 
they are not added deliberately (Chen et al. 2009). During play time or hand-to-mouth 
behaviour of children, PBDEs could come in contact with physiological fluids like 
sweat/sebum on the skin. A recent study (Hoffman et al. 2016) showed that playing with 
plastic toys was associated with higher handwipe levels of PBDEs. Moreover, at e-waste 
dumping and recycling sites, workers regularly come into dermal contact with BFR-
containing WEEE plastic. (Wu et al. 2016b, Wu et al. 2016a). Dermal exposure to chemicals 
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present as additives in polymers is of particular concern for pregnant women and children 
(Sutton et al.). When pregnant women are exposed to FRs, the maternal increase in body 
burdens can have detrimental effects on the fetus/baby via placental transfer or during 
lactation. Epidemiological research has linked prenatal exposure to the adverse outcomes; 
decrease in fecundability (Harley et al. 2010b), pregnancy loss, lower thyroid stimulating 
hormones (Chevrier et al. 2010), pre-term birth-low birth weight (Harley et al. 2011), 
childhood morbidity and impaired neurodevelopment (Herbstman et al. 2010). Children may 
be in frequent contact with plastic toys either by mouthing or via dermal contact. 
A study performed by (Ionas et al. 2016)  investigated the leaching behaviour of PBDEs from 
toys into saliva under simulated conditions. The results of this work revealed the leaching 
process to be congener dependent and that the proportion of lower brominated PBDEs 
leached was 4.5 times higher than the more brominated congeners. However, to our 
knowledge there are no studies where the leaching behaviour of PBDEs in other 
physiological fluids like sweat/sebum has been tested. Therefore, children’s toys and child-
care articles could be potential sources of dermal exposure to PBDEs. Despite a recent study 
by (Abdallah, Pawar and Harrad 2015a) highlighting the importance of dermal contact as a 
pathway of human exposure to brominated flame retardants, very little is currently known 
about human dermal exposure to additive FRs present in plastics.  
Given this, the aim of this chapter is to test the hypothesis that the PBDEs in plastic can leach 
out upon contact with human SSFL and become available for absorption via penetration of 
the stratum corneum. For the first time, we simulated real life dermal exposure scenarios by 
exposing a 3D-HSE EPISKIN™ model to 75-85 mg/cm2 of ERM micro-plastics (ERM-
EC590 “low density polyethylene” & ERM-EC591 “polypropylene”). The tested micro-
plastics were applied to the skin surface in the presence of 1:1 sweat sebum mixture (v/v) to 
mimic real-life exposure conditions (Pawar et al. 2016) (Stefaniak and Harvey 2008). The 
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concentrations of PBDEs in the SSFL were measured to assess the bioaccessibility of target 
compounds. This was followed by investigating their percutaneous penetration using the 3D 
Episkin model. 
6.2 METHODOLGY  
 6.2.1 Dermal bioaccessibility of PBDEs from ERM-EC590, ERM-EC591 plastics  
ERM-EC591 and ERM-EC590, obtained from the Institute for Reference Materials and 
Measurements (IRMM), were used as certified reference materials for the determination of 
BDE-28, BDE-47, BDE-99 & BDE-183 and BDE-209 in PP and PE matrices. The 
concentration range of the target compounds was between 87 mg/kg and 780 mg/kg in the 
two ERMs tested (Chapter 2, Table 2.12). Physiologically-simulated artificial sweat and 
sebum mixture (SSSM) was prepared according to a previously reported method (see section 
3.2.2). 
The ERM-EC590 plastic pellets (low density polyethylene polymer) and ERM-EC591 
(polypropylene) were accurately weighed (80-90 mg) and placed in a mortar and ground 
using a heavy grinding ball with the Vibratory Micro Mill PULVERISETTE 0, which 
provided impact and friction at amplitude 3.0 mm. To achieve appropriately fine 
comminution, liquid nitrogen was used to render the plastic pellets brittle.  
The resulting pulverised micro-plastics ERM-EC590 & ERM-EC591 were weighed (75-85 
mg) in triplicate and transferred to clean test tubes. The samples were spiked with IS BDE-
77, BDE-128 and 13C-labelled BDE-209, and the mixture incubated in 5 mL of 1:1 v/v sweat 
and sebum mixture. The mixture was agitated with magnetic beads on a hot plate at 32 °C for 
2 hrs exposure time to mimic the in vivo skin temperature. Due to the lower densities of the 
micro plastics they were found to be floating at the interface between the sweat and sebum 
layers. 
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                                     Fig 6.1: The Vibratory Micro Mill PULVERISETTE 0 
 
 
At the end of the exposure time, the liquid was collected using clean glass Pasteur pipettes 
(without the plastics) and the resulting samples generated (i.e. solid plastics and the liquid 
sweat/sebum mixture) were analysed separately and mass balance calculated. 
6.2.2 Dermal uptake of PBDEs from pulverised ERM-EC590 and ERM-EC591 plastics 
(Fig 6.2) A dose (75-85 mg accurately weighed) of the pulverised ERM-EC590 plastic and 
ERM-EC591 (polypropylene) were applied on Episkin tissues and equilibrated in 12 co-star 
well plates in 2.5 mL culture media at 37 °C. After 30 mins equilibration, the skin surface 
was exposed to ERM-EC590 & ERM-EC591 spread uniformly on the skin surface in the 
presence of 100 µL of sweat: sebum mixture (1:1 v/v). At serial time points, the receptor 
fluid (2.5 mL) was collected and replaced (2.5 mL). The exposure was terminated at 24 hr by 
removing the microplastics from the skin surface with a cotton bud soaked in hexane. The 
skin patches were removed with forceps and subjected to tape stripping (n=5). The receptor 
compartments were washed separately (5 × 2 mL) with PBS. All samples (receptor fluid, 
skin, cotton buds with microplastics, well wash and tape strips) were stored at −20 °C until 
chemical analysis. 
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6.3 EXTRACTION AND CLEAN-UP  
6.3.1 Bioaccessibility samples  
The microplastics and the liquid phase (i.e. sweat/sebum) were separated and subjected to 
extraction and clean-up separately. The micro-plastics were extracted with 100% DCM three 
times and the pooled solvent extracts reduced to incipient dryness under N2. Then the 
concentrated sample extracts were dissolved in 2 mL hexane and washed with ~ 2 mL of 95 
% H2SO4 to remove lipids. The organic layer and washings were combined and evaporated to 
incipient dryness under N2. Target analytes were reconstituted in 150 µL of isooctane 
containing 250 pg/µL of PCB-129 used as recovery determination standard (RDS) prior to 
GC-MS analysis using the method described in section 2.1.1. The liquid phase (i.e. 
sweat/sebum) samples were extracted with 3 mL hexane: ethyl acetate (1:1 v/v) and the 
pooled solvent treated via a procedure similar to that followed for the micro-plastics.  
6.3.2 Episkin dermal exposure samples  
Each permeation assay generated five different types of samples comprising: receptor fluid, 
skin tissue, cotton buds with microplastics (used to thoroughly wipe the skin surface), donor 
and receptor compartment solvent washes. The receptor fluid, skin tissue and cotton bud 
samples were extracted according to a previously reported QuEChERs based method 
(Abdallah et al. 2015). Briefly, each sample was spiked with 30 ng of BDE-77, BDE-128 and 
13C-BDE-209 used as internal (surrogate) standards. 
Extraction was performed using 2 mL of (1:1) hexane: ethyl acetate mixture and vortexing 
for 2 minutes, followed by ultrasonication for 5 minutes and centrifugation at 4,000 g for 3 
minutes. This extraction cycle was repeated twice before the combined organic extracts were 
evaporated under a gentle stream of N2 and reconstituted into 100 μL of isooctane containing 
100 pg/μL of PCB-129 used as recovery (syringe) standard for QA/QC purposes. The donor 
and receptor compartment washes were spiked with 30 ng of the internal standard mixture 
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and vortexed for 30 seconds prior to direct evaporation under a gentle stream of N2. Target 
analytes were reconstituted into 100 μL of methanol containing 100 pg/μL of PCB-129 used 
as recovery (syringe) standard for QA/QC purposes. Quantification of target PBDEs was 
performed using a TRACE 1310™ GC coupled to a ISQ™ Single Quadrupole mass 
spectrometer (Thermo Fisher Scientiﬁc, Austin, TX, USA) operated in negative chemical 
ionisation (NCI)  (Refer Chapter 2.1.1) 
6.4 Bioaccessibility Results  
The ERM-EC 590 & ERM-EC 591 pellets and the pulverised microplastics were subjected to 
incubation in the presence of 1:1 v/v sweat and sebum at 32°C to mimic normal physiological 
skin temperature. Both the pellets and the pulverised microplastics were chosen to study the 
effect of particle size on the release of PBDEs from the studied polymers. The reduced size of 
the pulverised plastics (~ 0.5 mm) resulted in higher surface area for easy dissipation of the 
polymers in the SSFL resulting in significantly higher bioaccessibility (%) for PBDEs (t-test, 
P<0.01, n=3) as compared to the intact pellet beads (~ 5 mm) for both the ERM-EC 590 & 
ERM-EC 591 reference plastics (Fig 6.4 & 6.5).The bioaccessibility ranged from 61% to ~ 
83% in ERM-EC590 in case of pellets and significantly increased to 70% to 94% when the 
size of the pellets were reduced (microplastics). Both the lower PBDEs as well as the higher 
PBDEs were able to dissolve efficiently in the sweat and sebum mixture. The reasons for this 
may be attributed to the unique composition of the SSFL which contains lipophilic sebum 
that would facilitate the dissolution of highly lipophilic congeners (e.g. 183 and 209) together 
with the electrolyte-rich sweat which may favour the leaching of less hydrophobic congeners 
(e.g. 17 and 28) from the pulverised plastics. It is noteworthy that the increase in % 
bioaccessibility was also dependent on the varying concentrations or amount of PBDE 
congeners in both the polymers. For example, BDE-28 was present only in ERM-EC 591 
polymer at a concentration of 2,500 ng/g whereas the concentration of BDE-209 was found to 
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be even at a higher concentration i.e. 780,000 ng/g than BDE-28. This difference in 
concentration for BDE 28 & BDE-209 resulted in bioaccessibility of 22.3 % to 31 % & 84 % 
to 93 % respectively. However there was no clear trend of increase in bioaccessibility due to 
increase in lipophilicity of the PBDEs which may again be attributed to the formulation 
reason because the formulation contains both the lipophilic sebum that facilitates the 
dissolution of highly lipophilic congeners together with the electrolyte-rich sweat which may 
favour the solubility of less hydrophobic congeners (e.g. 17 and 28) from the pulverised 
plastics. Our bioaccessibility results imply that in real life PBDEs could be bioaccessible to 
human sweat and sebum from low density polyethylene (LDPE) and polypropylene. 
Moreover, our data suggest it is invalid to assume 100% bioavailability for the chemicals 
when the rate limiting factor is their dissolution into physiological fluids (bioaccessibility). 
6.5 In vitro Dermal Exposure (microplastics) 
Due to the experimental costs and other technical reasons like lower surface area and particle 
size of intact ERM-EC 590 & ERM-EC 591 pellets, we performed the experiment only with 
pulverised (micro) plastics. When ERM-EC591 micro plastics were exposed to the Episkin 
model, the absorbed mass of PBDEs with increasing Br content from BDE-28 to BDE-154 
revealed a broad decrease in dermal absorption (fig 6.6). The former trend i.e. broad decrease  
from BDE-28 to BDE-47 was not observed for ERM-EC590 because BDE-28 is not present 
in the ERM-EC590 reference material. Maximal penetration was achieved for Tetra-BDE and 
Penta-BDE, however Octa-BDE and Deca-BDE showed no penetration, although they were 
found to be more highly accumulated in the skin than the less brominated PBDEs studied 
(Fig 6.7). This is because the less hydrophobic lower brominated PBDEs penetrated faster 
through the water-rich viable epidermis than Octa-BDEs and Deca-BDE which were instead 
found in the lipid-rich stratum corneum and showed no discernible penetration due to their 
higher hydrophobicity. The PBDEs thus accumulated represent a depot from which they may 
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be released to the systemic circulation over a prolonged period or could be metabolised to 
lower congeners. The reason for higher penetration of less brominated PBDEs and higher 
accumulation of more highly brominated congeners in the skin could be due to the 
differences in physicochemical properties between the congeners. In spite of the differences 
in the concentrations of the PBDE congeners in the both ERMs, we found no statistical 
differences (P>0.05) between the % absorption of PBDE congeners from the two ERMs. Our 
data are in good agreement with previous studies that show the tetra congener BDE-47 and 
the penta congener BDE-99 to be well absorbed and highly distributed to fatty tissues like 
adipose, adrenal glands, gastrointestinal tract, skin and liver (Hakk and Letcher 2003) when 
administered orally in Sprague Dawley rats. 
The higher dermal absorption for lower PBDEs could lead to higher toxicity concerns and the 
metabolism of the accumulated higher congeners to lower congeners might increase the 
overall toxicity by lower congeners.  
 177 
 
     
The Vibratory Micro Mill PULVERISETTE 0 
 
                                                              
                                                                                                                                                                        
                                                                                        
ERM-EC590 (LDPE)  
  
ERM-EC591 (polypropylene) 
Pour liquid nitrogen for fine Communition 
impact, friction heavy ball @ 3 mm 
amplitude  
Artificial Sweat/Sebum 
prepared 
  Equilibration 
Twelve HSE patches 
were placed in 2.5 mL 
maintenance medium 
Incubated at 37°C with 
5% CO2 and 98% RH 
for 24 hrs 
     Exposure 
Co-star plate containing 2.5mL of Williams 
Medium E with 5 % FBS as a receptor fluid and 
were exposed with the micro plastics in triplicates 
for 24 hrs in presence of 100 µL sweat: sebum (1:1 
v/v) to wet the plastics followed by incubation. 
Sampling  Receptor fluid collected at serial 
time points up to 24 hr 
 Exposure terminated at 24 hr by 
removing the micro plastics using 
the cotton swabs soaked in hexane: 
Ethyl acetate (1:1v/v) 
 Skin patches were removed and 
homogenised in same solvent 
Sample Extraction 
Clean-up 
Cotton swabs with the micro 
plastics were extracted with 
DCM and cleaned-up with ~ 2 
mL of 95 % H2SO4 to remove 
lipids 
 
 
Samples of skin, receptor fluid, 
and PBS fluid were analysed by 
GC-MS after extraction with 
hexane: ethyl acetate (1:1 v/v) 
 Fig 6.2 Schematic diagram for the Dermal bioaccessibility and uptake of PBDEs from the ERM-EC 590 & ERM-EC 591 plastics 
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Fig 6.3: Dermal bioaccessibility for PBDEs from ERM-EC 590 pellets and pulverised microplastics. 
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Fig 6.4: Dermal bioaccessibility for PBDEs from ERM-EC 591 full pellets and pulverised microplastics. 
ERM-EC 590 (Pellets)   VS  ERM-EC 590 (Microplastics) * Statistically significant (P<0.05)   ** Very statistically significant (P < 0.01)    *** 
Extremely statistically significant (P<0.0001) 
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Fig 6.5: Dermal penetration (%) of each PBDE congeners found in the receptor 
compartment. (n =3) 
 
Fig 6.6: Dermal accumulation (%) of each PBDE congeners (n =3) 
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6.6: Estimation of Human dermal exposure  
We estimated the dermal exposure of 2 age groups, adults and toddlers. Adults are exposed to 
plastics every day and are in constant contact with electronic gadgets (such as mobile phones 
or computer keyboards) made up of plastic materials. Typically toddlers are also exposed to 
plastics every day while playing with toys containing recycled plastics. In both age groups, 
chemicals like PBDEs might leach from plastics and dissolve in the SSFL and become 
available for subsequent dermal absorption. For the purposes of assessment of exposure via 
dermal uptake of PBDEs resulting from contact with plastics containing these BFRs, we 
presume that the highly exposed parts of the human body to plastics are the palms and the 
back of the hands. The palms and the hands contain many sebaceous glands that secrete both 
sweat and sebum, which facilitate absorption of PBDEs through the skin. Studies have not 
considered the influence of skin moisture on the adherence of the chemicals like PBDEs 
laden on the skin surface. Skin moisture varies for an individual depending on factors such as 
activity level and surrounding temperature/humidity. 
Incorporation of our dermal absorption of PBDEs from plastics (bioavailable fraction) into 
risk assessment models is hampered by the current lack of reliable information on the degree 
of contact between plastics and skin and the frequency and duration of such contact. 
Notwithstanding these caveats, a model is presented here that incorporates reasonable 
assumptions for such parameters. 
 ………….Eqn-1 
Where Ep = Estimated daily dermal exposure; ng/kg.bw/day, Cp = Concentration of PBDEs 
in plastics; ng/g of plastic,  = Body surface area exposed; cm2, PAS = Plastic adhered to 
the skin surface; mg/cm2, Fb = fraction absorbed by the skin (unitless) after 24 hr of micro 
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plastic exposure; N = Number of plastic exposure events per day; day-1, F = fraction of day 
exposed per exposure event (unitless), BW= bodyweight of the consumer; kg  
 
Table 6.1 Parameters used in dermal exposure assessment of target PBDEs in 
pulverised plastics. 
Parameter Adult Toddler 
Age >18 years 2-3 years 
Body weight 70 Kg 15 Kg 
Skin surface exposed to 
plastics  (US EPA 2011) 
 820 cm2 (palms, back of 
hands) 
230.4 cm2 (palms, back of 
hands) 
Plastics adhered to skin 
(Assumed) 
1 mg/cm2 1 mg/cm2 
Number of plastic 
exposure events per day 
(Assumed) 
1 day-1 1 day-1 
Fraction of day exposed to 
plastics per exposure event 
(Assumed) 
5/24 3/24 
 
Note: We assumed the palms and back of the hands to be the first point of contact to plastic 
articles (like toys or mobiles) so the exposed surface area of 820 cm2 (adults) and 230.4 cm2 
was assumed in the exposure model. For other factors like the amount of plastic adhered to 
the skin, we have assumed it a  “Unit” value. The exposure frequency and duration values are 
assumed based on experience. 
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Table 6.2: Assessment of human dermal exposure (ng/kg bw/day) to PBDEs present in 
micro plastics upon contact with a skin surface film composed of 1:1 sweat sebum 
mixture. 
 ADULTS  TODDLERS 
 ERM-EC 590 ERM-EC 591 
591  
ERM-EC 590590 ERM-EC 591   
BDE-28     -          0.0003 - 0.0002 
BDE-47    0.166         0.112 0.131 0.088 
BDE-99    0.146         0.146 0.115 0.115 
BDE-100    0.036         0.015 0.028 0.012 
BDE-153    0.011         0.011 0.009 0.009 
  BDE-154    0.002         0.003 0.001 0.003 
BDE-183     -            - - - 
BDE-209     -            - - - 
 
Fig 6.7:  Estimations of daily dermal intake (ng/kg bw/day) of PBDEs from the ERM-
EC 590 and ERM-EC 591 micro plastics in adults and toddlers. 
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Table 6.2 & fig 6.8 summarise the exposure estimates of adults and toddlers to the studied 
PBDEs via dermal exposure via plastics. It is important to compare the estimates of exposure 
to PBDEs via dust and the plastics. Based on our daily human dermal exposure (ng/kg 
bw/day) results we observe that we cannot compare the exposure via dust (Chapter 3 Table 
3.11) to that of plastics because, the dust exposure estimates include only bioaccessibility but 
not bioavailability, while our plastics exposure estimates include both the bioaccessibility and 
bioavailability. Another key factor to consider in exposure estimates is how representative the 
PBDE concentrations in the reference plastics and the real plastics because in real plastics the 
concentrations will be up to 2-3 % or more as opposed to the much lower concentrations (e.g. 
concentrations in ERM-EC 590 are 0.32 ± 0.04 g/kg and 0.78 ± 0.09 g/kg for BDE-99 and 
BDE-209 respectively), which means our dermal exposure will be greater if contact is with 
plastics containing PBDE concentrations.  
All the estimated values in both the scenarios i.e. dust exposure and plastics exposure are 
found to be below the current USEPA’S Rfd health-based limit values (BDE-47 & BDE-99 
HBLVs < 0.1 µg/kg/d) for PBDEs. For BDE-183 & BDE-209, we were unable to calculate 
the dermal exposure via plastics in humans due to its inability to penetrate the skin in the 
presence of sweat/sebum. Another factor worth discussing is the adherence factor for dust 
particles and plastic to the skin surface, as we apply some stress on the plastics while using 
the consumer products. We recommend future studies to elucidate the impact of stress on the 
transfer of chemicals from the plastics to the skin surface. 
It is obvious that the human skin poses a barrier to human exposure to these hazardous 
chemicals, however the dermal pathway should definitely be considered, along with other 
routes, when assessing the overall human exposure to FRs and the potential risk arising from 
it. 
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6.7: Summary   
In real life the exposure to plastics occurs mainly during direct contact with the consumer 
products made up of intact plastics, however sometimes we are exposed to the abraded 
plastics or microbeads for example in cosmetics. Such micro plastics have higher surface area 
for exposure and results in higher dissipation of PBDEs from the polymers leading to 
increase bioaccessibility to the skin fluids like sweat and sebum. This hypothesis is supported 
by our findings in bioaccessibility experiments where we found that PBDEs could be 
bioaccessible to human sweat and sebum from low density polyethylene (LDPE) and 
polypropylene. When ERM-EC591 micro plastics were exposed to the Episkin model, the 
absorbed mass of PBDEs with increasing Br content from BDE-28 to BDE-154 revealed a 
broad decrease in dermal absorption. Maximal penetration was achieved for Tetra-BDE and 
Penta-BDE, however Octa-BDE and Deca-BDE showed no penetration, although they were 
found to be more highly accumulated in the skin than the less brominated PBDEs studied. 
The higher PBDEs accumulated could undergo metabolism to the lower, toxic congeners or 
metabolites in the skin. At the end we tried to develop a risk assessment model by 
incorporating our dermal absorption of PBDEs from plastics. The exposure estimates of 
adults and toddlers were found to be below the USEPA’s HBLV values. However we 
recommend future dermal exposure studies with real life plastics which might contain higher 
levels of PBDEs. 
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                         CHAPTER VII 
DERMAL BIOACCESSIBILITY AND UPTAKE OF 
ORGANOPHOSPHATE FLAME RETARDANTS FROM 
UPHOLSTERED FABRICS 
 
This chapter contains some material taken verbatim from Pawar, G., M. A. Abdallah, et 
al. (2016). "Dermal bioaccessibility of flame retardants from indoor dust and the 
influence of topically applied cosmetics. J Expo Sci Environ Epidemiol 6(10): 84.  
 
7.1: INTRODUCTION  
In the UK, British Standard 5852:2006 applies to fabrics used to upholster domestic 
furnishings, primarily sofas and chairs. This standard requires testing of the fabric to ensure 
that fire or flame caused by a match or lit cigarette would not ignite the material. Fabrics 
tested under this standard require use for its intended purpose, which is to upholster 
furnishings. It is impossible to list accurately the application levels because of the diversity of 
formulations and fabric structures available. However, there are three methods of rendering 
synthetic fibres flame retardant:  
• Use of FR monomers during copolymerization,  
 • Introduction of an additive FR during extrusion,  
 • Application of flame retardant finishes or coatings. 
There are different standards used for commercial and domestic fabrics. For example, for 
normal domestic upholstery, the fabric should withstand match or lit cigarette testing 
however for the upholstery used in public buildings should comply more stringent (Crib 5 & 
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Crib 7) laboratory tests. Tris (1-chloro-2-propyl) phosphate (TCIPP) is currently the preferred 
FR used in the production of UK PUF due to lower production costs than other similar FRs 
such as tris (1, 3 –dichloropropyl) phosphate (TDCIPP) (EU RAR, 2008c).Tris-2-chloroethyl 
phosphate (TCEP) has not been used in the production of UK PUF since the introduction of 
the 1988 flammability regulations. However, TCEP is known to form as a reaction by-
product in the manufacture of TDCIPP and can be present as an impurity (EU RAR, 2008b). 
The substances TDCIPP and TCIPP have similar use patterns and chemical similarity. The 
three substances are predominantly used in various types of polyurethane foam applications 
in the EU (> 97.5% of TCIPP, > 85% of TDCIPP and > 75% of 2, 2-bis (chloromethyl) 
propane-1, 3-diyltetrakis (2-chloroethyl) bisphosphate -V6, which is another flame retardant 
used in flexible PUF for making expensive automative and furniture articles ). However, 
PFRs such as TCIPP, TDCIPP, and TCEP were reported to be both hazardous and multi-
organ toxic (van der Veen and de Boer 2012a). Furthermore, the EU has classified TCEP as a 
“potential human carcinogen” (category 3) and TDCIPP as suspected of causing cancer. 
Moreover, TCIPP is structurally related to TDCIPP and TCEP (chemical structures given in 
Chapter 1 Table 1.1) and could therefore cause similar effects. (ECHA, 2010). 
Further afield, TDCIPP is more commonly used as a flame retardant in US furniture where it 
was used as a replacement for Penta-BDE to meet the stringent California Technical Bulletin 
117 standard that comprises a series of flammability performance tests  (Stapleton et al. 
2012c).  
Additive FR chemicals may migrate/leach from the FR treated fabrics by abrasion or 
volatilisation or by physical stress ultimately leading to the skin deposition. However there is 
a paucity of data on the level of migration of PFRs from the underneath foams to the 
superficial fabrics in the upholstered furnitures. In 2005 a report by National Research 
Council (US) Subcommittee on Flame-Retardant Chemicals indicated that considerable time 
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(approx. 5 h) is spent in contact with the flame retarded fabrics and these fabrics renders this 
contact a potential pathway for human exposure. The paucity of data on human dermal 
absorption of PFRs and the extent of exposure to consumers is a research gap in accurate risk 
assessment. Thus the aims of this chapter were to: 
 Quantify FR release from the fabrics and subsequently dissolved in sweat/sebum 
mixture (Bioaccessible fraction)  
 Quantify FR penetration through the skin surface in the presence of moisture or 
sweat/sebum mixture 
 Estimate daily dermal intake of target FRs for adults and toddlers when exposed to 
FR-containing fabrics  
7.1.1: Determination of PFRs in upholstered fabrics 
The upholstery fabrics from chairs and sofas were collected from the waste piles at 
University of Birmingham. Our bioaccessibility and dermal uptake experiments employed the 
3 fabric samples shown below in Figure 7.1. 
Fig 7.1:  a) Fabric arm chair          b) Domestic sofa fabric      c) Office desk chair 
            
a)                           b)                       c) 
To quantify the identity and concentrations of the FRs present in these samples, the fabrics 
were first weighed (50-60 mg), spiked with 50 µL IS (d15-TPHP) and soaked in 5 mL hexane: 
ethyl acetate (1:1 v/v) overnight. Following soaking, the extract was filtered with Whatman® 
No.1 filter paper to remove colourants or pigments. The filtrate was subjected to incipient 
dryness under N2 (Turbovap) evaporator Target PFRs were reconstituted in 100 µL of 
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methanol and injected onto a LC-MS/MS. (Chapter 2 Section 2.1.2).Our analysis revealed the 
following PFRs concentrations in the three fabric samples. Note each sample was analysed in 
triplicate. 
 
Table 7.1 Concentrations (average ± standard deviation ng/g) for TCEP, TCIPP and 
TDCIPP in the upholstered fabrics 
Sample                                         Conc (ng/g) 
             TCEP TCIPP TDCIPP 
Sofa 390  ± 10 27000 ± 20 38780 ± 34 
Arm chair 1344  ± 19 1793904  ± 11 25447  ± 6 
Office desk chair 520  ± 5  79601  ± 17 42002  ± 13 
 
7.2: Methodology for dermal bio accessibility test for contaminated fabrics 
 The fabrics in triplicates were first weighed (50-60 mg) and were spiked with 50 µL IS (d15-
TPHP) of 1 ng/µL concentration and were incubated in the clean test tube containing 5 mL of 
1:1 v/v sweat-sebum mixture and agitated for 5 h with magnetic beads with agitation on a hot 
plate at 32 ºC to mimic the normal skin temperature. Fabrics were removed and the 
supernatant liquids subjected to extraction and clean-up (QuEChERS) and later the samples 
were analysed. As above, each sample was studied in triplicate. 
7.3: Methodology for in vitro dermal exposure test for contaminated fabrics 
Episkin was equilibrated in 12 co-star well plates in 2.5 mL culture media at 37 °C. After 30 
mins equilibration, skin surface was exposed to 100 µL of 1:1 v/v sweat/sebum and 
immediately 1 cm2 round cut out of the fabrics (facing the surface which will be contact with 
the human skin in real life scenario) is placed on the skin surface. In similar manner all the 
three type of fabrics were exposed to the skin surface in triplicates. A control skin experiment 
was also conducted consisting of the same experiment but without any exposure of the skin 
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model to fabric. Then followed by 15 mins of gentle shaking; the plate was incubated at 37 
°C with humidified air containing 5% CO2. The receptor fluid was collected at time points 5, 
10, 20, 30 hour & the exposure was terminated at 30 hour by removing the fabrics from the 
skin surface with tweezers and any residual chemical remaining on the skin surface removed 
with cotton swabs soaked in hexane. The skin patches were removed with forceps and stored, 
receptor compartments were washed separately (5 × 2 mL) with PBS. All samples receptor 
fluid, skin, cotton buds, well wash and fabrics) were stored at −20 °C until chemical analysis. 
7.4: Extraction and Clean-up  
The receptor fluid, skin tissue and cotton bud samples were extracted according to a 
previously reported QuEChERs based method (Abdallah et al., 2015). Briefly, each sample 
was spiked with 1 ng of 30 µL IS (d15-TPHP) used as internal (surrogate) standards. 
Extraction was performed using 2 mL of (1:1) hexane: ethyl acetate mixture and vortexing 
for 2 minutes, followed by ultrasonication for 5 minutes and centrifugation at 4,000 g for 3 
minutes. This extraction cycle was repeated twice before the combined organic extracts were 
evaporated under a gentle stream of N2 and reconstituted into 100 µL of methanol. The donor 
and receptor compartment washes were spiked with 30 ng of the d15-TPHP prior to direct 
evaporation under a gentle stream of N2. Target analytes were reconstituted into 100 µL of 
methanol. The exposed fabrics were also extracted in a fashion similar to that described in 
section 7.1.1 
7.5: Determination of PFRs by LC-MS/MS 
The details of the analytical procedures employed to determine concentrations of PFRs are 
provided in Chapter 2, Section 2.1.2. 
7.6: Assessment of dermal exposure via contact with fabrics  
We estimated daily dermal exposure to PFRs as a result of contact with the fabrics via the 
equation below; 
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  ………….Eqn-1 
 = ng/kg .bw/day, = ng of chemical /g of fabric 
  = Body surface area exposed (cm2), as a worst case scenario the body area in contact 
with the sofa or chair was assumed to be 1/4th of the bare upper torso  
FAS = Mass of fabric adhered to the skin surface per unit surface area (mg/cm
2)  
IEF = indoor exposure fraction (hours spent over a day on a sofa/ chair) (unitless) 
= fraction absorbed by the skin (unitless) after 5 hr of fabric exposure 
BW = bodyweight of the consumer (kg)  
Table 7.2: Exposure parameters (USEPA 2011) and estimated dermal exposure (ng/kg 
bw.day) of UK adults and toddlers to the studied PFRs via contact with upholstered 
fabrics. 
 
7.7: RESULTS:  
7.7.1: Bioaccessibility of PFRs from fabrics   
The first rate limiting step in dissolution of PFRs from the treated fabrics to the sweat/sebum 
mixture is the release or migration rate of FRs from the interwoven fabric fibres. However the 
wear and tear or abrasion during the physical stress exerted while sitting on a sofa or 
Parameter Adult Toddler 
Age >18 years 2 - 3 years 
Body weight 60  Kg 15  Kg 
Skin surface exposed  8800 cm 2 (head,  
forearms, hands 
and  trunk) 
4800  cm 2 (head,  forearms, hands  
trunk, legs and feet ) 
Time spent on Sofa/ 
Chair (Conservative  
Assumption ) 
5 hrs/day 5 hrs/day 
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upholstered fabric and the presence of sufficient sweat /sebum on the skin surface during 
summer days could assist in dissolution of PFRs to facilitate human exposure. Our in vitro 
bioaccessibility test data indicated that migration/leaching of TCIPP from different fabrics to 
the sweat: sebum were: 57 ± 7.28 %, 22.4 ± 4.42 % and 15 ± 1.91% of the initial 
concentration for domestic sofa, office chair fabric and domestic arm chair fabric 
respectively.  
For TCEP, the bioaccessible fraction was found to be 1.56 ± 0.18 %, 0.65 ± 0.08 % and 3.84 
± 2.8 % for arm chair fabric, sofa fabric and office desk chair fabric respectively. However 
TDCIPP was found be more bioaccessible than TCEP for 2 types of fabrics i.e. 2.36 ± 0.30 % 
(arm chair) and 5.56 ± 4.64 % (sofa fabric) but less so for office desk chair fabric at 1.16 ± 
0.20 %. Bioaccessibility is higher for TCIPP as compared to TDCIPP & TCEP. 
Our previous report (Pawar et al. 2016) on bioaccessibility from dust of the same PFRs 
revealed bioaccessible fractions of 10.4 ± 1.8, 17.4 ± 2.7 & 18.6 ± 0.8 % for TCEP, TCIPP 
and TDCIPP respectively. This was attributed to the easy dissolution of PFRs from the dust 
particles and was found to be concentration dependent. The bioaccesibility for PFRs from the 
fabrics are lower than that of the bioaccessibility of PFRS from the dust. This could be due to 
the fact that FRs applied to the fabrics might have different physical or chemical forms and 
also due to the back coating treatments or polymerisation or derivatization of the parent 
molecule, in case if the FR are treated on the surface it would be easily bioaccessible. 
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Table 7.3: FBIOACCESSIBLE of PFRs from upholstered fabrics in presence of 1:1 
sweat/sebum mixture 
Acronym Water Solubility (van 
der Veen and de Boer 
2012b) 
(µg/L) 
Log K
ow 
(van 
der Veen and de 
Boer 2012b) 
F
bioaccessible
 (%)-1:1 Sweat:Sebum 
Arm chair 
Fabric 
Sofa Fabric Office Desk 
chair  
TCEP 7 x 10
6
 1.44 1.56 ± 0.181 0.65 ± 0.08 3.84 ± 2.8 
TCIPP 1.6 x 10
6
 2.59 15.00 ± 1.91 57.00 ± 7.28 22.38 ± 4.42 
TDCIPP 1.5 x 10
3
 3.80 2.36 ± 0.30 5.56 ± 4.64 1.16 ± 0.20 
 
7.7.2: Bioavailability of PFRs from upholstered fabrics in presence of sweat: sebum 
mixture 
Following 30 hours exposure of Episkin to the 1 cm2 arm chair fabric, sofa fabric and office 
desk chair fabric (in triplicates) in the presence of 100 µL synthetic sweat/sebum mixture 
which was applied to the skin surface before placing the fabrics on to the skin surface, TCIPP 
showed the highest cumulative absorption (ng/cm2) with 523.58 ± 1.44, 414.29 ± 5.81, 64.9 ± 
0.34 in case of domestic arm chair fabric, office desk chair and sofa fabric respectively in the 
receptor fluid. For TCEP, cumulative absorption (ng/cm2) was found to be: 150.3 ± 0.94, 59.5 
± 12.09 & 37.0 ± 3.2 for arm chair fabric, sofa fabric and office desk chair respectively. 
Compared to TCIPP and TCEP, TDCIPP was less abundant in receptor fluid at a 
concentration of 37.8 ± 9.8, 37.0 ± 3.84 and 31.4 ± 1.68 for arm chair fabric, office chair 
fabric and sofa fabric respectively. Considerable quantities remained on the skin surface 
(Table 7.5) Analysis of the skin tissue resulted in recovery (%) of TCEP (12.43 ± 4.89, 18.76 
± 2.2, 31.46 ± 1.40), TCIPP (1.55 ± 0.13, 0.2 ± 0.01, & 2.67 ± 0.19) and TDCIPP (0.62 ± 
0.15, 0.48 ±0.034, 0.039 ± 0.014), for sofa fabric, arm chair fabric and office desk chair 
fabric respectively after 30 h exposure.  
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Table 7.4: Distribution of target PFRs (expressed as average percentage ± standard deviation of exposure dose) in different fractions of 
the in vitro diffusion system following 30 h exposure to 500 ng/cm2 (finite dose) of the studied compound. 
SOFA FABRIC               TCEP TCIPP TDCIPP 
Absorbed* 20.59 ± 3.57 0.30 ± 0.07 0.13 ± 0.006 
Unabsorbed# 33.57 ± 16.21 83.9 ± 5.6 94.6 ± 8.9 
Skin 12.43 ± 4.89 1.55 ± 0.13 0.62 ± 0.15 
Sum (Recovery) 66.59 ± 24.67 85.8 ± 5.75 95.35 ± 9.06 
ARM CHAIR FABRIC TCEP TCIPP TDCIPP 
Absorbed* 15.18 ± 2.09 0.03 ± 0.002 0.233 ± 0.06 
Unabsorbed# 41.62 ± 0.6 77.1 ± 15.2 88.33 ± 3.3 
Skin 18.76 ± 2.2 0.2 ± 0.01 0.48 ± 0.034 
Sum (Recovery) 75.56 ± 4.89 77.3 ± 15.2 89.04 ± 3.39 
OFFICE DESK CHAIR FABRIC TCEP TCIPP TDCIPP  
Absorbed* 16.25 ± 3.15 0.52 ± 0.005 0.12 ± 0.03 
Unabsorbed# 35.56 ± 0.68 86.34 ± 7.85 98.1 ± 24.81 
Skin 31.46 ± 1.40 2.67 ± 0.19 0.39 ± 0.014 
Sum (Recovery) 83.27 ± 5.23 89.53 ± 8.04 98.61 ± 24.85 
                  * Comprises cumulative concentrations in the receptor fluid over 30 h + receptor compartment rinse. 
                                    # comprises concentrations in the skin surface wipes after 30 h + donor compartment rinse
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Fig 7.2: Cumulative absorption of TCEP detected in receptor fluid up to 30 h. 
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Fig 7.3: Cumulative absorption of TCIPP detected in receptor fluid up to 30 h. 
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Fig 7.4: Cumulative absorption of TDCIPP detected in receptor fluid up to 30 h. 
 
7.7.3 Estimated human dermal exposure (ng/kg bw/day) to TCEP, TCIPP & TDCIPP in 
fabrics (Fig 7.5, 7.6 and 7.7) 
The average estimated human dermal exposure (ng/kg bw/day) for TCEP, TCIPP & TDCIPP 
in toddlers was found to be higher in toddlers than for adults which could be attributed to 
factors like higher body surface area by weight in toddlers. 
In case of sofa fabric, TCEP contributed more to the daily dermal intake i.e. 31.5 and 106.79 
ng/kg bw/day in both UK adults and toddlers respectively.  In case of TCIPP, fabric from the 
domestic arm chair contributed more to the exposure whereas in case of TDCIPP, the 
contribution is more from the office chair. 
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Fig 7.5: Estimated daily dermal intake (ng/kg bw/day) of TCEP from upholstered 
fabrics 
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Fig 7.6: Estimated daily dermal intake (ng/kg bw/day) of TCIPP from upholstered 
fabrics. 
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Fig 7.7: Estimated daily dermal intake (ng/kg bw/day) of TDCIPP from upholstered 
fabrics. 
 
 
7.8: Summary  
The paucity of data on human dermal absorption of PFRs and the extent of exposure to 
upholstered fabrics is a research gap hindering their accurate risk assessment. Thus we 
studied the transfer of FRs from upholstered fabrics. Bioaccessibility for TCIPP (~ 15-57 %) 
exceeds that of TDCIPP (~ 1-6%) and TCEP (~ 0.65-4%) for all three types of upholstered 
fabrics studied, suggesting that these flame retarded fabrics could act as a potential source of 
dermal exposure. The SSFL (sweat/sebum) influences the bioaccessibility of PFRs from 
fabrics. Bioaccessibility is higher for TCIPP from the fabrics as compared to TDCIPP  
The bioaccessibility of PFRs from fabrics is lower than from dust. This could be due to the 
fact that FRs applied to the fabrics might have different physical or chemical forms and also 
due to the back coating treatments or polymerisation or derivatization of the parent molecule. 
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We tried to mimic real life dermal exposure of upholstered fabrics to the Episkin surface in 
presence of sweat and sebum under controlled conditions and we found that among the PFRs 
studied, the cumulative absorption was higher for TCIPP and followed by TCEP and 
TDCIPP. This is due to higher amount of TCIPP applied in all the three fabrics.  
These data confirm the potential importance of the dermal route as a pathway of human 
exposure to TCEP, TCIPP & TDCIPP from upholstered fabric. 
Dermal exposure estimates fell far below the reported health based limit values (HBLVs) for 
TDCIPP (5.4 µg/day according to OEHHA, 2015). No other health based limit values 
(HBLVs) of legislative standing for TCEP and TCIPP. Interestingly for toddlers for TCIPP 
uptake from arm chair fabric, as it is 2.5 µg/kg bw/day, so for a 10 kg toddler this is 250 
µg/day. However, future research may erode this margin of safety. 
Detailed studies are required to study the forensic microscopic details of fabrics to know the 
extent of distribution of applied PFRs either on the superficial layers or deep layers of the 
fabrics and subsequently its dissolution into the sweat on the skin surface. Also it would help 
us to clarify whether the chemicals are migrating from PUR foams to the covering fabrics and 
contributing to the dermal exposure of PFRs. 
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CHAPTER VIII 
Summary and conclusions 
Organic flame retardants (FRs) are widely added to polyurethane foam, plastics, electric and 
electronic equipment and textile coatings in furniture. The capacity of these chemicals to 
leach out from these consumer goods by volatilisation/abrasion and pollute the indoor 
environment coupled with evidence of their persistent, bioaccumulative and toxic properties 
is a cause of concern. Although many studies have examined the relationship between 
concentrations of FRs in indoor dust and in human biological fluids/tissues, we do not yet 
fully understand the exact mechanism via which FRs transfer from the indoor dust or the 
consumer goods to the body (i.e. whether it is ingestion of dust or dermal contact with dust 
and/or the consumer goods themselves). To date, the role of the dermal pathway has been 
somewhat overlooked, although some authors have suggested that it may be of importance.  
This need for data on human dermal uptake of FRs coupled with the ethical and scientific 
problems associated with extrapolation of dermal data obtained from animals to humans, 
provided the driver for this research to evaluate alternative in vitro approaches to studying the 
dermal uptake of FRs. Specifically, we evaluated commercially-available 3D-HSE (human 
skin equivalent) models developed and applied widely in the cosmetics and pharmaceuticals 
sectors. Initially we evaluated the bioaccessibility of FRs from source matrices to skin fluids 
using artificial sweat and sebum. Then we developed a standard protocol according to the 
guidelines of OECD- 428 for dermal absorption of FRs as a neat compounds. The protocol 
was applied to two commercially available 3D HSE models namely, EpiDermTM and 
EPISKINTM. To evaluate the barrier function of 3D-HSE models, the permeability 
coefficients for FRs obtained from two models were evaluated against the ex vivo human 
skin. After establishing the protocol we tried to mimic the real life exposure scenario by 
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exposing the Episkin model to the potential sources of FRs like dust (dry or wet condition or 
in presence of moisturising cream), reference material plastics and contaminated upholstered 
fabrics. Finally we applied the PK model to predict the daily dermal intake of different FRs 
for UK adults and toddlers with contaminated dust, plastics and upholstered fabrics using 
different exposure scenarios. 
8.1: SUMMARY AND CONCLUSIONS 
The main achievements and outcomes of this research are summarised below: 
 We successfully designed and applied an in vitro physiologically based extraction test 
to provide new insights into the dermal bioaccessibility of various FRs from indoor 
dust, upholstered fabrics and powdered plastic pellets to a synthetic sweat/sebum 
mixture (SSSM). The composition of the SSSM, compound-specific physicochemical 
properties (e.g. KOW) and matrix properties (e.g. organic carbon content, FR 
concentration) were the major factors influencing FR bioaccessibility. 
 Average bioaccessible fractions of α-, β-, γ- HBCD and TBBPA from indoor house 
dust to a physiologically-relevant 1:1 (sweat: sebum) mixture were: 41 %, 47 %, 50 % 
and 40 %, respectively. For TCEP, TCIPP and TDCIPP, the bioaccessible fractions 
were 10 %, 17 % and 19 % respectively.  
 For BDE-209, the bioaccessibility to 100% sweat was 0.04 ± 0.01 %. This was the 
lowest value obtained for our target PBDEs, and is likely due to its low water 
solubility (<0.0001 mg/L) compared to other congeners. The reverse trend was 
observed for bioaccessibility to 100% sebum, with fBIOACCESSSIBLE highest for BDE-
209 (98.5 ± 7.78 %), followed by BDE-28 (98.2 ± 7.08 %) and BDE-47 (87.18 ± 3.13 
%). At the most physiologically relevant SSSM (i.e. 1:1 sweat: sebum), 
fBIOACCESSSIBLE was highest for BDE-209 (79.37 ± 7.66 %); however, no significant 
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relationship was observed between the degree of congener bromination and the 
fBIOACCESSSIBLE.  
 Previous studies have shown certain sunscreen lotions to act as inadvertent enhancers 
of the dermal penetration of potentially harmful chemicals (Pont et al. 2004, Walters 
et al. 1997). Therefore, we investigated the effect of topically-applied cosmetics on 
the dermal bioaccessibility of FRs in indoor dust. The results indicated that except for 
TBBPA, the presence of cosmetics (moisturising cream, sunscreen lotion, body spray, 
and shower gel) had a significant negative effect (P < 0.05) on the bioaccessibility of 
the studied FRs. The presence of cosmetics decreased the bioaccessibility of HBCDs 
and PBDEs from indoor dust, while shower gel and sunscreen lotion enhanced the 
bioaccessibility of target PFRs. The decrease in bioaccessibility for HBCDs and 
PBDEs was due to the retention of these lipophilic chemicals by skin cream products. 
 A recent study (Hoffman et al. 2016) showed that playing with plastic toys was 
associated with higher handwipe levels of PBDEs. We hypothesise that the PBDEs in 
plastic can leach out upon contact with human SSFL and become available for 
absorption via penetration of the stratum corneum. The bioaccessibility ranged from 
61 % to ~ 83 % in ERM-EC590 (LDPE) in case of pellets and significantly increased 
to 70 % to 94 % when the size of the pellets were reduced (microplastics). Both the 
lower PBDEs as well as the higher PBDEs were able to dissolve efficiently in the 
sweat and sebum mixture. The reasons for this may be attributed to the unique 
composition of the SSFL which contains lipophilic sebum that would facilitate the 
dissolution of highly lipophilic congeners (e.g. BDEs-183 and 209) together with the 
electrolyte-rich sweat which may favour dissolution of less hydrophobic congeners 
(e.g. 17 and 28) from the pulverised plastics. The reduced size of the pulverised 
plastics (~ 0.5 mm) resulted in a higher surface area for easy dissipation of the 
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polymers in the SSFL resulting in significantly higher bioaccessibility (%) for PBDEs 
(t-test, P<0.01, n=3) as compared to the intact pellet beads (~ 5 mm) for both the 
ERM-EC 590 & ERM-EC 591 reference plastics. Our results imply that in real life 
PBDEs could be bioaccessible to human sweat and sebum from low density 
polyethylene (LDPE) and polypropylene. 
 The paucity of data on human dermal absorption of PFRs and the extent of exposure 
to consumers is a research gap hindering their accurate risk assessment. Thus we 
studied the transfer of FRs from upholstered fabrics. Bioaccessibility for TCIPP (~ 
15-57 %) exceeds that of TDCIPP (~ 1-6%) and TCEP (~ 0.65-4%) for all three types 
of upholstered fabrics studied, suggesting that these flame retarded fabrics could act 
as a potential source of dermal exposure. The bioaccessibility of PFRs from fabrics is 
lower than from dust. This could be due to the fact that FRs applied to the fabrics 
might have different physical or chemical forms and also due to the back coating 
treatments or polymerisation or derivatization of the parent molecule. 
In the second phase of the research we developed a protocol for studying dermal uptake of 
legacy and novel brominated flame retardants using two 3D-HSE models, EpiDerm™ and 
EPISKIN™ in compliance with the OECD guidelines 428. The results were then validated 
against a viable human ex vivo skin model to evaluate the barrier function of the 3D-HSE for 
the studied FRs. 
 Our results showed a significant negative correlation between the permeability 
constant of FRs and their Log KOW values. (Fig 4.27) 
 For the first time we have mimicked real life dermal exposure in vitro by 
incorporating dry and wet conditions in our experiments. This provided insights into 
the influence on dermal uptake of the type of skin e.g. dry or oily. Dust was applied to 
the skin surface to show that it could be a potential source of dermal exposure to FRs. 
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Our results suggested that dermal absorption of lipophilic chemicals like HBCDs and 
PFRs was enhanced when the skin model was treated with a sweat: sebum mixture 
compared to a “dry” skin scenario. However, this effect was not significant. 
 When ERM-EC591 micro plastics were exposed to the Episkin model, the absorbed 
mass of PBDEs with increasing Br content from BDE-28 to BDE-154 revealed a 
broad decrease in dermal absorption. Maximal penetration was achieved for Tetra-
BDE and Penta-BDE, however Octa-BDE and Deca-BDE showed no penetration, 
although they were found to be more highly accumulated in the skin than the less 
brominated PBDEs studied.  
 We applied our data on dermal bioaccessibility in worst case scenarios and 
bioavailability to estimate the internal exposure of UK adults and toddlers to our 
target FRs via dermal contact with dust, plastics and upholstered fabrics.  
The high concentrations of PBDEs in the ERM-EC 590 and ERM-EC 591 plastic 
matrices studied resulted in higher  estimated dermal exposure than for dust but are 
still reassuringly below the current USEPA’s health-based limit values (BDE-47 & 
BDE-99 HBLVs < 0.1 µg/kg/d) for PBDEs. For BDE-183 & BDE-209, we were 
unable to calculate the dermal exposure via plastics in humans due to its inability to 
penetrate the skin in presence of sweat/sebum.  
For the sofa fabrics studied, TCEP contributed more than other PFRs like TCIPP & 
TDCIPP to the daily dermal intake i.e. TCEP (31.5 and 106.79 ng/kg bw/day in both 
UK adults and toddlers respectively).  In case of TCIPP, fabric from the domestic arm 
chair contributed 653.0 ng/kgbw/day & 2494 ng/kgbw/day in adults & toddlers 
respectively more to the exposure whereas in case of TDCIPP, the contribution is 
more from the office chair 29.0 ng/kg bw/day in toddlers group. These data confirm 
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the potential importance of the dermal route as a pathway of human exposure to 
TCEP, TCIPP & TDCIPP from upholstered fabric. 
8.2: Future research recommendations 
Although current commercially available HSE models may provide a useful alternative to 
study human dermal absorption of FRs, there remain several challenges and research gaps 
that need to be addressed in the near future. These include: 
 Further improvements like the presence of hair follicles, sweat and sebaceous 
glands in the 3D-HSE models are still required to provide further potential 
pathways for percutaneous penetration. Vascularised full thickness models would 
allow the models to more closely mimic in vivo skin. 
 More realistic repeated chronic exposures of the skin models are required to 
closely mimic the real life exposure scenarios without compromising the 
stability/viability of the 3D-HSE models. This would be helpful to study the tissue 
perturbations due to repeated and intermittent exposure, degradation/metabolism 
due to skin deposition and sustained release into the systemic circulation. 
 To employ dynamic models like flow-through diffusion cells that offer an 
important advantage over static models i.e. the continuous flow of receptor fluid 
through the receiver compartment which helps to maintain the skin condition for 
compounds having large permeability coefficients. Also this set up helps to mimic 
the in vivo subcutaneous vasculature.  
 Currently, very little is known about the dermal biotransformation of FRs so the 
conduct of future studies in this area is strongly recommended. Such work would 
enhance understanding of percutaneous metabolic pathways and identification of 
the metabolites thus formed. 
 206 
 
 Further improvements can be made by mimicking real life exposure scenarios – 
e.g. using environmentally relevant exposure concentrations present in exposure 
media like soil, dust and different consumer products treated with FRs.    
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